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Several studies have found an effect of reducing the intake of food rich in FODMAPs when 
having an irritable bowel. As far as we know, there are no published papers on low FODMAP 
diet to patients with coeliac disease. We therefore wanted to investigate whether the diet could 
have an effect on symptoms, quality of life, gas production and microbiota in addition to a 
gluten free diet.  
 







Background: Around 20-30% of coeliac disease patients have IBS-like symptoms. The low 
FODMAP diet (low in fermentable oligo-, di-, monosaccharides and polyols) is used as 
treatment for irritable bowel syndrome (IBS) to reduce gastrointestinal symptoms. As far as we 
know, there are no published papers on low FODMAP diet to patients with coeliac disease. 
 
Purpose: We wanted to investigate whether patients with coeliac disease and IBS-like 
symptoms could have a benefit from using this diet in addition to their gluten free diet, 
especially regarding abdominal symptoms and quality of life. Traditionally, these have been 
given advice to further eliminate traces of gluten in their diet. We compared this strategy to a 
reduction in FODMAPs as instructed by a clinical dietitian.  
We also wanted to investigate whether a low FODMAP diet would have any effect on the gut 
microbiota and the degree of fermentation by gut bacteria, measured with breath tests and stool 
samples (another Master’s Thesis). The objective was to investigate whether this is a treatment 
which can be recommended for coeliac patients with IBS-like symptoms or not. 
 
Method: Forty patients with coeliac disease-, and IBS-like symptoms confirmed by the Rome 
III criteria and score> 75 on IBS-SSS (Symptom Severity Scale) were included in the study. 
They were randomized into two groups. Group A followed a more strict gluten free diet for six 
weeks and were supposed to exclude all wheat starch and food labelled “traces of gluten” from 
their diet. Patients in group B continued to follow a traditional gluten free diet in addition to 
following a low FODMAP diet for six weeks. Symptoms (Irritable bowel syndrome- Symptom 
Severity Scale) were recorded at baseline, three and six weeks. Quality of life (SF-36), 4 days 
prospective dietary intake records, blood tests, breath tests and stool samples were carried out at 
baseline and after six weeks on their diets. Compliance and satisfaction with the two diets were 
evaluated by VAS-scales after 6 weeks, and 1 month after the intervention ended in group B. All 
the patients were given dietary counselling by master students in clinical nutrition. Dietist Net 
Free was used to calculate the amount of FODMAPs in the diets at baseline and at six weeks. 





Results: Twenty patients were included in each group; group A (18F/2M, age 39±15) and group 
B (15F/5M, age 43±12). At baseline, 42.5% had constipation problems (IBS-C), 27.5% 
diarrhoea problems (IBS-D) and 30% both (IBS-M). At baseline, 20% in group A vs. 10% in 
group B had mild IBS, 45% vs. 65% moderate and 35% vs. 25% severe IBS symptoms. After 
six weeks there were statistically significant differences between the groups (p=0.0425); 10% vs. 
25% were in remission, 15% vs. 45% had mild IBS, 65% vs. 25% moderate and 10% vs. 5% 
severe. 
There were 5 patients in group A and 1 in group B that had raised anti-transglutaminase 2 IgA-
levels, vs. 2 and 3 with raised anti-deamidated gliadin IgG-levels. The FODMAP intake 
decreased statistically significant from 7.7 (2.7-19.2) g/day at baseline to 1.3 (0.9-2.1) g/day at 
six weeks in group B (p=0.0001), vs. a non-significant decrease from 14.5 (10.9-21.6) to12.1 
(6.4-19.5) g/day in group A.  
There was a statistically significant reduction in total IBS-SSS for both groups from baseline to 
six weeks. The mean score in group A at baseline was 260 ± 90, while it was 204 ± 75 at six 
weeks (p=0.0022), vs. 263 ± 70 at baseline, and 145 ± 84 at six weeks in group B (p<0.0001).  
There was a statistically significant difference between the two groups at 6 weeks (p=0.025). 
The five main IBS-SSS-questions were all statistically significant reduced in group B at six 
weeks; abdominal pain severity (41.0 (28.8-52.5) vs. 14.5 (0.0-23.5), p<0.0001), abdominal pain 
frequency (4.0 (2.3-7.0) vs. 2.0 (0.0-4.0), p=0.0016), abdominal bloating severity (60.0 (44.0-
72.8) vs. 19.5 (2.0-34.5), p<0.0001), dissatisfaction with bowel habits (61.5 (41.5-88.5) vs. 43.5 
(27.0-56.5), p=0.0196) and interference with daily activities (57.5 (40.5-84.5) vs. 24.0 (15.8-
45.4), p<0.0001). The question about abdominal pain severity was also statistically significant 
reduced in group A, but the four other main questions were not.  
Regarding quality of life, there was an improvement in physical component summary in group B 
(45±8 vs. 48±8, p= 0.0061) but not in group A or when looking at mental component summary. 
Patients in group B were statistically significant more satisfied with pain relief (p=0.0132) and 
though it was more challenging to follow their diet (p=0.0008), than group A. 
 
Conclusion: This study showed a statistically significant improvement in abdominal symptoms 
and subjective report of physical health in a group of patients with coeliac disease and irritable 
bowel syndrome-like symptoms after following a low FODMAP gluten free diet for six weeks. 
The low FODMAP diet was more effective than a more strict gluten free diet, and should be 
offered to coeliac patients with IBS- like symptoms.  
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1.1 COELIAC DISEASE  
 
1.1.1 What is coeliac disease? 
Coeliac disease is a chronic inflammatory, autoimmune 
disease and it is multisystemic which means that the whole 
body is affected, not just the bowel. The small bowel is 
sensitive to gluten (1) which is a composite of the proteins 
gliadin and glutenin (see figure 1).  These proteins are 
primarily found in wheat, but immunogenically similar 
proteins are found in barley and rye. It is especially the 
gliadin which is responsible for the damage and it can 
induce oxidative stress. Gliadin can stimulate both the 
innate and the adaptive immune system.                                     Figure 1: Gluten is composed of                                                     
…                                                                                                      gliadin and glutenin (2).                                                                                                                                                                                                             
 
When a person with coeliac disease eats gluten, the gluten peptides will react with tissue 
transglutaminase 2 and be deamidated. Gluten peptides will thereafter stimulate T-cells and this 
leads to a binding to the molecules HLA-DQ2/8 which are expressed on antigen-presenting 
cells. Through B-cells antibodies will develop and can be released into the blood stream. The 
mucosal layer and the villi in the small bowel will be damaged. There is not  enough knowledge 
about why and how gluten harms the gut (1).                                                
 
1.1.2 Pathophysiology and causes 
The duodenum wall has four layers. The innermost layer is the mucosa, the next submucosa, 




Figure 2: The four wall layers of the duodenum (3) . 
 
Villous atrophy in the mucosal layer of the duodenum, crypt hyperplasia and intraepithelial 
lymphocytes are typical findings in a damaged small bowel in coeliac disease (1) (see figure 3). 
The cause of villous atrophy can be increased apoptosis of enterocytes. A leaky gut will allow 
antigenes to pass, one will react with autoimmunity and an influx of white blood cells is the first 
thing that happens (inflammation) (4). Tight junctions play an important role in the 
pathomecanism of coeliac disease. A deterioration of these can cause an increased permeability 
of the epithelial barrier function, and abnormal passage of antigenes through the epithelial layer 
can continue (5, 6).  
 
Figure 3: A healthy gut (to the left) and a damaged gut (to the right) (7). 
The Marsh classification of the microscopic findings in duodenal biopsy is used to describe how 
serious the damage in the bowel is (8). Classified with type 0 means that the gut looks normal 
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and coeliac disease is not present or is in remission. Increasing numbers means more damage. 
Type 1 is nonspecific and often common in patients eating a gluten free diet with small amounts 
of gluten. The number of lymphocytes is increased, but the crypts and the villi will be normal. 
This type can also be seen when having infections. Latent coeliac disease is when the biopsies 
from the duodenum are normal, but the serology is changed (9). Type 3c is the most severe and 
dramatic type, and the patient is having complete villous atrophy. 
 
Breastfeeding and a small amount of gluten-protein in the breast milk is a protective factor in 
developing the disease (10-12), and the child should not be exposed to gluten for the first six 
months of life (13). Coeliac disease has a strong genetic component. More than 95% of all the 
patients have the HLA (human leukocyte antigen)-genotypes DQ 2 or 8 (9, 14).  
 
1.1.3 Epidemiology 
The prevalence is about 1 in 100 in Europe and the disease can be diagnosed at any age (1, 9, 15, 
16). Earlier, researchers believed that the disease was a children’s disease, and that it 
disappeared when the children grew up. The prevalence has increased the last 50 years (17), and 
there is data suggesting that a lot of people have the disease without knowing it (18). One is born 
with a hereditary tendency to develop coeliac disease. The HLA DQ2 or DQ 8-genes are almost 
always present (19). The prevalence in first-degree relatives is about 10%, and in second-degree 
about 2% (20). One has to ingest gluten to develop the disease.  
 
1.1.4 Signs and symptoms 
When the small bowel gets damaged, the area where nutrients are absorbed will be reduced, and 
this can cause malabsorption. Malabsorption can lead to deficiencies in macro- and 
micronutrients, which again can cause weight loss and children may fail to thrive (1). Other 
frequent symptoms are tiredness, irritability, diarrhoea, abdominal pain, depression, anaemia, 
bone disorders, infertility and neurological symptoms (1). Approximately 50% do not have 
symptoms at all (silent coeliac disease) and therefore live with the disease undiagnosed for many 
years (21, 22).  
 
When the patients attain a strict gluten free diet, they usually do not feel symptoms (anymore). 
Unfortunately, some do. Irritable bowel syndrome, microscopic colitis, pancreatic insufficiency 





The patient has to eat a normal diet with gluten for > 4 weeks before the blood tests and biopsies 
are taken. This is extremely important to avoid false negatives (1). Blood antibodies are 
measured in serological tests. IgA (immunoglobulin A)-antibodies against the tissue 
transglutaminase 2-enzyme (tTG) is the most important blood test. This will normally be raised 
in coeliac patients. Anti-deamidated gliadin IgG (immunoglobulin G) is also measured (1, 4). If 
both these blood tests are raised, the patient most likely has coeliac disease. If only the anti-
deamidated gliadin IgG is raised, total IgA is also measured to check for IgA-deficiency (23). If 
IgA-deficiency is found in addition to a raised anti-deamidated gliadin IgG, the diagnosis is 
likely (23).  
 
To make a positive diagnosis in adults, a gastroscopy with a biopsy of the duodenum is also 
needed (24). The biopsy will identify if the bowel is damaged (1), and be used to Marsh-classify 
the severity of the disease. 
 
As mentioned, the HLA-genotypes DQ2 or DQ8 are the most common in coeliac patients (9, 14, 
19). About 33% of the Norwegian population has the DQ2-genotype (9).  In the absence of one 
of these genotypes, the diagnosis is very unlikely. Genetic typing is on the other hand not 
enough to get diagnosed.  
 
1.1.6 Treatment 
The only treatment for coeliac disease today is a life-long exclusion of gluten from the diet, 
regardless of the severity of symptoms (1). When gluten is avoided, the bowel will start to heal, 
and after a year or more the bowel is usually completely restored (1, 25-29). A study found that 
around 40% of the patients still had some extent of villous atrophy after following a gluten-free 
diet for two years though (30), and 10% after five years (31). Antibodies will probably still be 
present for 6 months-1 year. Some nutritional deficiencies can persist (32, 33), but when the 
disease is controlled, nutrients will usually be absorbed normally again, symptoms will decrease 





Coeliac disease is a multisystem disease, and patients should be monitored and followed-up for 
the rest of their lives, ideally yearly or more often if abnormalities and/or symptoms are present. 
This is unfortunately not always possible. The National Institutes of Health (NIH) in the U.S. 
suggests this treatment (34): 
- Consultation with a skilled dietician  
- Education about the disease 
- Lifelong adherence to a gluten-free diet 
- Identification and treatment of nutrient deficiencies 
- Access to an advocacy group 
- Continuous long-term follow-up by a multidisciplinary team 
 
1.1.7 The gluten-free diet  
When eating a gluten-free diet all dietary sources of wheat, 
barley, rye, triticale, kamut, manitoba and spelt, and all 
products made from these grains (bread, pasta, biscuits, 
cakes, bulgur, couscous etc.) have to be excluded. Gluten is 
also added to a lot of other products such as sauces, soups 
and semi-manufactured foods (1), so it is important to read 
the labels carefully. Gluten-free products are often marked 
with a symbol (see figure 4), and gluten-containing 
products should be allergen labelled.                               Figure 4: The “gluten-free”-symbol (35).  
 
There are two ways of labelling gluten-free products (36): 
- “Very low gluten-content”: Up to 0.1 g gluten/kg. Gluten is removed from these products, but 
“traces of gluten” and wheat starch is OK.  
 - “Gluten-free”: Up to 0.02 g gluten/kg. The product is gluten-free.  
 
It is important to replace the excluded foods with other gluten-free foods to maintain a nutrient-
rich and balanced diet. Carbohydrates, fibre, proteins, iron, calcium, folate and thiamine are 
nutrients there can be deficient (37). The need for these should be met with other foods or 
supplements. One should use a multivitamin- and mineral supplement to correct for possible 
deficiencies the first four months and later if the diet is undiversified. In particular, the gluten 
free diet can easily get poor in dietary fibre. It is recommended to eat five fruits or vegetables a 
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day, and fleawort seeds, potato fibre or oat can be used as dietary fibre replacements.   
 
Today, there are a lot of alternative products, and the assortment is expected to increase in the 
future. Semper ®, Schar ®, Finax ®, Holmen-Crisp ®, Toro ® and Fria ® are some 
manufacturers. Fresh meat, poultry, fish, cheese, eggs, fruit, vegetables, milk, milk products, 
legumes, potatoes, mushrooms, berries, nuts, seeds, oil and butter are naturally gluten-free and 
should therefore be included in a gluten-free diet.  
 
Oat does not contain gluten, and is therefore advised to be a part of a gluten-free diet if it is not 
contaminated with gluten (1). Oat is a good source for soluble fibre, vitamins and minerals, and 
is prebiotic for the good bacteria in the intestine. It can give symptoms to a small number of 
patients with coeliac disease if it is contaminated with small amounts of gluten (38-40). Some 
will be temporary lactose intolerant before the duodenum has healed, and get symptoms when 
ingesting milk and milk products. Cultured milk is often better tolerated. The patients can 
usually start to ingest whole milk and milk products 6 weeks after starting on a gluten-free diet 
(41). 
 
Wheat starch is usually tolerated since both the fat and the gluten protein is removed, and there 
are only carbohydrates left. Hydrolysed vegetable proteins, glutamate and additives are also 
gluten free.  
 
People with coeliac disease should learn which foods that contain gluten and which are gluten-
free, and the label should be read carefully every time. Hygiene in the kitchen is also extremely 
important. Patients should have a “gluten free- zone” to avoid any gluten-contamination during 
preparation of meals and storage of foods (1, 42). Separate and clean toasters, bread boxes and 
baskets, knives, chopping boards, utensils etc. should be used. 
 
Some patients do not have symptoms at all, and may therefore be inclined to eat gluten since 
they can’t feel any difference. It is still important that these people attain a gluten-free diet. 
Others may think it is embarrassing or nagging to say that they can’t eat gluten, and therefore 





1.1.8 Associated conditions and possible long-term consequences  
Patients with coeliac disease have a greater risk of getting other autoimmune diseases such as 
diabetes type 1, Sjogren’s syndrome, multiple sclerosis and thyroid disease (43-45). Coeliac 
disease and diabetes type 1 has a similar genetic background. Around 5% of the patients with 
coeliac disease also have type 1 diabetes mellitus (43). Around 9.3% of patients with coeliac 
disease have small intestine bacterial overgrowth (SIBO) (46). Dermatitis herpetiformis, 
anaemia, abnormal liver function, Down’s syndrome and osteoporosis are also more common in 
people with coeliac disease (1).  
 
Bread and cereals are products rich in calcium. The intake of these products is often reduced on 
a gluten-free diet (47) and there can also be a malabsorption of calcium (48). This leads to a 
reduced bone mineral density and can develop to osteoporosis (47, 49).  
 
The patient with coeliac disease has to adherence to a lifelong strict gluten-free diet. If not, the 
risk of developing other symptoms and diseases increases. The disease can also affect other 
organs than the bowel. Malignancy (50)  and infertility are some possible long-term 
consequences. There is an increased risk of developing lymphoma if the patient do not adhere to 
a strict gluten free diet, compared to the general population (51).  
 
Some few will develop refractory coeliac disease although eating a strict gluten free diet (52). 
They will still have villous atrophy and abdominal symptoms, and the disease often requires 
additional treatment. There is no evidence of other pathology. Weight loss and diarrhoea is 
common. There are two types of refractory coeliac disease; type 1 and type 2. Having type 2 can 
increase the risk of getting gut cancer and there is a greater mortality after two years (41%) 










1.2 IRRITABLE BOWEL SYNDROME (IBS)  
 
1.2.1 Functional gastrointestinal disorders  
Functional gastrointestinal disorders (FGID) are diseases where the doctors can’t find any 
organic, structural, metabolic or infectious damage when doing gastroscopy and taking biopsies 
of the small bowel (4). These disorders are exclusion diagnoses based on symptoms, and the 
different diseases often have common and overlapping symptoms. Irritable bowel syndrome 
(IBS), food intolerances, gastroesophageal reflux disease (GERD) and functional dyspepsia are 
some examples. It is normal to have more than one of these diseases (4). 
 
1.2.2 Irritable bowel syndrome and symptoms 
Typical symptoms when having an irritable bowel are problems with evacuation like diarrhoea 
and constipation, nausea, vomiting, abdominal pain, exhaustion and flatulence. The gut reflex is 
enhanced and many will feel pain relief when evacuating.  
 
In addition, people with IBS often have a reduced quality of life (QoL) (54-58). IBS-patients do 
have an equal or worse QoL than patients with GERD, heart failure, kidney disease and diabetes 
(57-59). The physical symptoms and the mental discomfort both affect each other. It can be 
really demanding having an irritable bowel in social settings. Patients with IBS often have more 
anxiety, depression and tiredness than others (60). It is especially the restrictions in the diet, 
mood changes and limitations in the daily life that reduces IBS-patients QoL (61).  
 
1.2.3 Pathophysiology and causes 
IBS is a multifactorial disease (1). There are many different hypotheses about the development. 
The abdomen and the bowel are more sensitive to extern- (food, stress, psychosocial 
disturbance) and intern stimulus and this leads to altered motility and reflexes in the gut (62). 
Stress and anxiety can affect the stomach’s motor function and therefore worsen the situation 
(63-65). Changes in the diet and/or the emotional life in a person with IBS can give abdominal 
symptoms more often than in people without IBS. This is called visceral hypersensitivity (66, 
67), and the mobility in the abdomen and the gut is altered and causing a gastrointestinal 





The syndrome is often called “the brain-gut axis syndrome”, since researchers believe that 
people with IBS are more sensitive and have alterations in brain-gut signals. Different nutrients 
activate different receptors and control evacuation. It is particularly CCK (cholecystokinin) and 
serotonin that are changed in people with IBS (68).  
 
Other possible causes are genes, microbiota, low grade inflammation and food intolerances. The 
syndrome can also arise after an infection (post-infectious IBS), like for example the Giardia-
breakout in Bergen in 2004 (69, 70). Infections and inflammations leads to approximately 10-
20% of the IBS-onsets (1).  
 
1.2.4 Epidemiology 
The syndrome is more common in women than men (1). The prevalence is about 9-23% (71), 
but it is expected that it is actually higher. The disease is often symptomatic in stressful 
situations and transitional periods in life, especially in people younger than 45 years (72). 
 
1.2.5 Diagnosis 
IBS is a diagnosis of exclusion. Differential diagnoses like coeliac disease, food intolerances, 
colorectal cancer, bacterial overgrowth and inflammatory bowel diseases have to be excluded 
before diagnosing IBS (1).  
 
The Rome III criteria are used to set the diagnosis. The diagnostic criteria are:  
Recurrent abdominal pain or discomfort at least 3 days per month during the last 3 months, 
present for at least 6 months, associated with two or more of the following:  
1. Improvement with defecation 
2. Onset associated with a change in frequency of stool 
3. Onset associated with a change in form (appearance) of stool (73) 
 
There are three different categories of the disease according to what form of stool that is 
predominant; diarrhoea (IBS-D), constipation (IBS-C) or a mix (IBS-M) (4, 73). IBS can be 





Breath tests are used to measure the amount of methane and hydrogen in exhaled air. 
Unabsorbed saccharides in the gut will lead to gas production by bacteria in the colon. Then, the 
gases will be absorbed into the blood and excreted in the breath. In this way, malabsorption of 
carbohydrates and then fermentation can be evaluated (1, 4, 75). Before this test, the patient 
can’t eat or drink for at least 10 hours. Studies (76, 77) have found that 22-54% of patients with 
IBS have a positive hydrogen or lactulose breath test. Nevertheless, there is not always a 
correlation between symptoms and amount of gas produced in the gut (78, 79).   
 
1.2.6 Treatment 
There is no satisfactory medical treatment for IBS (80). It is important to tell the patients that the 
condition is without risk and not an organic damage. The syndrome can nevertheless be 
annoying and have a negative impact on the patient’s social life (1). The recommended strategy 
is to combine dietary management with pharmacological- and lifestyle management. Probiotics 
and peppermint oil may have an effect. Kerutabs and Lactrase (lactase enzymes) are medications 
which can be used if a patient is bothered with diarrhoea after ingesting lactose. These 
medications are taken together with food rich in lactose, and can be used when eating at 
restaurants etc. (41). Faecal transplantation is another possible treatment, but there is a need for 
more research in this field.  
 
Dietary management 
Dietary management is amongst the best management for IBS. It is hard to give general dietary 
advice to people with IBS since the toleration for different types of food can be very different 
(81). Patients with IBS should be encouraged to eat a normal, varied and healthy diet (1) with 
small and frequent meals (5-7 a day) instead of few and big meals. The goal for the nutritional 
management is to secure an adequate intake of all the macro- and micronutrients and to reduce 
symptoms. It is important that there are as few restrictions as possible in the diet (41). 
 
Fatty, roasted, spicy or smoked food, caffeine, alcohol, lactose, fructose and sorbitol can often 
cause problems when having an irritable bowel. It is also important to sleep enough, be 
physically active, drink enough water, and aim to have regular evacuations (1).  
At Haukeland University Hospital (HUS), patients are offered two days on an IBS-school. Here 
they will get information from a doctor, a clinical dietitian, a psychologist, a physiotherapist and 
also a representative from the Norwegian Labour and Welfare Organisation.  
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1.3 The low FODMAP diet 
 
1.3.1 Background and hypothesis 
The low FODMAP diet was invented by Sue Shepherd and her Australian colleagues in 1999 at 
Monash University for people with IBS (82). The diet is well documented (67, 75, 83-90) and 
may give symptom relief instead of curing the disease (67). FODMAP is an acronym for 
fermentable oligosaccharides (fructans and galactans), disaccharides (lactose), monosaccharides 
(fructose) and polyols (sorbitol, mannitol, xylitol, maltitol etc.). These are short-chained 
carbohydrates and sugar alcohols which are not fully digested in the small bowel and will 
therefore be fermented by bacteria in the colon.  
 
Malabsorption of FODMAPs happens to everyone to a certain degree (91), but patients with IBS 
will have abdominal pain or other symptoms as a consequence. The FODMAPs have a high 
osmotic effect, gas and short-chained fatty acids are produced (see figure 5) and this can cause 
pain, flatulence, an alteration in the motility and sensation of the gut and altered evacuation 
pattern (diarrhoea, constipation) (1, 4, 54, 92).  
 
Figure 5: FODMAPs are poorly absorbed in the small intestine and can cause gas production and 
abdominal symptoms (75). 
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1.3.2 The different FODMAPs 
Fructose is a monosaccharide and is transported across the intestinal epithelium to a low degree 
by GLUT-5 (fructose transporter 5). A very high intake of fructose will not be absorbed (with or 
without IBS). Around 50% of the world’s population have problems absorbing 25 g of fructose 
(93). The absorption is more effective if a glucose-molecule is absorbed together by the GLUT-2 
(glucose transporter 2). On a low FODMAP diet fructose should therefore not be eaten in excess 
of glucose. On the other hand, eating fructose together with sugar alcohols can worsen the 
absorption.    
Lactose is a disaccharide consisting of galactose and glucose. The enzyme lactase hydrolyses 
lactose so it can be absorbed into the blood. People with IBS can have brush-border enzymes 
with a reduced activity, and this can lead to a lactose-malabsorption. Approximately 2-3% has 
lactose-intolerance in Norway, while as many as 70-90% has it worldwide (94). A double-blind 
clinical trial found that 17 out of 70 (24.3%) patients with IBS vs. 2 out of 35 (5.7%) of the 
controls had lactose intolerance (95). In comparison, a case-control study performed in Norway 
found the prevalence to be 4.1% in IBS-patients and 3.8% in the controls (96).  
 
Oligosaccharides consist of between two and ten monosaccharides. Galacto-oligosaccharides 
(GOS) are fructose, galactose and glucose connected to each other. The two main types are 
raffinose and stachyose.  
Another group of oligosaccharides are fructans which consist of fructose-molecules and a 
glucose-molecule. There are two main subgroups. Fructo-oligosaccharides (FOS) have less than 
10 monosaccharides while inulin has more than 10. Inulin and FOS are often added to gluten 
free products to raise the content of dietary fibre. The mean intake of fructans in England is 4 
g/day and 2,6 g/day in USA (97). Approximately 69% of the fructans being consumed in 
England is from wheat (97). Type of grain, growth conditions and preparation method affect the 
amount of fructans in grain. Everyone (including people without IBS) has a lack of hydrolase 
enzymes which breaks down the bindings in these saccharides, which leads to a malabsorption 
of galactans and fructans, and then symptoms for IBS-patients.  
 
Polyols are sugar-alcohols that are too big to get transported passively through pores in the gut 
(98). They are absorbed slowly and incomplete. IBS-patients also have a lack of transport 




1.3.3 The diet 
The principle of the diet is to first have a very low intake of food rich in FODMAP for six weeks 
and thereafter start gradually to introduce one FODMAP group at a time, and find an individual 
limit of tolerance for FODMAPs (99). There is no threshold level or an absolute amount of 
FODMAP that is well tolerated. FODMAPs have an accumulating effect. Therefore, it will vary 
between patients which of the different FODMAP groups and what total amount that is 
tolerated. Patients should be guided by a dietitian and it is important to not exclude more food 
than necessary. The dietitian should emphasize that FODMAPs are carbohydrates, but it is 
anyhow not a low carb-diet. Food such as clean meat, poultry, fish, egg, fats and oils do not 
contain FODMAPs and can be eaten. Glucose, sucrose, dietary fibre and starch usually do not 
give symptoms, and can be a part of the diet.  
 
Table 1 shows food rich in the different FODMAP groups. These foods should be avoided or 


















Table 1: Food high in FODMAP (99).  
FODMAP group Food with a high amount of FODMAP 
Fructans and galactans Cereals: Wheat and rye. 
Vegetables: Artichoke, asparagus, beetroot, 
sprouts, broccoli, onion, cabbage, fennel, 
garlic, peas, shallot.  
Legumes: Chick-peas, lentils, beans. 
Fruit: Watermelon, apple, peach, Japanese 
persimmon.  
Lactose Milk (from cow, goat and sheep), ice cream, 
soft cheeses (cottage cheese). 
Fructose Fruit: Apple, pear, peach, mango, garden 
pea, hermetic fruit, watermelon, dried fruit, 
fruit juice. 
Sweeteners: Honey, corn syrup. 
Polyols Fruit: Apple, apricot, cherry, pear, nectarine, 
peach, plum, prune, watermelon. 
Vegetables: Avocado, cauliflower, 
mushroom. 
Sweeteners: Sorbitol, mannitol, isomalt 
maltitol, xylitol and others with the ending «-
ol». Chewing gum and sugar free pastilles. 
 
Phase 1: Strict low FODMAP diet for six weeks 
The intake of food rich in lactose, polyols, fructose and the oligosaccharides fructans and 
galactans should be reduced or avoided in the first period of six weeks. Food with more glucose 
than fructose can be eaten, but not the other way round (67). It can be a good idea to only eat 






Phase 2: Reintroduction 
After six weeks on a low FODMAP diet, the reintroduction should start (see figure 6). This can 
be a demanding and complicated process. It is important to introduce the FODMAPs gradually 
and only one group at a time. If this is done systematically, it is easier to find out what foods that 
















Figure 6: Testing schedule for the reintroduction phase (99). 
 
Figure 6 is showing an example of a testing schedule for how the FODMAPs can be 
reintroduced (99). If symptoms occur when introducing one of the FODMAPs, the group should 
be avoided. This does not mean that this food has to be avoided for the rest of the life, so it is 





FODMAP, the amount should be doubled the next day and symptoms monitored. On day three, 
the amount can be tripled. If the patient does not get any symptoms after day 3, the FODMAP 
group is tolerated and can be a part of his/her diet. Then, a new FODMAP group can be tested.  
 
Some foods are more suitable for the reintroduction phase. Here are some examples (100): 
- Galactans: 2 tablespoons with beans or lentils 
- Fructans: ½ piece of bread (wheat/rye), 1 tablespoon prepared onion, leek or 1 clove garlic 
- Lactose: 125 ml milk or 1 slice of brown cheese (15 g) 
- Fructose: ¼ mango or 1 teaspoon with honey 
- Polyols: 2 dried apricots, 1 sugar free chewing gum or some sugar free pastilles with sorbitol 
 
1.3.4 Evidence basis 
In 2006 Shepherd and Gibson did a pilot study with 62 patients with IBS and fructose 
malabsorption (101). 74% of all the patients in the study responded positively in all abdominal 
symptoms (p<0.01). In 2008 the first randomized placebo-controlled study on IBS patients with 
fructose malabsorption came (82). It included 25 patients and found that symptoms were 
induced in a dose-dependent manner. Fructose and fructans caused more symptoms than placebo 
(glucose). The conclusion was that a restriction of poorly absorbed short-chain carbohydrates in 
general is likely responsible for symptomatic improvement in IBS patients.  
 
Another study performed by Staudacher et. al in 2011 did also state that a low FODMAP diet is 
the ideal IBS diet (85). The researchers compared the traditional IBS-guidelines with low 
FODMAP diet. The participants who ate a diet low in FODMAPs had a greater improvement in 
all the typical IBS symptoms (flatulence, abdominal pain, passage of wind, diarrhoea, nausea, 
fatigue and total), except constipation, than the participants who ate a standard IBS diet. 
Nevertheless, both diets caused an improvement in symptoms, but the low FODMAP diet had a 
statistically significant better effect than the traditional IBS diet.  
Halmos et. al (2014) did a randomized controlled crossover study including 30 patients with IBS 
and 8 healthy controls (86). The participants were randomized into two groups; one should be 
eating a diet low in FODMAPs for 21 days, and the other should eat a typical Australian diet for 
21 days, and there was a wash-out period lasting for at least 21 days in both groups - before they 
exchanged diets. Symptoms were registered. Patients with IBS had less gastrointestinal 
symptoms (flatulence, abdominal pain, gas production and hydrogen in exhaled air) when they 
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were eating the diet low in FODMAP compared to the Australian diet. The conclusion was that a 
low FODMAP diet effectively reduces symptoms and should be used as first-line-therapy in 
people with IBS.   
 
NICE (National Institute for Health and Clinical Excellence) (102) and other British 
recommendations (103) also recommend a diet low in FODMAPs for patients with IBS. A study 
(104) compared traditional dietary IBS-advice and the low FODMAP diet. Symptoms were 
reduced in both groups, and the researchers concluded that a low FODMAP diet reduces the IBS 
symptoms as good as traditional dietary IBS-advice. 
 
A recent meta-analysis published in April 2016 supports that a diet low in FODMAPs is a good 
treatment for functional gastrointestinal symptoms (105).  
 
The most of the studies are done in Australia. One Danish study did also find an effect of the 
low FODMAP diet on patients having IBS (106). There is probably also a mental component 
with the effect of the diet (60). There is a need for more studies from our own population and to 
investigate long-term effects of the low FODMAP diet (17).  
 
1.4 COELIAC DISEASE AND IRRITABLE BOWEL SYNDROME 
Till now, I have written about coeliac disease and IBS separately. The patients in our study 
though, had coeliac disease with residual symptoms compatible with IBS. Patients with for 
example IBD like Crohn’s disease and ulcerative colitis can also have residual symptoms 
compatible with IBS (IBD-IBS).  
 
The majority of coeliac disease patients will feel symptom relief when adhering to a strict gluten 
free diet. Nonresponsive coeliac disease is a condition where the patient still feel abdominal 
symptoms or is having laboratory abnormalities in spite of following a gluten free diet for at 
least six months (107). Leffler et. al reports that 19% of their coeliac patients have 
nonresponsive coeliac disease (108). The main reason for still feeling symptoms is not being 
strict enough and therefore being exposed to gluten (36-51% of the patients) (108-110). 
Serological testing is useful to predict a potential non-adherence to the diet. Both the duration 
and the degree of gluten exposure will affect the tests. Other reasons for nonresponsive coeliac 
disease are IBS-like symptoms (our patients), refractory coeliac disease, lactose intolerance, 
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pancreatic insufficiency etc.  
 
A study by Stasi et. al (107) found that 21.8% of the patients in their study still had typical 
coeliac symptoms. They evaluated the cause in 80% of these patients, 15 had normal histology 
when doing gastroscopy. Out of these, 9 had IBS-like symptoms in addition to their coeliac 
disease.  
 
Some will therefore still have abdominal symptoms compatible with IBS in spite of eating a 
gluten free diet (111). One study found that 20-50% fulfilled the Rome III criteria (112, 113), 
while another found 38% (114) and again a study (108) found that IBS-like symptoms was the 
cause for having nonresponsive coeliac disease in 22%. The inflammation of the mucosa seen in 
coeliac disease is thought to predispose for IBS (113), and these patients will likely benefit from 
a diet low in FODMAPs (67, 86).  
 
1.5 PURPOSE AND OBJECTIVES 
Several studies have found an effect of reducing the intake of food rich in FODMAPs when 
having an irritable bowel. As far as we know, there are no published papers on low FODMAP 
diet to patients with coeliac disease. The purpose of this project was to investigate whether 
patients with coeliac disease and IBS-like symptoms could have a benefit on abdominal 
symptoms and quality of life, from a reduction in FODMAP in addition to their gluten free diet. 
We also wanted to investigate whether a low FODMAP diet would have any effect on the gut 
microbiota and the degree of fermentation by gut bacteria, measured with breath tests and stool 
samples.  
 
The objective was to investigate whether the low FODMAP diet could be a helpful 
supplementary treatment for coeliac patients with IBS-like symptoms or not.  
 
Ha1: A FODMAP reduction in addition to a gluten free diet will give symptom relief and 
increased quality of life in coeliac disease patients with IBS-like symptoms.  





2. METHODS AND PATIENTS 
 
2.1 Choice of project, planning and applying to REK 
The future master projects where presented by the supervisors 21.11.14. We started to plan the 
project and the optional subject “Z-K1” with focus on coeliac disease and IBS was created. 
Scientific protocol (see attachment 12) and information letters (see attachment 13) were made. 
During the spring, we had meetings, attended the IBS-school and learned how to use the 
machine for the breath tests. 
 
REK approved our application in July 2015 (see attachment 14). In the autumn 2015, Jan 
Gunnar Hatlebakk, Gudrun E. Kahrs, Ida Strindmo and I continued to meet for short meetings 
approximately every second or third Tuesday. I started to read background information and we 
planned the project.  
 
Implementation and logistics like available rooms, keys, teaching, ordered equipment for breath 
tests and stool specimens, storage of samples, envelopes for randomization, envelopes and 
stamps for sending questionnaires, schemes for travel expenses, interpretations of questionnaires 
etc. were discussed. Jan Gunnar Hatlebakk, Gro Olderøy and Trygve Hausken helped us with 
this. We also had a meeting with Eva Rosendahl (clinical dietitian working with coeliac disease 
at Haukeland University Hospital) were we got some advice for the teaching in the more strict 
gluten free diet without wheat starch and “traces of gluten”. We asked her to contact us if she 
met some patients who could fit in our study. In April, an abstract was sent to the ESPEN 
conference in Copenhagen (see attachment 16) and later also to UEGW (see attachment 17) in 
Vienna.   
 
2.2 The project 
The study was an open, prospective, randomized and controlled clinical study carried out in co-
operation between the University of Bergen (UiB) and the Medical Department at Haukeland 
University Hospital in Bergen.  
 
2.3 Recruitment of patients  
The objective was to include 40 patients in the study (group A and B). There are approximately 
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500 000 inhabitants in Hordaland, and about 1% (5000) of these has coeliac disease. Around 
20% (1000) of these will statistically also have IBS.  
Inclusion criteria: 
- Confirmed coeliac disease diagnosis for at least 6 months 
- IBS-like symptoms confirmed by the Rome III criteria 
- Score > 75 on the IBS-SSS-questionnaire 
- 18-75 years of age 
 
Exclusion criteria: 
- Subjects with therapy-resistant coeliac disease 
- Recent biopsy with abnormal findings 
- Relevant comorbidity 
- Problems with eating a strict gluten free diet 
- Following a low FODMAP diet at the moment 
- Following a natural gluten free diet at the moment  
 
Many different methods were used to recruit enough patients: 
 
NCF - The Internet, Facebook and e-mails 
An announcement about the project where made and NCF (Norwegian Coeliac Society) was 
contacted. The announcement was published on NCF’s national web page and Hordaland’s 
regional web page. In addition, information about the project was published on NCF’s, NCFU’s 
(Norwegian Youth Coeliac Society), NCFU Hordaland’s Facebook page and one called “Coeliac 
disease”. NCF Hordaland’s and NCFU Hordaland’s leaders were asked to e-mail this 
information to all their members, and it was done to a certain degree. Around 11-15 interested 
people e-mailed us, they were called and appointments were made. Some changed their minds, 
others were excluded and the rest included. The purpose was to try to only recruit patients from 
Hordaland, but after a while we had to include two from Trondheim, one from Oslo and one 
from Molde to get enough participants. Information was put on my personal Facebook-account 





LMS – Earlier participants and waiting lists 
LMS (Learning and Mastery Centre in Bergen) at Haukeland University Hospital was contacted 
and asked if it was possible to get email addresses to all previous participants. LMS is teaching 
newly diagnosed coeliac patients about the gluten free diet and how to cope with the disease. 
Unfortunately, we did not get their email addresses, but lists with names back to 2008 and lists 
for the upcoming courses were collected. In total, there were about 20 lists with 13-20 names on 
each. All the names were looked up in DIPS (an electronic medical record-system) and the 
medical records were searched for relevant information. Then, we called all the possible 
participants which met the inclusion criteria. This was a long process which lasted for many 
days/weeks. They were asked how it was going and if they still had any abdominal pain, 
diarrhoea or constipation problems. Most of them were fine and therefore not proper participants 
for this project. The ones who still had abdominal problems were informed about our project, 
and told that we would call them back later with more information about start-up. Later, 
appointments were made.  
 
Waiting lists for LMS’s coeliac school and the IBS-school were collected. Again, medical 
records were checked in DIPS and suitable patients contacted. It was hard to find people who 
fulfilled the criteria since most of the ones who were called, did not have symptoms anymore. 
 
The Coeliac Disease Outpatient Clinic – Earlier and new referrals 
Another strategy for recruiting participants, was lists with patients who were referred back to the 
coeliac disease outpatient clinic at Haukeland University Hospital. Lists for the rest of 2015 
were collected. Again, we checked their medical records and called all the suitable participants. 
Only four possible participants were called.  
 
All the patients were checked up in DIPS who had been to the coeliac disease outpatient clinic 
the last year, since 01.01.15. Many of these were not considered possible participants for 
different reasons: already evaluated, comorbidity like IBD for example, problems with eating a 
strict gluten free diet, eating a gluten free diet for a short period of time, no abdominal 





Figure 7: The design 
NCF Hordaland meeting  
The project was also presented at a NCF Hordaland meeting 19.09.15. Some said they were 
interested in participating, but none contacted us later on. We considered attending other 
happenings arranged by NCF, but found out that a baking course wasn’t the right arena to 
present our project. A request for putting information about the project on the web side was also 
sent to Semper. 
 
Announcement in newspapers (BT and BA) and posters 
Announcements in the newspapers Bergens Tidende and Bergensavisen were published, but the 
response was unfortunately disappointing. An application was sent to REK VEST with the 
proposed text before they were printed. The same announcement (see attachment 15) was put on 
28 different walls, for example at Rema 1000, Bunnpris, the BBB-building, the Laboratory 
building, in the cafeteria at the hospital, the student cafeteria, in the medical outpatient clinic, 
next to different elevators and escalators etc. Approximately 3 people called us after seeing one 
of these, but only one was included. 
 
2.4 Design 
There were two groups in the study; group A which followed a more strict gluten free diet 
without wheat starch and “traces of gluten”, and group B which followed a low FODMAP diet 











Figure 8: Time schedule.  




Randomization was used to split the 40 patients by chance into two treatment groups. This was 
to avoid bias. The randomization list was based on secret variable block sizes. There should be 
just as many A’s as B’s, but we did not know at what number between 40 and 50. The list was 
made by a person not involved in the study. We got envelopes labelled with numbers, and 





Baseline: The first appointment 
The first appointment with each participant lasted for about 15-30 minutes. Usually, we both 
attended these meetings which were held in the second floor in the central building at Haukeland 
University Hospital, medical outpatient clinic. The patients were informed about the study; 
background, objects and design. The patients read the information letter and we emphasized that 
it would be completely random which of the two groups the patient would end up in and that 
they could drop out at any time if they changed their minds. Then, both the patient and we 
signed two information letters, and the questionnaires Rome III and IBS-SSS were filled in by 
the patient. If the patient fulfilled the criteria for being a participant in the project, we gave 
information about breath tests and blood tests, and made two new appointments. They were 
asked to fast for 10 hours before the breath tests which measures the amount of hydrogen and 
methane in a person’s exhaled air. They got equipment and advice for taking a stool specimen 
and how to fill in a dietary intake record, and we told them to bring this next time. In the 
33 
 
meantime, the participants could contact us anytime if they had questions, both by phone and 
email.    
 
Baseline: The second appointment 
The second meetings were held in the morning between 07.30 and 11.30 because of the fasting. 
Sometimes we had meetings one and one; other times groups of 2-3 people. Breath tests and 
blood tests were done, stool specimens and dietary intake records collected, the participants 
filled in the SF-36 (short-form health survey)-questionnaire and were told which group they 
were in. Thereafter they got thorough counselling in either a more strict gluten free diet without 
wheat starch and “traces of gluten” (group A) or low FODMAP diet (group B) without gluten as 
described in the introduction, and got brochures with information.  
 
The patients in group A were told to continue eating a gluten free diet, to be careful with 
hygiene and eating outside the house, and be aware of possible contamination sources. In 
addition they should exclude all wheat starch from their diet and food labelled “traces of gluten”. 
Wheat starch is cleansed for gluten, but some coeliac patients with a very sensitive bowel can 
still get symptoms. “Traces of gluten” does not mean that the product consists of gluten; but that 
the product is made in surroundings were products with gluten also is made, so there is a risk of 
contamination. This more strict gluten free diet is today’s treatment practice, and we wanted to 
compare it to a low FODMAP diet, which the patients in group B followed.  
 
A new appointment after six weeks were agreed and the participants got new equipment for a 
stool sample, dietary intake record and an IBS-SSS questionnaire which should be filled in after 




All the patients were called 3 weeks after they started on one of the diets to hear how it was 
going, if they had any benefits from following the diet and they could ask us questions if they 
had any. They were also reminded about the IBS-SSS questionnaire, the dietary intake record 






These visits were similar to the baseline visits. Breath test and blood test were done and we got a 
new stool sample and a new dietary intake record. Again, the patients filled in SF-36 and IBS-
SSS. They could also fill in a bill for travel expenses if they wanted to. In addition, they filled in 
a compliance questionnaire which was different dependent on which group they were in.  
 
The patients in group A were offered teaching in the low FODMAP diet and got the same 
brochure that the patients in group B. Patients in group B were instructed in the reintroduction 
phase of the FODMAP diet, and told to contact us later if they had any questions. 
 
10 weeks  
Patients in group B were also asked to send a compliance form to us after four new weeks (10 
weeks after starting on the low FODMAP diet), and got a post-paid envelope for this. 
 
A medical record was written in DIPS to every patient to document their participation in the 
project and wrote if they had an effect of the diet or if follow-up was needed. This was also sent 




2.7.1 Dietary intake record 
A dietary intake record measures a person’s quantitative food intake, is the gold standard and is 
very precise (1). The goal is to measure the actual intake, though it is natural that it (and 
therefore also nutrients) will vary from day to day and also with the time of the year. In our 
study prospective weighed food records were used. The registration form is developed by the 
Department of Clinical Nutrition at Haukeland University Hospital (see attachment 7). The 
patients were supposed to record everything that they had been eating and drinking for four days 
at two different times; at baseline and after following one of the diets for six weeks. One of the 
days should be a weekend day because people’s eating habits are usually different then. They 
were told to be as precise as possible and to write down amounts/weights in addition to 
manufacturer etc. These records were used to calculate the amount of macronutrients, 





Basal metabolic rate (BMR) is the energy one need to sustain metabolic activity of cells and 
tissues and to maintain blood circulation and respiration when awake. We need 50-65% of our 
total energy needs to basal metabolism, 10% to thermic effects of food and 30-50% to physical 
activities. Age, body temperature, stress and hormones can affect BMR. BMR is calculated by 
different standardized equations from the World Health Organization (115) that consider gender, 
age, weight and height. BMR-factor is then calculated by dividing energy intake for each person 
by their BMR. This factor was used to evaluate the degree of underreporting of energy intake in 
the patients dietary intake records at baseline. 
 
2.7.3 Blood test 
Serological tests were ordered for each patient in DIPS at baseline and after six weeks. We 
wanted to look at antibodies and nutritional status. 22 different analyses were done: 
Haemoglobin, MCV (mean cell volume), leukocytes, thrombocytes, cobalamin, folate, ferritin, 
CRP (C-reactive protein), creatinine, GFR (glomerular filtration rate), sodium, potassium, 
calcium, ALAT (alanine aminotransferase), ALT (alanine transaminase), GT (gamma-glutamyl 
transpeptidase), albumin, TSH (thyroid-stimulating hormone), PTH (parathyroid hormone), 
Vitamin D3, anti-transglutaminase 2 IgA and anti-deamidated gliadin IgG. The blood tests were 
performed by bioengineers at the Laboratory for Clinical Biochemistry (LKB) at Haukeland.  
 
2.7.4 Breath test and stool samples 
These methods are not described here, because it is done in another Master’s Thesis by Ida 
Strindmo 2016.  
 
2.8 Questionnaires  
 
2.8.1 Rome III criteria for IBS 
The Rome III questionnaire was developed by the Rome Foundation in 2006 and is used to 
diagnose patients with IBS. It has five main questions about abdominal symptoms (see 
attachment 1). Answering “yes” on the first two questions (1.1 and 1.2) and two of the three 
following (1.3-1.5) is compatible with the diagnosis (73). Accordingly, there are five 




In our study, the patients filled in this questionnaire at the first meeting. Their IBS symptoms 
had to be confirmed by this questionnaire to be included in the study.  
 
2.8.2 IBS-SSS 
IBS-SSS is short for Irritable Bowel Syndrome Severity Scoring System and is a standardized 
and validated (74, 116) questionnaire measuring the severity and frequency of the patient’s IBS 
symptoms (see attachment 2). There are five main questions with a score on a VAS (Visual 
analogue)-scale from 0-100 mm about abdominal pain severity (2b), abdominal pain frequency 
(2c), abdominal bloating severity (3), dissatisfaction with bowel habits (4) and interference with 
daily activities (5). Question 2b, 3, 4 and 5 give a score from 0 to 100, where 0 is no 
symptoms/very pleased and 100 is severe symptoms/very displeased. Question 2c gives a score 
from 0-10, which is multiplied by 10. In addition, there are some supplementary questions about 
other common symptoms like headache, fatigue, nausea, muscle pain etc. 
  
IBS-SSS gives a total score between 0-500, where <75 is remission, 75-175 is mild, 176-300 
moderate and >300 severe IBS (116).  A reduction in 50 or more in total IBS-SSS score is 
considered clinically significant and a response to the treatment. In our study, the patients filled 
in this questionnaire at baseline, after 3 weeks and after 6 weeks. At baseline, they had to score 
more than 75 in total on question 2b, 2c, 3, 4 and 5 to be included in the study. 
 
2.8.3 SF-36 
SF-36 is a questionnaire developed from the Medical Outcomes Study (MOS) and is an 
abbreviation for The Short Form (36) Health Survey. The second version translated to 
Norwegian was used in this study. It has 36 questions about physical and mental health (see 
attachment 3). There are questions about the patient’s activity level, general health, severity of 
symptoms etc. It is used to get a picture of how the patient’s quality of life is affected by 
different diseases and is generic meaning that it can be used for different ages and diseases. The 
patients get two main scores - physical and mental, and in addition 8 dimensions. The 8 
dimensions are physical functioning, role-physical, bodily pain, general health, vitality, social 
functioning, role-emotional and mental health. By using formulas where the different questions 
and dimensions are weighed different, the first four aspects together give the physical 
component summary (PCS), and the last four give the mental component summary (MCS). The 
participants are scored between 0 and 100 in each of the eight dimensions, where 0 is the lowest 
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HRQOL (health related quality of life), and 100 the highest. This method is considered valid in 
many studies (117-120). In our study, the patients filled in this questionnaire at baseline and 
after six weeks.  
2.8.4 Compliance with low FODMAP diet (group B) 
A compliance questionnaire made by previous master students in clinical nutrition was used to 
assess adherence to the low FODMAP diet through the 6 weeks in group B (see attachment 5). 
There were questions about the effect, accuracy, if they want to continue following the diet, 
deviation, extent and reason for deviation etc. Three of the questions had a VAS-scale from 0-
100. They also got a questionnaire about compliance four weeks after finishing the first phase of 
the diet (see attachment 6), and were asked to send it to us by mail. This questionnaire included 
questions about compliance, reasons for quitting the diet (if they quitted), the reintroduction 
phase etc.  
 
2.8.5 Compliance with a more strict gluten free diet (group A) 
Based on the compliance questionnaire for the low FODMAP diet mentioned above, we made a 
similar for the more strict gluten free diet through the 6 weeks (see attachment 4). There are 
questions about effect, accuracy, if they want to continue following this diet, deviations, extent 
and reason for deviation etc. Three of the questions had a VAS-scale from 0-100.  
 
2.9 Delivered information 
Patients in group A got the brochure “Kostråd til deg som skal spise glutenfritt” developed by 
the Department of Clinical Nutrition at Haukeland (see attachment 8) (41). In this brochure the 
patients could read more about coeliac disease, a gluten free diet, find lists of gluten free 
ingredients and products, list of ingredients containing gluten, advice and recipes. In addition, 
they got a list with products without wheat starch and the labelling “traces of gluten”, at baseline 
(see attachment 9).  
 
Patients in group B got the brochure “Kostråd ved irritabel tarm, FODMAP redusert kost» also 
developed by the Department of Clinical Nutrition at Haukeland, but done gluten free by us, at 
baseline (99). This brochure was also given to patients in group A after six weeks (see 
attachment 10). In this brochure the patients could read more about the background for the diet 
and the different phases. There are also lists with «yes» and «no»-food, alternatives and recipes, 
which makes it easier to go through such a diet. The patients in group B also got a list with 
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ingredients which are gluten free, but still high in FODMAP (inulin, apple fibre, oligo fructose 
etc.), at baseline. There was also a list with products which are both gluten free and low 
FODMAP (see attachment 11). We also informed about books and an application for smart 
phones.  
 
2.10 Dietist Net Free and the Factory Table 
All the data from the dietary intake records were entered into Dietist Net Free delivered by 
«Kost och Näringsdata AB” in Sweden. This is a program for nutrient calculation based on the 
Norwegian “Matvaretabellen”, the Danish “Fødevaredatabanken” and the Swedish 
“Livsmedelsverkets database”. The free version was used to calculate the amount of total 
FODMAPs in the patient’s diet at baseline and after six weeks after following a diet. In addition 
the intake of lactose and non-lactose FODMAPs were looked at. FODMAP contents in different 
foods were not in this database before, so we had to make our own database. Australian studies 
(121, 122) were used and also some Danish and Norwegian data (123, 124) and some American 
(125). The data were first entered into Excel and then into the Factory Table which was linked to 
Dietist Net Free. There are no data on FODMAP content in composite products like pizza, 
lasagne and sauces. Standard recipes from www.matprat.no were therefore used for estimations 
(126). The content in spices, hot dogs and liver paste where not included because of secret 
recipes, and the data would therefore be unprecise.  
 
2.11 Kostholdsplanleggeren  
Kostholdsplanleggeren is a tool for assessing the amount of energy, macronutrients 
(carbohydrates, dietary fibre, fat, proteins) and micronutrients (vitamins and minerals) in a 
person’s diet. All the dietary intake records (four days each at baseline and 6 weeks) from all the 
participants in the two groups were put in this program, and nutrition facts came out.  
 
2.12 Data analyses 
All the raw data from the questionnaires (Rome III, IBS-SSS, SF-36, compliance), the dietary 
intake records, blood tests, breath tests and stool samples were plotted into Microsoft Excel. In 
Excel, means were calculated and values compared between the different groups and also at 
different time points. The data were then copied to and analysed in the statistical program 
GraphPad Prism 6 which is developed by GraphPad Software Inc., San Diego, California, USA. 




D’Agostino & Pearson omnibus normality test was used on all the data to check if it were 
normally distributed. Normally distributed data were analysed with paired t-tests when having 
matching pairs of data in one group (baseline and 6 weeks from group A or group B), and 
unpaired t-tests when having two separate sets of data (from group A and from group B at 
baseline or 6 weeks). RM one-way ANOVA with Geisser-Greenhouse correction assuming no 
sphericity was used to find the trend when having three or more time points, sometimes with 
Tukey’s multiple comparisons test.  
Non-parametric data were analysed with Wilcoxon matched-paired test (paired data), Mann-
Whitney test (unpaired data) or Friedman when having three or more time points, sometimes 
with Dunn’s multiple comparisons test. The F statistics is found by dividing the variance 
between the groups by the variance inwards a group. A high Friedman statistics means that the 
treatment has a good effect.  
Chi-squared test was used for categorical data, and Fishers exact test when there were numbers 
lower than 5 in at least one of the boxes.  
Correlation analyses were performed. Pearson test was used when the data were normally 
distributed and Spearman test when they were not.  
 
Outliers were checked for in all the data sets by using the ROUT-method in Prism, Q= 1%. After 
removing the outliers, the normality test was repeated and the new p-value compared to the old. 
Nevertheless, all the extreme values were included since the patient group is heterogenic.  
 
Two different methods were used to calculate scores from SF-36. First, all the data from every 
questionnaire were put in an electronical calculator: http://www.sf-36.org/demos/SF-36v2.html 
(127). Scores for the eight dimensions and the two main categories were calculated. These 
scores can be used to look at differences before and after an intervention, but the calculator does 
not adjust for age and sex. These scores can therefore not be used to compare with other studies 
and are not presented here. Thereafter, all the answers from all the questionnaires with different 
numbers of alternatives were entered into Excel. For some of the questions answering “1” is the 
worst alternative and for example “5” the best, while it is the opposite for other questions. The 
latter questions were therefore recoded in such a way that all the answers were comparable; 
(1=5, 2=4, 3=3, 4=2, 5=1) for example. Then, different syntaxes were used in Excel to calculate 
the scores from 0 (the worst) -100 (the best) for all the eight dimensions. There were 10 
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questions for “physical function”, 4 for “physical role”, 2 for “bodily pain”, 5 for “general 
health”, 4 for “vitality”, 2 for “social function”, 3 for “role emotional” and 5 for “mental health”. 
As an example, the formula for scoring general health is shown:  
 
GH = ((question 1 + question 11a + question 11b + question 11c + question 11d - 5) /20) * 100. 
 
Then, to be able to compare the scores with other studies and normal values for the Norwegian 
population, other formulas were used in SPSS to make norm based scores were 50 is the mean 
and 10 the standard deviation in a general population (128, 129) . Each of the scores for every 
patient was compared to what is normal in a general population when age and sex were taken 
into consideration. Again, the formula for scoring the norm based score for general health is 
shown:  
 
GH = 50 + 10 * (actual score - normal score) / 21.72,  
 
where 21.72 is the standard deviation of the scores for general health in the general population 
(scale 0-100).  
 
Formulas in SPSS were also used to calculate PCS and MCS. General health is still used as an 
example. Z-scores were first calculated:  
 
GH = (score for general health – 72.21) / 20.17.  
 
Then, formulas (not shown) in three steps were used to calculate norm based scores for PCS and 
MCS and again compared to what is normal in a general population when age and sex were 
adjusted for (128, 129). 
 
2.13 Ethics  
The study was approved by REK and there was no risk of getting personal injury or health 
damages in this study. The intervention and the data collection might be perceived as demanding 
for some, but it would not cause any harm. The study was voluntarily, they signed an informed 







3.1 Patient responses 
We included 40 patients in the study, 20 in each group. One did not meet the Rome III or IBS-
SSS criteria and were therefore not included, while three dropped out. Sixteen people were 
recruited from the Internet; from announcements on NCF’s homepages, Facebook-pages and e-
mails. Eight people were included from the coeliac disease outpatient clinic, seven from the 
coeliac school and four from the IBS-school. Further three were included after seeing the 
announcements in the newspapers, one after seeing a poster and one by the word of mouth (see 
figure 9). 
 
   
Figure 9: The number of patients included from the Internet, the coeliac disease outpatient clinic, LMS, 
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It was clearly more women in the study (82.5%) than men (17.5%) and the mean age was 41 
years. The youngest participant was 22 years old and the oldest 73 years old. The median BMI 
was 23.2 kg/m
2
 in the total group, while the lowest was 17.8 kg/m
2
 and the highest 43.2 kg/m
2
. 
42.5% of the patients had constipation problems (IBS-C), 27.5% diarrhoea problems (IBS-D) 
and 30% both (IBS-M). In total, the mean total IBS-SSS score was 262 and none were in 
remission at baseline. 15% had mild IBS, 55% moderate and 30% severe IBS-like symptoms. 
Regarding quality of life, 44.7 (PCS) and 47.1 (MCS) were the mean scores for the total group. 
The mean BMR-factor was 1.39 and 11.1 g/day the median FODMAP intake. 6 patients had 
raised anti-transglutaminase 2 IgA-levels at baseline and 5 had raised anti-deamidated gliadin 
IgG-levels.  
 
There were no statistically significant differences in the baseline characteristics between the two 
groups (see table 2), which means that the randomization was successful. There were 18 women 
in group A and 15 in group B, whereas 2 men in group A and 5 men in group B. The mean age 





 in group B. The mean total IBS-SSS score in group A was 260 and 263 in group 
B. The mean physical component score in group A was 44.9 in group A and 44.5 in group B at 
baseline, while the mean mental component score was 47.3 and 46.9 respectively.  
 
The mean BMR-factor for group A was 1.42 and for group B it was 1.35. The median FODMAP 
intake in group A was 14.5 g/day, while it was 7.7 g/day in group B. Five patients in group A 
and one in group B had raised anti-transglutaminase 2 IgA-levels at baseline, while two and 














Table 2: Baseline characteristics in 40 patients with coeliac disease and IBS-like symptoms. An 
overview of sex, age, BMI, IBS subtype, total IBS-SSS score, severity of IBS, PCS, MCS, BMR-factor, 
total FODMAP intake, raised anti-transglutaminase 2 IgA- and anti-deamidated gliadin IgG-levels for 
group A and B. Unpaired t-tests are used for normal distributed data which are given in mean±SD, 
Mann-Whitney tests for non-normal which are given in median (IQR), Chi squared test and Fishers exact 
tests for categorical data. 
 Group A (n=20) Group B (n=20)  P-value 
Sex, n Women: 18 
Men: 2  
Women: 15 
Men: 5  
0.408 
Age, mean ± SD 39 ± 15 43 ± 12 0.308 
Age, min-max (range) 23-73 22-61  
BMI, median (IQR) 23.0 (21.5-27.3) 23.3 (20.3-26.1) 0.654 
BMI, min-max (range) 18.8-34.7 17.8-43.2  







Total IBS-SSS score, mean ± SD 260 ± 90 263 ± 70 0.889 









PCS, mean ± SD 44.9 ± 8.3 44.5 ± 8.1 0.886  
MCS, mean ± SD 47.3 ±7.5 46.9 ± 8.0 0.850 
Energy intake, (kcal/day),  
mean ± SD 
2051 ± 609 2043 ± 492 0.960 
BMR-factor, mean ± SD 1.42 ± 0.45 1.35 ± 0.31 0.585 
Total FODMAP intake, (g/day), 
median (IQR) 
14.5 (10.9-21.6) 7.7 (2.7-19.2) 0.0786 
Raised anti-transglutaminase 2 
IgA-levels, n 
5 1 0.182 
Raised anti-deamidated gliadin 
IgG-levels, n  
2 3 1 
SD= standard deviation, BMI= body mass index, IQR= interquartile range, IBS=irritable bowel 
syndrome, IBS-SSS= irritable bowel syndrome-symptom severity scale, PCS= physical component score, 
MCS= mental component score, BMR= basal metabolic rate, FODMAP=fermentable oligo-, di-, 
monosaccharides and polyols.  
 
3.3 Dietary intake record 
In group B there were statistically significant reductions in total FODMAP intake (p=0.0001), 
lactose (p<0.0001) and non-lactose FODMAPs (p<0.0001) from baseline to 6 weeks, but not in 
group A (see figure 10). The median intake of total FODMAP in group B at baseline was 7.7 
g/day, while it was reduced to 1.3 g/day at six weeks. In group A it was 14.5 g/day at baseline 
and 12.1 g/day at six weeks. There were no statistically significant differences in total FODMAP 
intake, lactose or non-lactose FODMAPs between the two groups at baseline (p=0.0786), but 
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after six weeks there were (p<0.0001, p<0.0001, p=0.0299) (see table 3 and figure 11).  
 




















In te rve n tio n  





Figure 11: Intake of total FODMAPs and distribution of lactose and non-lactose FODMAPs in g/day 
eaten by the patients in group A and B at baseline and at six weeks. Lactose is the FODMAP group that 


















There was no statistically significant reduction (but a reduction) in energy intake from baseline 
to six weeks in group A (p=0.119), but in group B (p=0.0134). The mean intake at baseline was 
2043 kcal/day for group B and 1807 kcal/day at six weeks. There were no statistically significant 
differences between the two groups at baseline (p=0.961) or at six weeks (p=0.912) (see table 3).  
 
The intake of carbohydrates, dietary fibre and calcium was not statistically significant different 
at the different time points in any of the groups and not between them. Fat intake was 
significantly lower at 6 weeks in both groups, but no statistically significant difference between 
the groups was found (p=0.187 at baseline and p=0.134 at 6 weeks). The protein intake was 
statistically significant lower at 6 weeks in group A than at baseline (p=0.048). There were no 
statistically significant differences between the protein intake in group A and B at baseline 
























Table 3: Information from the dietary intake records given in kcal, gram or milligram for group A and B 
at baseline and at six weeks. Paired and unpaired t-tests were used for normally distributed data which are given 
in mean ± SD, and Wilcoxon tests and Mann-Whitney for non-normal, which are given in median (IQR).  
  Baseline 6 weeks p-value Reference value 
Energy, kcal A 2051 ± 609 1790 ± 503 0.119 1465.9
1 
 B 2043 ± 492 1807 ± 448 0.0134* 1525.4
1 
Carbohydrates, g A 269.4 ± 94.9,  
52.5 E% 
230.4 ± 75.7,  
51.5 E% 
0.127 45-60 E%/day 
 B 227.0 ± 57.3,  
54.0 E% 
206.8 ± 72.1,  
46.0 E% 
0.0719  
Dietary fibre, g A 18.8 ± 6.8 16.5 ± 5.1 0.0973 25-35 g/day 
 B 20.7 ± 6.5 19.1 ± 8.4 0.149  
Fat, g A 80.5 ± 31.3,  
35.3 E% 
64.2 ± 24.4,  
32.3 E% 
0.0328* 25-40 E%/day 
 B 92.9 ± 27.1,  
40.8 E% 
75.3 ± 21.3,  
37.9 E% 
0.0134*  
Protein, g A 81.3 ± 30.7,  
5.9 E% 
70.7 ± 21.2,  
15.8 E% 
0.0483* 10-20 E%/day 
 B 89.2 ± 27.3,  
7.4 E% 
82.3 ± 20.4,  
18.4 E% 
0.221  
Calcium, mg A 802 (587-1109) 778 (507-986) 0.231 800 mg/day 
 B 832 (504-1044) 814 (728-970) 0.929  
Total FODMAP, g A 14.5 (10.9-21.6) 12.1 (6.4-19.5) 0.522  
 B 7.7 (2.7-19.2) 1.3 (0.9-2.1) 0.0001*  
Lactose, g A 11.3 (7.6-17.3) 10.3 (4.8-15.4) 0.784  
 B 4.7 (1.2-16.4) 0.12 (0.1-0.3) <0.0001*  
Non-lactose 
FODMAPs, g 
A 3.1 (1.8-5.5) 1.8 (0.8-3.2) 0.202  
 B 2.8 (1.6-3.1) 1.0 (0.6-1.7) <0.0001*  
1






BMR-factor was used to evaluate the degree of underreporting of energy intake in the patients’ 
dietary intake records at baseline. There is a cut-off limit at 1.35 (130). BMR-factors under this 
limit are too low to maintain the energy that the person needs and therefore suggests 
underreporting of energy intake. 9 patients in group A (45%) and 9 in group B (45%) had BMR-
factors under the cut off limit, and there was no statistically significant difference between the 
two groups (p=0.585). The mean BMR-factor though is over the cut-off limit for both groups 
(1.42 for group A and 1.35 for group B) (see table 4).  
 
Table 4: Mean ± SD BMR-factor (energy intake/BMR) and number of patients with BMR-factor under 
the cut-off limit, at baseline for group A and group B. Unpaired t-tests were used because of normally 
distributed data. 
 Group A Group B p-value 
BMR-factor baseline 1.42 ± 0.45 1.35 ± 0.31 0.585 
BMR-factor <cut-off limit, n 9 (45%) 9 (45%) 1.0 
 
3.5 Symptoms (IBS-SSS)  
The patients filled in the IBS-SSS questionnaire at baseline, during the diet at 3 weeks and at the 
end of the diet at 6 weeks. 
 
3.5.1 Total IBS-SSS score:  
The total IBS-SSS score (0-500) is found by adding the five main questions. In group A the 
mean baseline total IBS-SSS score was 259.8 and 263.3 in group B (see table 5 and figure 12). 
There were statistically significant reductions from baseline to 6 weeks in both groups 
(p=0.0022 for A and <0.0001 for B). The reductions were also statistically significant in group B 
from baseline to 3 weeks and from 3 weeks to 6 weeks, but not in group A. There was no 
statistically significant difference between group A and B at baseline (p=0.890) or at 3 weeks 







Table 5: Total IBS-SSS score at baseline, 3 weeks and 6 weeks for group A and group B. The scores are 
given in mean ± SD from 0 to 500. The data are normally distributed, so RM-one-way ANOVA is used 
inwards the two groups and unpaired t-tests between the two groups. 
 Group A Group B 
Baseline, mean (SD) 260 ± 90 263 ± 70 
              , min-max 95-440 150-406 
3 weeks, mean (SD) 225 ± 99 199 ± 99 
             , min-max 61-415 29-419 
6 weeks, mean (SD) 204 ± 76 145 ± 84 
             , min-max      46-325 33-347 
 

































p = 0 .0 0 2 2 * p < 0 .0 0 0 1 *
< 7 5 :  R e m is s io n
7 5 -1 7 5 : M ild
1 7 6 -3 0 0 :  M o d e ra te
> 3 0 0 :  S e v e re
 
Figure 12: IBS-SSS total score for every patient at baseline, 3 weeks and 6 weeks for the different 
patients in group A (n=20) and group B (n=20). 
 
3.5.2 Reduction in total IBS-SSS score 
The total IBS-SSS score was reduced with 56.1 in group A from baseline to six weeks, while 
with 118.7 in group B. Twelve (60%) of the patients in group A reduced their total IBS-SSS 
score with more than 50 from baseline to six weeks, while seventeen (85%) did it in group B 






Table 6: Reductions in total IBS SSS score from baseline to three weeks, from three to six weeks and 
total from baseline to six weeks in group A and B, given in mean ± SD. 
 Group A Group B 
Baseline to 3 weeks -35.0 ± 72.5 -64.8 ± 62.3 
3 weeks to 6 weeks -21.1 ± 53.9 -53.9 ± 64.2 
Total (baseline to 6 weeks) -56.1 ± 65.3 -118.7 ± 74.3 
 
Unpaired t-test was done to check if the patients with IBS-D and IBS-C in group B had different 
reductions in abdominal symptoms after following the low FODMAP diet, measured by IBS-
SSS. No statistically significant difference was found (p=0.240), but the mean reduction for 
patients with IBS dominated by diarrhoea was greater (-163.2±60.9) than for the constipated 
patients (-110.4±84.9). No statistically significant difference was found in group A neither 
(p=0.914), but the difference between IBS-D and IBS-C was smaller here  
(-66.3±52.3 vs. -62.9±65.8).  
 
3.5.3 Severity of IBS 
After 6 weeks, 2 in group A and 5 in group B were in remission. 4 in group A and 2 in group B 
had mild symptoms at baseline, 3 and 9 after six weeks. The number of patients with moderate 
symptoms went from 9 and 13 at baseline to 13 and 5 after six weeks, and severe was reduced 
from 7 and 5 to 2 and 1 (see table 7). There was not a statistically significant difference between 
the groups at baseline (p=0.422), but after six weeks it was (p=0.0425).  
 
Table 7: Numbers of patients having remission, mild, moderate and severe IBS at baseline and after six 
weeks in group A and B. Chi-squared test was used. 
 Baseline A Baseline B 6 weeks A 6 weeks B 
Remission: <75 0 0 2 5 
Mild: 75-175 4 2 3 9 
Moderate: 176-300 9 13 13 5 






3.5.4 The 5 main questions:  
There was a numerical reduction from baseline to six weeks in all the five main symptoms in 
group A, but only the question about abdominal pain severity was statistically significant (see 
table 8).  
 
Table 8: Scoring for each of the five main questions at baseline, 3 weeks and 6 weeks for group A. The 
data are normally distributed, but are given in median (IQR) to be comparable to group B.     
2b, 3, 4 and 5: 0-100. 2c: 0-10. RM-one-way ANOVA-test is used for each of the five questions. 















































In group B, there are statistically significant reductions in all the five main questions from 














Table 9: Scoring for each of the five main questions at baseline, 3 weeks and 6 weeks for group B. The 
data for question 2c, 2b and 3 are not normally distributed, and therefore all the data are presented with 
median (IQR). 2b, 3, 4 and 5: 0-100. 2c: 0-10. RM-one-way ANOVA-test is used for normally 
distributed data and Friedman test for non-normal. 















































When comparing the two treatment groups, all the symptom scores at six weeks were numerical 
lower and the reductions in all the five main symptom-scores were greater in group B than in 
group A, except for question 4 (19.0 vs. 18.0). The differences between the groups were 
statistically significant in question 2b (p=0.0016), 3 (p=0.0029) and 5 (p=0.0213), but not in 
question 2c (p=0.456) and 4 (p=0.0678). The difference in reduction in abdominal pain severity 
is not that big between the two groups (25.6 in A and 26.5 in B), but the median scores at six 
weeks are. In question 2c the difference in reductions was 10.0, 1.0 in question 4 and 27.0 in 
question 5. The biggest difference was regarding question 3 about abdominal bloating severity, 








3.5.5 Abdominal pain severity (question 2b)  
At baseline in group A the median for abdominal pain severity (question 2b) was 51.1, at 3 
weeks 38.5 and 25.5 at 6 weeks. When using Tukey multiple comparisons test (normally 
distributed data), a statistically significant change from baseline to three weeks or from three 
weeks to six weeks was not found, but from baseline to six weeks (25.6, p=0.0015).  
In group B, the median was 41.0 at baseline and was reduced to 24.5 at three weeks and 14.5 at 
6 weeks. When using Dunn’s multiple comparisons test (non-normal data), a statistically 
significant change from baseline to three weeks and from baseline to six weeks (26.5, p<0.0001, 
Friedman statistic=20.55) was found, but not from three to six weeks. The reduction was highest 
from baseline to three weeks (see figure 13). 
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Figure 13: Median scores with IQR for abdominal pain severity (question 2b) at baseline, 3 weeks and 6 







3.5.6 Abdominal pain frequency (question 2c)  
In group A the median in abdominal pain frequency went from 4.0 days at baseline to 3.0 days at 
6 weeks and there was not a statistically significant reduction from baseline to three and six 
weeks (1.0, p=0.374). The median for group B was 4.0 days at baseline and 2.0 days at 6 weeks, 
and when using Dunn’s multiple comparisons test (non-normal data), a statistically significant 
change from baseline to three weeks or from three to six weeks was not found, but from baseline 
to six weeks (2.0, p<0.0016, Friedman statistic=12.90). The reduction was highest from three to 
six weeks (see figure 14). 
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Figure 14: Median scores with IQR for abdominal pain frequency (question 2c) at baseline, 3 weeks and 









3.5.7 Abdominal bloating severity (question 3) 
In group A the median in abdominal bloating severity went from 53.0 at baseline to 40.5 at 6 
weeks, but the reduction was not statistically significant (12.5, p=0.243). The median in group B 
at baseline was 60.0 and 19.5 at 6 weeks and when using Dunn’s multiple comparisons test 
(non-normal data), a statistically significant change from baseline to three weeks was not found, 
but from baseline to six weeks and from three weeks to six weeks (40.5, p<0.0001, Friedman 
statistic=22.16). The reduction was highest from baseline to three weeks (see figure 15).  
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Figure 15: Median scores with IQR for abdominal bloating severity (question 3) at baseline, 3 weeks and 










3.5.8 Dissatisfaction with bowel habits (question 4)  
In group A the median in “dissatisfaction with bowel habits” went from 69.0 at baseline to 50.0 
at six weeks, and there was no statistically significant reduction from baseline to three or six 
weeks (19.0, p=0.0724). The median in group B reduced from 61.5 at baseline to 43.5 at six 
weeks and when using Tukey multiple comparisons test (normally distributed data), a 
statistically significant reduction from baseline to three weeks or from three to six weeks was 
not found, but from baseline to six weeks (18.0, p=0.0196). The reduction was highest from 
baseline to three weeks in group B (see figure 16).  
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Figure 16: Median scores with IQR for dissatisfaction with bowel habits (question 4) at baseline, 3 









3.5.9 Interference with daily activities (questions 5) 
In group A the median in “interference with daily activities” went from 56.5 at baseline to 50.0 
at 6 weeks, and there was no statistically significant reduction from baseline to three and six 
weeks (6.5, p=0.155). The median in group B reduced from 57.5 at baseline to 24.0 at 6 weeks 
and when using Tukey multiple comparisons test (normally distributed data), statistically 
significant reductions from baseline to three weeks, from three to six weeks and also from 
baseline to six weeks (33.5, p<0.0001) were found. The reduction was highest from baseline to 
three weeks (see figure 17). 
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Figure 17: Median scores with IQR for interference with daily activities (question 5) at baseline, 3 











3.5.10 “In the last seven days, have you had satisfactory relief of your IBS symptoms?” 
In the beginning of the questionnaire we asked if the patients had felt satisfactory relief of their 
IBS symptoms the last seven days. At baseline only 5% of the patients in both group A and 
group B were satisfied. After 6 weeks, 45% in group A and 55% in group B were satisfied (see 
table 10). There were no statistical differences between the two groups at any time points.  
 
Table 10: Number of patients having a satisfactory relief of their IBS symptoms at baseline, 3 weeks 
and 6 weeks, in group A and B. 
 Baseline 3 weeks 6 weeks 
Group A, n 1 (5%) 6 (30%) 9 (45%) 
Group B, n  1 (5%) 12 (60%) 11 (55%) 
 
  
3.5.11 Additional questions on general health 
There were 10 additional questions on general health; nausea and/or vomiting, early satiety, 
headache, backache, fatigue, gas/belching, heartburn, dysuria and urgency, thigh pain and 
musculoskeletal pain (see table 11 and figure 18 and 19). 
 
The reductions were greater in group B than A for all the general symptoms, except for 
heartburn and thigh pain. When using Dunn’s multiple comparisons test, a statistically 
significant reduction from baseline to three weeks or from three to six weeks was not found, but 
from baseline to six weeks on the questions on nausea and/or vomiting (p=0.0013) and 
gas/belching (p=0.005) in group B. The reduction from baseline to three weeks in fatigue was 
not statistically significant, but from three to six weeks and from baseline to six weeks 
(p=0.0017) it was. The lowest p-value in group A (but not statistically significant) was for 
headache (p=0.0081). There were no statistically significant reductions in the other general 
symptoms, but all of them except backache in group B were reduced from baseline to six weeks 









Table 11: Additional questions on general health at baseline, 3 weeks and 6 weeks for group A and B. 
Scores from 0 (never) to 100 (all the time) presented as median (IQR). RM-one-way ANOVA-test is used 
for normal distributed data and Friedman test for non-normal data, F for Friedman statistics. Multiple 
testing is adjusted for since there were 20 statistical tests. The significance level is therefore stricter, and 
the p-value has to be <0.0025 (0.05/20 tests) to be statistically significant. 
  Baseline 3 weeks 6 weeks p-value 
Nausea and/or 
vomiting 
A 11.0 (6.0-34.0) 5.5 (0.0-20.8) 2.5 (0.0-25.8) 0.0238, 
F=7.479 
 B 17.0 (6.3-31.0) 10.5 (0.8-25.0) 4.0 (0.0-13.5) 0.0013*, 
F=13.290 
Early satiety A 5.0 (0.0-13.0) 2.5 (0.0-20.8) 2.5 (0.0-13.8) 0.732, 
F=0.623 
 B 8.5 (0.5-19.5) 10.0 (0.0-22.3) 3.5 (0.0-11.5) 0.182, 
F=3.404 
Headache A 33.5 (14.3-71.0) 41.0 (7.3-66.8) 29.5 (7.8-54.5) 0.0081, 
F=9.629 
 B 39.5 (11.5-56.8) 34.0 (6.3-50.8) 23.5 (5.8-31.8) 0.0077 
Backache A 39.0 (8.8-61.8) 25.0 (3.3-53.0) 25.0 (12.0-48.8) 0.474 
 B 5.5 (0.5-45.9) 8.0 (0.5-43.5) 6.0 (0.0-41.5) 0.361, 
F=2.039 
Fatigue A 68.0 (52.0-87.3) 60.0 (39.5-83.3) 58.0 (29.3-78.0) 0.0515 
 B 56.5 (48.0-87.3) 53.5 (34.0-83.8) 41.0 (22.0-74.0) 0.0017* 
Gas/belching A 70.0 (31.0-87.3) 45.0 (26.0-81.5) 40.0 (25.0-82.0) 0.0229, 
F=7.549 
 B 63.5 (40.0-73.8) 38.5 (25.3-70.3) 27.0 (22.5-49.3) 0.0005*, 
F=15.150 
Heartburn A 23.5 (0.0-60.5) 3.0 (0.0-19.8) 2.0 (0.0-25.0) 0.0208, 
F=7.750 




A 50.0 (4.3-73.8) 34.0 (15.5-69.3) 29.5 (7.0-62.0) 0.0421, 
F=6.333 
 B 61.5 (13.0-74.3) 29.0 (6.8-57.5) 25.0 (3.8-50.0) 0.0031 
59 
 
Thigh pain A 8.0 (0.0-47.5) 0.5 (0.0-25.0) 1.0 (0.0-28.8) 0.254, 
F=2.739 




A 46.5 (4.5-78.0) 40.0 (15.5-80.0) 36.0 (25.0-75.0) 0.4093, 
F=1.787 
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Figure 18: Additional questions on general health at baseline, 3 weeks and 6 weeks for group A. Scores 







































N a u se a /vo m itin g
S a tie ty
H e a d a c h e
B a c k a c h e
F a tig u e
G a s /b e lc h in g
H e a rtb u rn
D y s u r ia  a n d  u rg e n c y
T h ig h  p a in
M u s cu lo s ke le ta l p a in
In te rve n tio n
 
Figure 19: Additional questions on general health at baseline, 3 weeks and 6 weeks for group B. Scores 






3.6 Quality of life (SF-36)  
The patients filled in the SF-36 questionnaire at baseline and at the end of the diet at 6 weeks.  
 
3.6.1 Physical component summary (PCS)  
At baseline the mean score for physical health (PCS) in group A was 44.9, while it was 44.5 in 
group B. After six weeks, the mean score in group A was 44.5 and 48.1 in group B. There was a 
statistically significant increase in PCS in group B (p=0.0061), but not in group A. There were 
no statistically significant difference between the two groups neither at baseline (p=0.886) nor at 
6 weeks (p=0.157) (see table 12 and figure 20). 
 
Table 12: Physical component summary (PCS) in group A and B at baseline and at 6 weeks, given in 
mean ± SD. Paired and unpaired t-tests were used for the normally distributed data. 
 Baseline 6 weeks p-value Normal value 
Group A 44.9 ± 8.3 44.5 ± 7.9 0.740 50 ± 10 
Group B 44.5 ± 8.1 48.1 ± 7.9 0.0061* 50 ± 10 
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3.6.2 Mental component summary (MCS)  
At baseline the mean score for mental health in group A was 47.3, while it was 46.9 in group B. 
After six weeks, the mean score in group A was 47.4 and 48.3 in group B. There was an increase 
in MCS in both groups, but it is not statistically significant in neither of them (p=0.949 for group 
A, p=0.245 for group B). There was no statistically significant difference between the groups at 
baseline (p=0.850) nor at 6 weeks (p=0.772) (see table 13 and figure 21).  
 
Table 13: Mental component summary (MCS) in group A and B at baseline and at 6 weeks, given in 
mean ± SD. Paired and unpaired t-tests were used for the normally distributed data.   
 Baseline 6 weeks p-value Normal value 
Group A 47.3 ±7.5 47.4 ± 8.7 0.949 50 ± 10 
Group B 46.9 ± 8.0 48.3 ± 9.2 0.245 50 ± 10 
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3.6.3 The eight dimensions 
There were no statistically significant changes in the eight dimensions in group A, but all except 
for role emotional increased numerically. In group B the scores increased from baseline to six 
weeks in seven of the dimensions and were constant in the eight’. Three dimensions were 
statistically significant improved in group B (physical role, p=0.036, bodily pain, p= 0.0039 and 
general health, p=0.0033).  
 
When removing outliers in group B (2 for PF, 1 for RP and 1 for RE), there was a statistically 
significant change in PF from baseline to six weeks (p=0.0170), but no differences in RP or RE. 
Nevertheless, all the outliers should be included since the patient group is heterogenic. There 
were no statistically significant differences in the eight dimensions between the two groups at 
baseline or at 6 weeks (see table 14 and figure 22). 
 
Table 14: The eight dimensions in group A and B at baseline and at 6 weeks. The normed based scores 
are given in median (IQR). Paired and unpaired t-tests were used for normally distributed data, and 
Wilcoxon and Mann-Whitney tests for non-normal data.  Multiple testing is not adjusted for.  
 Baseline 6 weeks p-value 
PF (physical function) A 51.8 (47.1-53.7)
 52.5 (45.4-53.7) 0.134 
 B 50.3 (46.9-53.5) 52.7 (48.2-53.9) 0.287 
RP (physical role) A 49.1 (44.9-53.3) 49.2 (46.5-51.8) 0.532 
 B 48.8 (42.6-54.2) 51.2 (49.0-54.6) 0.036* 
BP (bodily pain) A 43.5 (37.1-47.8) 43.7 (36.2-49.2) 0.696 
 B 41.6 (39.2-45.2) 48.9 (40.8-55.7) 0.0039* 
GH (general health) A 37.9 (32.9-50.2) 40.1 (31.6-48.9) 0.700 
 B 39.6 (31.6-49.3) 44.2 (35.0-51.6) 0.0033* 
VT (vitality) A 40.2 (36.1-48.8) 40.5 (30.4-48.8) 0.826 
 B 39.5 (33.2-50.9) 44.5 (30.8-55.2) 0.112 
SF (social function) A 44.2 (38.1-55.7) 44.3 (43.3-55.8) 0.479 
 B 44.1 (37.8-54.4) 44.1 (32.2-56.0) 0.168 
RE (emotional role) A 53.8 (46.1-54.4) 53.1 (46.3-54.1) 0.475 
 B 47.6 (43.7-54.1) 51.6 (46.2-54.1) 0.288 
MH (mental health) A 45.8 (40.1-54.6) 46.6 (38.7-54.6) 0.825 
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Figure 22: The eight dimensions in group A and B at baseline and at 6 weeks. 
 
3.7 Self-reported compliance at 6 weeks (group A and B)  
In group A the mean for the question about dissatisfaction with the diet and pain relief was 66.7, 
while it was 41.3 in group B. In this question 0 was very satisfied and 100 very displeased. 
There was a statistically significant difference between the two groups (p=0.0132). There was no 
statistically significant difference in how strict the two groups had followed the diet (accuracy, 
p=0.972). Here 0 was not following the diet at all and 100 only following the diet, and the mean 
were 93.3 for both groups.  It was also a statistically significant difference in feasibility 
(p=0.0008) where 0 was “very easy” and 100 “very hard”. The mean in group A was 27.9, while 
it was 64.3 in group B (see table 15 and figure 23). 
 
Table 15: Self-reported compliance at six weeks in group A and B given in mean ± SD. The three 
questions with a VAS-scale from 0 to 100 is presented. Unpaired t-test for normally distributed data. 
 Group A Group B p-value 
How satisfied are you with the diet as symptom 
relief? 
66.7 ± 31.1 41.3 ± 30.8 0.0132* 
How closely have you followed the diet? 93.3 ± 9.2 93.3 ± 8.3 0.972 
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Figure 23: Self-reported compliance at six weeks in group A and B. The three questions with a VAS-
scale from 0 to 100 are presented.  
  
There were 50% in both group A and group B who reported that they wanted to continue to 
follow the diet after the intervention-period. Six patients in group A and two in group B reported 
that a lack of improvement in symptoms was the reason for not wanting to continue to follow the 
diet, while 1 in group A and 2 in group B reported “missed other foods” as the reason. 1 in group 
A said it was too time-consuming. When asking if they had any deviations from the diet, 40% in 
group A and 35% in group B reported none at all, 50% in group A and 55% in group B said 1-5 
times in the period of 6 weeks and 10% in each group reported 1-3 times per week. The main 
reasons for the deviations in both groups “did not know that the food was -containing wheat 
starch/traces of gluten (group A)/-high in FODMAPs (group B)”. Food rich in lactose were the 
reason for deviation in 69% of the cases in group B.   
 
3.8 Self-reported compliance at 10 weeks (group B)  
Nine patients (45%) in group B reported that they had continued following the low FODMAP 
diet the last four weeks, while seven (35%) said they did it a little/sometimes and four (20%) had 
quitted. The mean for how well they had maintained the diet the last four weeks was 61.9 
(±36.5), on a VAS-scale from 0 to 100 were 100 is “only eating low FODMAP”. The two main 
reasons for not continuing/only continuing a little were not feeling enough effect (5 patients) or 




Sixteen (80%) had tried to reintroduce all or some of the foods which had been excluded during 
the test period for six weeks. The mean for how hard they though it was to reintroduce food was 
42.6 (±32.5), on a VAS-scale from 0-100 were 0 is very easy and 100 is very hard. Thirteen 
reported that it was hard to know if they got symptoms from exactly the food they were 
reintroducing, and 7 said it was hard to distinguish between “normal symptoms” and these 
symptoms. No one were in doubt about how to do the reintroduction. There was a trend to start 
with introducing food with fructans or fructose first.  
 
4 patients said they wanted to continue to follow the diet 100%, twelve partially, one maybe and 
three did not want to. In the end we asked which group of FODMAPs they believe that they do 
not tolerate. None answered “none”, while fructans and lactose were clearly the most frequent 
answers.  
 
3.9 Blood tests 
Everyone had normal calcium levels at baseline in group A and at six weeks in group B. At six 
weeks in group A and at baseline in group B there were two patients having too low values. The 
mean calcium levels were normal for both groups at both time points though. There was a 
statistically significant increase from baseline to 6 weeks for group B (p=0.0476), but not for 
group A. There were no statistically significant differences between the two groups at baseline 
(p=0.851) nor at six weeks (p=0.159) (see table 16).  
 
Everyone had normal vitamin D3 levels in group B at baseline, while 1 patient had a high level 
and two low levels in group A. At six weeks, three patients in group A had lowered levels, and 2 
patients in group B had high levels. The mean vitamin D3 levels were normal for both groups at 
both time points. There was a statistically significant decrease from baseline to 6 weeks for 
group A (p=0.0037), but not for group B. There was not a statistically significant difference 








Table 16: Calcium- and vitamin D3 blood levels at baseline and 6 weeks in group A and B, given in 
mean ± SD. Paired and unpaired t-tests were used for the normally distributed data.  
  Baseline 6 weeks p-value Reference value 
Calcium (mmol/L) A 2.39 ± 0.09 2.39 ± 0.10 0.741 2.20-2.55 mmol/L 
 B 2.39 ± 0.07 2.41 ± 0.07 0.0476*  
Vitamin D3 (nmol/L) A 73.6 ± 18.7 63.9 ± 18.5 0.0037* 50.0-113.0 nmol/L 
 B 81.6 ± 19.9 81.5 ± 22.1 0.961  
 
At baseline and at six weeks 5 patients in group A (max. 44.5 and 39.3) and 1 patient in group B 
(121.5 and 110.9) had raised anti-transglutaminase 2 IgA-levels. There were 2 patients from 
group A (max. 35.8 and 250.0) and 3 patients (max.35.5 and 250.0) from group B who had 
raised anti-deamidated gliadin IgG-levels at baseline and after 6 weeks. The median levels were 
normal and there was a statistically significant decrease in both tests from baseline to six weeks, 
in both groups. Regarding anti-transglutaminase 2 IgA there were statistically significant 
differences between the two groups both at baseline (p=0.0315) and at six weeks (p=0.0405), but 
this was not the case regarding anti-deamidated gliadin IgG (p=0.356 and p=0.281) (see table 
17).  
 
Table 17: Anti-transglutaminase 2 IgA- and anti-deamidated gliadin IgG blood levels at baseline and 6 
weeks in group A and B. The levels are given in median (IQR). Wilcoxon tests are used because of non-
normal data, and Mann-Whitney-tests are used between the groups.   
  Baseline 6 weeks p-value Reference 
value 
Anti-transglutaminase 2 IgA A 5.2 (1.0-15.3) 5.1 (0.5-16.0) 0.0175* <14.9 
 B 1.7 (0.5-2.9) 1.4 (0.5-3.3) 0.0072*  
Anti-deamidated gliadin IgG A 4.8 (0.6-8.0) 4.3 (0.7-6.0) 0.0012* <14.9 
 B 0.9 (0.4-8.7) 0.7 (0.4-6.8) 0.0039*  
 
3.10 Breath test and stool samples 





3.11 Correlation analyses  
Correlation analyses were performed, but no statistically significant correlations were found in 
neither of the groups between the changes in for instance FODMAP intake and; IBS-SSS total 
score, the five main IBS-SSS questions or PCS (data not shown). A statistically significant 
positive correlation was found in group B between the change in FODMAP intake and MCS 
(r=0.473, p=0.0351), which means that approximately 22% (r
2
) of the change in MCS 
(increasing) in group B can be explained by the change in FODMAP intake (decreasing). A 
statistically significant positive correlation was also found in group B between the change in 
total IBS-SSS and the change in MCS (r=0.555, p=0.011). Approximately 31% (r
2
) of the 
change in MCS-score (increasing) in group B can be explained by the change in total IBS-SSS 
(decreasing).  
 
There were no statistically significant correlations between how satisfied the patients were with 
the diet and pain relief, and if they had continued to follow the diet after the intervention, in 
group A nor B, or between how hard they though it was to follow the diet, and the same with the 

















4. DISCUSSION  
 
4.1 Main findings 
In this randomized controlled clinical trial the effect of a low FODMAP diet was studied as an 
addition to a gluten free diet in coeliac patients with IBS-like symptoms, especially regarding 
abdominal symptoms and quality of life. The patients in group B reduced their FODMAP intake 
from 7.7 g/day to 1.3 g/day. Their baseline FODMAP intake is already low which means that 
these patients have a reduced intake already at start. This is probably because of their exclusion 
of wheat, rye and barley from their diets which are food rich in FODMAPs. 1.3 g/day is a low 
intake and shows good compliance to the diet. The reduction was associated with a statistically 
significant improvement in abdominal pain severity, abdominal pain frequency, abdominal 
bloating severity, dissatisfaction with bowel habits and interference with daily activities. Other 
symptoms like nausea/vomiting, gas/belching and fatigue was also statistically significant 
improved in group B. An improvement in subjective report of physical health after following a 
low FODMAP diet for six weeks was also found. An improved quality of life was the superior 
goal and having a good quality of life is maybe even more important than reducing the amount 
of symptoms. It is reasonable to think that less abdominal pain and bloating will lead to a better 
quality of life. In this study, the physical health improved statistically significantly in group B 
already after six weeks. When looking at the dimensions; physical role, bodily pain and general 
health were statistically significant improved. The reason for this might be that the patients’ 
abdominal symptoms are less prominent in their everyday life, which the statistically significant 
reduction in question 5 in IBS-SSS (Interference with daily activities) indicates. Approximately 
31% of the improvement in mental health in group B may be explained by the reduction in 
abdominal symptoms. The improvement would maybe be greater if the intervention lasted for a 
longer time.  
 
80% in group B reported that they had continued to follow the low FODMAP diet four weeks 
after the intervention ended, which indicates an ongoing effect. As far as we know, there is no 
published research on low FODMAP diet to patients with coeliac disease. The results in this 
study show for the first time that this treatment may help to relieve abdominal symptoms and 
improve physical health in many patients, and that such dietary change is an important part of 
the treatment for this patient group. Although a gluten free diet is basically most important, 
instruction about reduction in FODMAP content in the diet should be offered to coeliac patients 
70 
 
with IBS-like symptoms.  
 
In addition to the intervention group, a control group only getting placebo instead of following a 
low FODMAP diet was considered, but the classical solution of further gluten reduction was 
found to be a better comparison. The traditional approach and today’s treatment practice when 
still having abdominal symptoms on a strict gluten free diet, is to follow an even more strict 
gluten free diet without wheat starch and “traces of gluten”. Our aim was to compare this regime 
to the low FODMAP diet. In this way the patients in group A also had to make changes in their 
diets, intended to reduce their abdominal symptoms and improve their quality of life. This makes 
the treatment group and the control group comparable. Indeed we did find a statistically 
significant reduction in abdominal pain severity and an overall reduction of IBS symptoms in 
group A, but not in the other main abdominal symptoms and improvement of quality of life seen 
in group B. In our view this shows that the low FODMAP diet is superior to the traditional 
treatment approach for these patients.  
 
The mechanism behind the IBS-like symptoms in otherwise well-treated coeliac patients is not 
known. The inflammation of the mucosa seen in coeliac disease is thought to predispose for IBS. 
Differential diagnosis like coeliac disease has to be excluded before diagnosing IBS since it is a 
diagnosis of exclusion. Some of the patients in this study may have sought health care because 
of their IBS-like symptoms and then coeliac disease has been detected. Patients with for 
example IBD like Crohn’s disease and ulcerative colitis can also have residual symptoms 
compatible with IBS (IBD-IBS), the inflammation again predisposing. Some of the patients in 
our study may have a temporary secondary lactose intolerance which can be tested for with a 
breath test. 
 
4.2 The design 
Randomized controlled trials are the gold standard in research on medical interventions and very 
strong evidence for causality. When using this design confounding factors can be largely 
eliminated and there is no information bias on exposure or selection bias at baseline because the 
groups are made up by randomization. The two groups in our study were comparable for 
prognostic factors. The patients could have got better anyway as a natural course of their 
disease, and therefore another group was added to know if they got better because of the 
intervention or not. Group A in some way act as a control group, but the patients in this group 
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did not get placebo, but an actual intervention and can be compared to group B. Our study was 
not blinded and that is an obvious weakness. It would of course be better if the patients did not 
know which group they were in regarding the placebo effect, but it is hard to do this in practice.  
 
4.3 Patient response and recruitment 
It was hard to recruit enough patients for this project. The objective was to include 40 patients in 
total, 20 patients in group A and 20 in group B. This goal was reached and considered a 
reasonable number of patients based on previous research. As mentioned, around 1000 people in 
Hordaland may have coeliac disease and IBS-like symptoms. It would maybe be better to 
include more patients, but since the intervention in group B was so effective it would maybe be a 
little bit unethical to let more patients follow the diet in group A. In addition, the number of 
patients was found a suitable amount of work for a Master Project. Calculation of strength was 
not performed since this was a smaller project, and the intervention in group B was very 
effective. We made no log with the number of patients considered and contacted, but 
information about the study has probably reached a high number of people.  
 
Some patients were not included in the study for different reasons. Travel distance, time 
pressure, pregnancy, a wish to only attend one of the groups, lack of a verified coeliac disease 
diagnosis and bad appetite are some examples. In addition, some did not show up and some sent 
us emails without an explanation. The Rome III criteria-questionnaire is a simple tool used for 
including or excluding participants in our study. It does not have many questions, so it should 
not be demanding. Some patients found some of the questions hard to understand. The patients 
could possibly exaggerate their abdominal symptoms in order to be included in the study and 
then get more counselling. Only one did not fulfil the Rome III and/or IBS-SSS questionnaires, 
which mean that the coeliac disease patients had IBS-like symptoms and were the wanted patient 
group. Three dropped out of the study because they said FODMAP reduction was too 
demanding in their busy life.  
 
There are some potential sources of error regarding the recruitment. Some suitable patients could 
have been missed and excluded when reading medical records because of comorbidities and 
medications, not all the participants had attended a course at LMS, maybe the information they 
got were not good enough, not everyone is on Facebook, people are maybe seldom at NCF’s 
webpage etc. It is imaginable that the younger patients are more active on the Internet and on 
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Facebook. Newly diagnosed patients or the patients with the most severe symptoms are maybe 
more active in the advocacy group, and more likely to see our announcements. Nevertheless, 
bias in the recruitment is not very likely since we have probably reached a wide range of people 
by using many different recruitment methods. 
 
The upper age limit was set to 60 years as a starting point. This was because the patients should 
be employed, not have that much comorbidity, have a good memory, being able to follow a strict 
diet etc. The lower age limit was set to 18 years to exclude children who can have another 
response to the diets and they are maybe not capable of following these diets.  Nevertheless, two 
patients older than 60 years were included in the project. That was because they contacted us 
several times and really wanted to be a part of the project. Afterwards, they should maybe not 
been included based on their personalities, bad memory and lacking ability to follow a strict diet.  
 
4.4 Implementation 
Altogether, the implementation of the project went very well. The patients were instructed both 
in groups and one by one. Maybe it would be better to instruct them all one and one to have the 
possibility to individualize more, like for example going through their dietary intake records 
together. On the other hand, this is maybe of smaller importance since we found such a great 
effect in reducing the FODMAP intake, symptoms and improving quality of life. The threshold 
for asking questions would maybe be lower if the meetings were individual. On the other hand, 
the patients were told to contact us anytime – both by phone, SMS and e-mail if they wanted to, 
and FODMAP reduction was adequate in all the patients in group B.  
      
4.5 The two diets 
The only treatment for coeliac disease today is a life-long exclusion of gluten from the diet, 
regardless of the severity of symptoms. These patients are therefore already used to follow a 
strict diet, and will maybe easier manage to follow an even stricter diet like the two used in this 
study, than for example an IBS group. If a patient still has abdominal symptoms, the classical 
solution is to try to find sources of gluten in his/her diet and to avoid them. Thereafter wheat 
starch and “traces of gluten” can be excluded, which was the intervention in group A. It is 
reasonable to try this diet before the low FODMAP diet as the compliance questionnaires 
interpret that it seems to be less demanding to follow. There was a statistically significant 
improvement in some abdominal symptoms in both groups, and the antibodies were lowered 
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after six weeks which interpret a lower intake of gluten. 
 
The low FODMAP diet is well documented as a treatment for IBS, and in this study it also gave 
a reduction in abdominal symptoms and improved physical quality of life in patients having 
coeliac disease and IBS-like symptoms. There are apparently some limitations with the low 
FODMAP diet. In the first phase the diet can be less varied and therefore less nutrient-rich. 
Especially the fibre intake can be reduced in addition to calcium, but there were no statistically 
significant reductions in this study even though the intake of dietary fibre decreased in both 
groups. Dietary fibre is found in bread, cereals, fruits and vegetables and even though it is not 
the intention to reduce the intake of these kinds of foods, the choices are fewer on the strict diets, 
and this may be the reason for the reduced intake. If the fibre intake is low on this diet, it is 
important to find good replacements or take a supplement. For constipated patients which there 
were most of in our study, Visiblin could be used.  
 
The diet can also be really demanding for the participants and it requires a lot of time, desire and 
energy to go through it. The labelling of food does not show what kind of food which is high in 
FODMAP and which is low, so the patients have to read a lot of information. It is important 
though, to remember that the exclusion period is not forever, only for six weeks. It can be 
expensive and social gatherings can be a challenge. Some will feel that they are nagging, and 
think it is unpleasant to avoid basal food. A good advice is to ask for the menu in advance. It can 
also be challenging when making food for the whole family, and when travelling to other 
countries. The clue is to see possibilities instead of limitations.  
 
In this study, it seemed to be important to follow the most restrictive FODMAP reduction for 6 
weeks and not 3 weeks. It may be individual if 4 or 8 weeks is the ideal time period to follow the 
strict diet. It takes some time to get the routines and it can be demanding and a change in the 
everyday life. It is important to encourage the patients to continue even if they are struggling 
after a few weeks, because it might be easier to follow the diet after a while and the symptoms 
will also often continue to decrease. In this study there were greater reductions in abdominal 
symptoms from baseline to three weeks than from three to six weeks in group B, but still they 
continued to decrease from three to six weeks. There is not a threshold limit regarding 




There is a need for research on possible long-term effects of the diet. How will it affect the gut 
microbiota for example? Food like legumes and onion has a high content of FODMAPs and 
prebiotics which can have a positive effect on the gut. What will a reduction in prebiotics lead 
to? Because of this it is maybe not advisable to follow this diet for more than six weeks, and it is 
important to do the reintroduction.  
 
4.6 Demography  
There were no statistically significant differences in baseline characteristics between the two 
groups, and this is a strength which means that the randomization was successful. It also means 
that the two groups are comparable and gives a better picture of the effects of the different 
treatments.  
 
We included four patients out of Hordaland, the rest from Hordaland. Clearly more women than 
men were included in this project which agrees with the fact that more women than men have 
IBS. There are also more women than men having coeliac disease, although the imbalance in sex 
distribution is minor here than for IBS. Some possible explanations could be that more women 
tend to seek health care, women are maybe more willing to make a change in their lives and are 
often responsible for the cooking. This imbalance in sex can be a source of error, because the 
diets may have different effects in men and women.  
 
IBS is more common in people younger than 45 years, while coeliac disease is more common in 
people between 50 and 69 years old. In our study 23 patients were younger than 45 years, while 
7 were between 50 and 69 years old. The mean age was 39 years old in group A and 43 years old 
in group B.  
 
The median BMI was in the normal range at baseline when comparing with a healthy 
population. BMI in IBS patients may be different though (131). Most patients had constipation, 
and it is possible that the diets have different effects on patients with constipation and diarrhoea. 
If the study should be done all over again, the patients should be weighed at baseline and after 
six weeks to see if there was a difference. Data on when the different patients got the coeliac 
disease diagnosis, how long they have had it and for how long they had been eating a gluten free 




4.7 Dietary intake record and FODMAP intake 
This method is the gold standard for measuring a person’s food intake. Some advantages with 
the method are that trends in meal pattern can be spotted and representative details can be 
collected by including week- and weekend-days. A study found that the accuracy in the 
recording decreased if the patient had to record for more than four days (132). The fact that 
foods and beverages are weighed is a huge advantage, because the calculations of nutrients are 
getting more precise.   
 
There are as always some possible sources of error. First of all, underreporting of food intake is 
common, especially with women. BMR-factor was therefore calculated at baseline for every 
patient to evaluate the degree of underreporting of energy intake. Over reporting is another 
potential problem. A change in behaviour and in what food you are eating can happen, because it 
is easier to report or to avoid some types of foods. Sometimes, patients report things they have 
or have not been eating, trying to impress the researcher or to avoid criticism (1). It is also 
natural that the intake (and therefore also nutrients) will vary from day to day and also with the 
time of the year. 
 
Bad memory can be a problem if the patient is filling it in a long time after eating the food. It is 
therefore preferred that the patients record their intake continuously (4, 133), and the patient has 
to be motivated. Eating at restaurants or at friends is another potential problem, because then the 
patients do not know the exact contents in what they are eating. In addition, people have 
different interpretations of portion sizes and weighed records are therefore more precise. Some 
filled in the record very precise, while others did not write portion sizes. Plotting and 
calculations in Kostholdsplanleggeren can also be done wrong by the researchers. The nutrition 
values in the database can come from one single analysis or the mean of more analyses, 
calculations or other countries’ databases. Kostholdsplanleggeren did not have information on 
all the food-items the patients had been eating.  
 
Finding the amount of FODMAPs in different foods was quite challenging since there is no 
database on this as far as we know. There were analyses from Australia, Denmark and Norway, 
so these were compared. Sometimes the data were similar, but some data were quite different. 
Different methods were used for the analyses and these could be inaccurate. The amount of 
FODMAPs in food is likely different in Australia and Norway because of climate, soil, growth 
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conditions etc. There are also some foods which are not analysed. Products are not labelled with 
FODMAP amount, and when different manufacturers were contacted, they did not know the 
amount. Recipes were asked for, but these were secret. The calculations on FODMAP amount 
are therefore unprecise. On the other hand, FODMAP content is also unprecise in other studies. 
The total FODMAP intake, lactose and non-lactose FODMAPs were studied. It would of course 
be even better to look at all the other FODMAP groups separately in addition, but that would be 
too demanding because of lacking data, and estimations would therefore be unprecise. All the 
data were entered into Excel first, then the Fabricant table and Dietist Net. The composite 
products were especially demanding. All the manual calculation could also be a source of error.  
 
The total FODMAP intake was statistically significant reduced in group B. Coeliac disease 
patients already have a lower amount of FODMAP in their diet since they do not eat wheat, 
barley and rye which are grains rich in FODMAPs. The findings in this study are therefore even 
more uplifting. They show that a further reduction in FODMAP intake is of great importance 
and reduces abdominal symptoms and improves physical quality of life. At baseline the patients 
in group B ate 7.7 g/day, and in comparison 23.7 g/day is the mean intake in a typical Australian 
diet (86) while 8.0 (6.0-19.0) g/day was the median (IQR) intake in a group of IBS patients 
(134). After six weeks the patients in our study reduced their FODMAP intake to 1.3 g/day, in 
comparison with 3.8 g/day in a Swedish study (104) and 3.1 g/day in the Australian study (86).  
 
Lactose was looked at because Norwegian data was available and the lactose amount could 
therefore be separated from the total FODMAP intake. The majority of people in Norway are 
lactose tolerant (135), have a relatively high level of lactase and are not having a primary lactose 
intolerance. It is maybe likely that the other FODMAP groups are causing the IBS symptoms. 
Some lactose could therefore maybe be included in the low FODMAP diet here in Norway? On 
the other hand, some of these patients possibly have a temporary secondary lactose intolerance 
which is normal to have if they are newly diagnosed. A breath test can tell if a patient has lactose 
intolerance. The patients in our study though, should have been diagnosed for at least six months 
ago, and lactose should normally be tolerated after eating a strict gluten free diet for six weeks. 
Lactose was the dominating FODMAP group, since it is normal to ingest a lot of milk and dairy 
products in Norway. Another study did also find that lactose was the dominating FODMAP 
group (104). It is not known if it was especially lactose or some of the other FODMAP groups 
which led to the reduction of abdominal symptoms. It would be interesting to perform a study 
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where all the FODMAP groups except for lactose were reduced, to see if there is still a great 
effect. There is not a threshold limit regarding FODMAP intake; it has an accumulating effect. A 
“bucket” is often used as a picture for the capacity.  
 
It is imaginable that some patients in group A started on a low FODMAP diet (in addition to the 
more strict gluten free diet) even though it was not the intention. The median total FODMAP 
intake actually reduced from 14.5 g/day to 12.1 g/day even though it is not a statistically 
significant reduction. Reasons for doing so could be a misunderstanding or a desire to try the 
diet. If this was the case, the results in our study would be even clearer. Also the other way 
around; maybe some patients in group B started on a more strict gluten free diet in addition to 
their low FODMAP diet. It is even not sure that the patients actually followed their diets even 
though they said so. 
 
There was a trend (statistically significant in group B) of reducing the energy intake when eating 
one of these diets. A similar trend was found in other studies on IBS patients eating a low 
FODMAP diet (86, 104). Some has maybe done it on purpose, but it can indicate that it is harder 
to find suitable food when following such a strict diet. The mean BMR-factor is over the cut-off 
limit for both groups in total, but 9 (45%) from each group has a factor under the limit which 
may suggest underreporting of food intake. A study in Sweden found that the coeliac patients 
had the same energy intake as the control group after eating a gluten free diet for 10 years (136).  
 
When comparing the patients’ macronutrient intakes (carbohydrates, fats and proteins) with the 
Norwegian recommendations, they were fulfilled (in E%/day) both at baseline and after six 
weeks in both groups. This is a great finding meaning that the strict diets do not affect the 
recommended intake of important macronutrients. It is also representative for the mean intake in 
the Norwegian population in 2014 which was 47 E% from carbohydrates, 37% from fats and 
15% from proteins (137). The calcium intake declined in group A and was below the 
recommendation (800 mg/day) at six weeks, even though there is nothing with the intervention 
that should require this and it could be a coincidence. It also reduced non-significantly in group 
B, and a lower intake of milk and dairy products can be a possible explanation. Some of the 
patients took calcium-supplements. None of the groups met the recommended intake of dietary 
fibre, neither at baseline nor after six weeks, and it declined from baseline to 6 weeks. In 
comparison, the general population in Norway meets the recommendations by eating 26.0 g/day 
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(137), but a study in Sweden found that the intake was lower in a group of coeliac patients 
compared with a control group (136). Other studies on IBS patients on a low FODMAP diet 
have also found a decreasing intake of dietary fibre (86, 104). Bread, cereals, fruits and 
vegetables are rich in dietary fibre and foods that the patients maybe have been eating less of on 
the diets.  
 
4.8 Symptoms (IBS-SSS)  
This questionnaire was used to grade the patients’ IBS symptoms, and to include them in our 
study together with the Rome III criteria. First, the lines (VAS-scales) were measured to check if 
they actually were 100 millimetres. The majority of patients did not find the questionnaire 
demanding. Some filled it out carefully, while others hurried through it, and this may have 
caused over- and underreporting. When the patients are asked about different symptoms, they 
will probably feel more of them since they are more focused. The answers are subjective and 
patients will have different opinions on what is good and bad. Quality of life may also affect 
how the patients feel about their abdominal symptoms. In addition, the severity of symptoms 
will vary from day to day. All the patients scored more than 75, and from this I interpret that the 
questionnaire was appropriate to use. On the other hand, the questionnaire is not a questionnaire 
for coeliac disease and is not specific for IBS. People with other gastrointestinal disorders like 
Crohns disease, ulcerative colitis, tropical sprue and colorectal cancer may also score on the 
questionnaire without having IBS. Patients with IBD etc. were therefore excluded. There is as 
far as we know no questionnaire that is better though.  
 
90% of the patients in total had fewer symptoms after the intervention, which is a high number 
and indicates a high success rate. In comparison, a study on IBS patients showed symptom relief 
in 75% of the patients (67). Only two of the patients were taking Idoform or Visiblin which may 
have affected the amount of their gastrointestinal symptoms. 
 
A reduction of 50 or more in total IBS-SSS score is considered clinically significant and as a 
response to the treatment (116). Quantifying the reduction in percent would maybe be a better 
measure, since a reduction from 300 to 250 may have a different effect than a reduction from 
100 to 50 for example. The mean reductions from baseline to six weeks were more than 50 in 
both groups (56.1 in group A and 118.7 in group B), but it was highest in group B. This means 
that both the groups responded to the treatment, but the patients in group B the most and much 
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more than 50 which reflects a great effect of the diet. In group B they responded already at three 
weeks, showing a relatively quick effect of the low FODMAP diet. Other studies with IBS 
patients (without coeliac disease though) have also found reductions in total IBS-SSS and 
abdominal symptoms after following a low FODMAP diet (86, 89, 104). In our study the mean 
IBS-SSS in group B reduced from 263±70 at baseline, to 199±99 at three weeks and to 145±84 
after six weeks. In comparison, the mean IBS-SSS reduced from 325±69 at baseline to 246±127 
after 4 weeks in a study on IBS patients by Bohn et. al (104). The same study did also find a 
reduction in all the five main symptoms, but the reductions were lower than in our study.  
 
The severity of the patients’ IBS also improved over the six weeks in both groups, but especially 
in group B. In an IBS population, around 40% have mild IBS, 35% moderate and 25% severe 
(74). At baseline, the mean total IBS-SSS score was 260 in group A and 263 in group B, which 
indicates moderate IBS.  After the study, the mean score in group A still indicated moderate 
IBS, while the mean score in group B was lowered and compatible with mild IBS. In our study 
20% in group A and 10% in group B had mild IBS at baseline, and 15% and 45% after six 
weeks. 45% and 65% had moderate IBS in group A and B respectively at baseline, and 65% and 
25% after six weeks. At baseline 35% in group A and 25% in group B had severe IBS, and 10% 
and 5% after six weeks. 
 
In our study, there were more patients having constipation problems than diarrhoea problems. 
We did though find a trend that the patients with IBS-D had a greater effect (not statistically 
significant) of the low FODMAP diet on abdominal symptoms, than those with IBS-C. This is a 
reasonable finding since a lowered intake of FODMAPs leads to less gas production, osmosis 
and pressure on the bowel. Other studies on IBS patients have also found a better effect of the 
low FODMAP diet in patients with diarrhoea than in patient with constipation (85, 104, 106).  
 
The majority of patients were more satisfied with the relief in their IBS symptoms in the end of 
the study than at baseline. Still, seven patients in group A and four in group B did not want to 
continue to follow the diet after the intervention period, while 80 % in group B reported that 
they actually still followed the low FODMAP diet after 10 weeks. 
 
A reduction in 10 or more for each of the five main questions is then considered clinically 
significant and a response to the treatment, but again this might be a too low reduction as 
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mentioned above. In group A the reduction was 10 or more in abdominal pain severity, but not 
in the others even though they were reduced too. The patients in group B responded to the 
treatment in all the five questions, which means that all these symptoms improved after eating a 
low FODMAP diet, while only abdominal pain severity improved when eating a stricter gluten 
free diet.  
 
Other gastrointestinal symptoms like heartburn, nausea/vomiting and gas/belching also 
improved in both groups, the last two statistically significant for group B. This is not that 
surprising since abdominal pain and bloating can often cause nausea and gas for instance. Other 
types of pain (headache, backache, thigh pain and musculoskeletal pain) were also less frequent 
after following one of the diets. The only exception was backache in group B, but these patients 
had much less of this pain already at start. Dysuria and fatigue also improved in both groups, 
fatigue statistically significant in group B. It is nearby to think that less abdominal symptoms 
will give more energy and drive. Flatulence may give a pressure on the bladder which may give 
frequent urination.  
 
There is possibly also a placebo effect with the low FODMAP diet, and it was therefore 
important to have another intervention group acting as a control group in addition. The fact that 
someone takes you seriously, cares about you, includes you in a study and gives you advice can 
make the patients feel relieved and cheered up which can make it easier to manage their IBS 
symptoms. It would have been interesting to ask the patients to fill in this questionnaire also six 
months after the end of the intervention period to evaluate the effect after the study. The placebo 
effect is usually strongest in the beginning of a study, and since an improvement in symptoms 
were observed also from three to six weeks, it is reasonable to say that the effect was not only 
placebo. Contrary, a nocebo effect could be present in group A. Maybe they wanted to end up in 
group B, and did not believe that a stricter gluten free diet would have any effect on their 
symptoms and quality of life. 
 
4.9 Physical and mental quality of life (SF-36)  
There are as many as 36 questions about physical and mental health in this questionnaire, and it 
can feel demanding for some patients (elderly, weak-sighted etc.) to fill them in, which maybe 
can cause incorrect or wrong answers. Some of the questions can also appear to be very similar. 
Gastrointestinal disorders often affect a person’s quality of life, so it was found important to 
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assess it. Several studies have found that patients with IBS have a reduced quality of life 
compared to a control group (58, 138-142). A study found that Swedish women with coeliac 
disease have a lower quality of life than men with coeliac disease after having the disease for a 
long time (143). In our study such a difference was not found neither at baseline nor at six 
weeks, but there were few men in our study so it is not a standard of comparison.  
 
The physical health improved statistically significant in group B, but not in group A, which 
underscores the improvement in symptoms. With less abdominal symptoms it is reasonable to 
think that a person will feel better physically and wants to be more active. The normal PCS is set 
to 50, so both groups were below this, but not that much in group B at six weeks and within the 
standard deviation of normals ±10. One study found that SF-36 was invalid for severe functional 
somatic syndromes like IBS, especially regarding PCS (144), so there is a need for more 
research to find out if SF-36 is a good tool in IBS- and coeliac patients or not.  
 
Mental health improved numerically in both groups, but the improvements were not statistically 
significant. Less abdominal symptoms will probably make a person less fatigued, unenterprising 
and depressed. Average scores in both groups were below the normal value 50 which is the 
mean in the Norwegian control population (128, 129), at baseline and by the end of the diet, but 
not that much and within the standard deviation of normals ±10. There would maybe be a 
greater improvement if the intervention lasted for a longer time, since it can feel demanding to 
learn and adapt to a new diet.  
 
When looking at the eight dimensions; physical role, bodily pain and general health were the 
factors that were statistically significant improved in group B. There are four questions about the 
physical health’s influence on work and daily activities that are summed and give the score for 
physical role. Physical role improved to a bit higher score than the general population. Two 
questions about the severity of bodily pain and its influence on work and daily activities gives 
the score for bodily pain, which was a bit lower for group B compared to the general Norwegian 
population. General health is made up of five questions where the patients should answer what 
they think about their health, if they expected to get more ill, if they think they are sicker than 
others etc. General health in group B was quite lower than the general population, indicating that 




The scores for physical function and emotional role are better than the general population in 
both groups at both time points except for emotional role at baseline in group B. Ten questions 
about the physical health’s influence on performance of activities like running, lifting heavy 
objects, walking and dressing up are summed and give the score for physical function. There are 
three questions about emotional problems’ influence on work and daily activities that are 
summed and give the score for emotional role. 
 
Social function is made up of two questions; if the health is influencing the patient’s social life 
and to what degree. The patients in our study scored lower than the general population on this 
dimension, indicating that their diseases affect their social life in a bad way. Five questions 
about quantification of for example nervousness, depression, harmony and happiness is giving 
the score for mental health. The patients in group B scored better than the Norwegian control 
population at the end of the diet, while group A did not. As discussed earlier, group B had the 
greatest effect in reducing abdominal symptoms, which may be the reason for scoring higher on 
the mental health since physical and mental health are clearly connected. Vitality improved in 
both groups, but was still lower than the general population. Quantitative questions about 
initiative, energy and tiredness are summed up in this score. Another study found that vitality 
and general health were the dimensions coeliac patients scored lower on than a general 
population (145), which is consistent with our findings. Several studies on IBS patients have 
also found a reduced quality of life compared to a general population/control group by using SF-
36 (58, 139-142), and one study found that the quality of life was lower in a group of patients 
who had both IBS and functional dyspepsia, than a group with IBS only (138).  
 
4.10 Self-reported compliance  
The compliance questionnaires are not validated. Misreporting and misunderstandings are 
possible problems. The forms could have been developed better by making the VAS-scales the 
same for all the questions (0 the worst and 100 the best for example). This would make it easier 
to compare the different questions. The patients could maybe fill in the form after three weeks in 
addition to baseline and six weeks, to see if the diet was followed strictly after three weeks or if 
they needed more time to get the routines.  
 
It is not surprising that the patients in group B in general were more satisfied with the diet’s 
effect on pain relief than group A, since group B got the greatest decrease in abdominal 
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symptoms and improvement in physical quality of life. Both groups reported high accuracy 
which is reflected in a statistically significant reduction in FODMAP intake for group B. Ideally 
the intake of gluten should be measured in both groups to check for compliance (especially 
group A), but this would have been really difficult. The low FODMAP diet was the most 
demanding diet to follow, most likely because there are more exclusions and changes in the diet. 
16 patients (80%) in group B said they had continued with the diet 4 weeks after the intervention 
finished, which may express an ongoing effect in reducing symptoms and improving the quality 
of life. 
 
4.11 Blood test 
The blood tests were used as an explanatory variable. It was interesting to check the patients’ 
values of different nutrients, liver tests and of course the coeliac tests. Based on these findings, 
efforts like more tests or supplementation could be suggested. Both patients with raised and 
normal coeliac tests were included. Antibodies will probably still be present for 6 months to 1 
year after starting on a gluten free diet. Maybe patients with abnormal tests should be excluded 
or maybe the participants should be given treatment based on their coeliac tests? One idea is to 
give the participants with raised levels a more strict gluten free diet without wheat starch and 
“traces of gluten” first, before perhaps trying a low FODMAP diet, to see if this more strict 
gluten free diet would normalize their coeliac tests. The participants with normal coeliac tests 
could try the low FODMAP diet at once. Then it wouldn’t be a randomized trial though.  
 
The mean calcium- and vitamin D3 levels were normal in both groups at both time points. The 
dietary intake affects the calcium level in blood to a low degree. Osteoporosis is more common 
in people with coeliac disease because of a malabsorption of calcium and then a reduced bone 
mineral density (1, 47-49). The decrease in vitamin D3 from baseline to six weeks in the two 
groups is probably not because of the diets, since none of the interventions reduced or excluded 
good sources of vitamin D3 like for instance fatty fish. It is more reasonable to think about the 
time of the year.  
 
Regarding anti-transglutaminase 2 IgA and anti-deamidated gliadin IgG, the median of both 
values were statistically significant lowered after six weeks in both groups. All the values except 
for one in group A (anti-transglutaminase 2 IgA) were lowered after six weeks. This indicates 
that less gluten was ingested when following the more strict diets, but their values at the time of 
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diagnosis are not known. There are possible sources of error. In the pre-analytical phase there is 
biological variation (inwards and between persons), medication-use, stress, body position, 
fasting, physical activity, circadian rhythm etc. There can also be errors in the pre-instrumental 
phase, in the sampling, the analytical phase and the post-analytical phase like transport and 
storage. 
 
4.12 Breath test, gas production, stool samples and microbiota 
This is not discussed here, because it is done in another Master’s Thesis. 
 
4.13 Possible improvements to the study 
With more resources and money, the study could maybe been better. If the study should be done 
all over again, the recruiting process should be started earlier and more patients could be 
included to get a better scientific power and make the study even more representative for the 
population. A third group continuing eating their regular gluten free diet serving as a placebo 
group, or a group eating their gluten free diet in addition to following the general 
recommendations when having an irritable bowel (but not the low FODMAP diet) could also be 
possibilities. Making the study double blind is really hard, but would have been even better. 
Provocation with FODMAP after the strict phase could also be a possibility, but it is maybe 
unethical to cause more symptoms in patients. 
 
More and better information about the FODMAP content (total and the different types) in food 
is necessary to get more precise results, especially from Norway. It would have been interesting 
to study other micronutrients in addition to calcium and vitamin D3. Making the compliance 
questionnaires simpler, using SF-12 instead of SF-36 maybe, a longer intervention-time (8 
weeks?) and more precise dietary intake records are other efforts that could have been done. It 
would also be interesting to know when the patients got the coeliac disease diagnosis and for 
how long they had been eating a gluten free diet, to see if these factors affect the response to the 
diets or not. It would maybe be better to individualize the meetings. The patients reported their 
weight and height at baseline, but it would be better to measure their actual weight and height at 
the baseline meeting and also after six weeks to see if the strict diets lead to weight loss. 
Calculating the amount of gluten intake and all the different FODMAP groups and not only 





The purpose of this project was to investigate whether patients with coeliac disease and IBS-like 
symptoms could have a benefit on abdominal symptoms and quality of life, from FODMAP 
reduction in addition to their gluten free diet. The aim was also to investigate whether a low 
FODMAP diet would have any effect on the gut microbiota and the degree of fermentation by 
gut bacteria, measured with breath tests and stool samples (another Master’s Thesis).  
 
This study showed a statistically significant improvement in abdominal symptoms and 
subjective report of physical health in a group of patients with coeliac disease and irritable 
bowel syndrome-like symptoms, after following a low FODMAP diet for six weeks. The low 
FODMAP diet was more effective than a more strict gluten free diet without wheat starch and 
“traces of gluten”, and should be offered to coeliac patients with IBS-like symptoms. A lowered 
intake of fermentable oligo-, di-, monosaccharides and polyols which leads to less production of 
gas, and then less water and pressure on the bowel, is probably the cause for the improvement. 
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Attachment 2: IBS-SSS 
IBS-SSS 
 
1.  Har hatt tilfredsstillende lindring av dine IBS-smerter/-ubehag de siste 7 dager? 
Sett en ring rundt svaret ditt. JA NEI 
 
2. a) Har du magesmerter? Sett en ring rundt svaret ditt.  JA NEI 
 
b) Dersom ja, hvor sterke er magesmertene? (marker på linja) 
0%          100% 
 
 
Ingen smerte        Veldig mye smerte 
 
 
c) Oppgi antall dager du har kjent magesmerter i løpet av en 10 dagers periode. Dersom 
du f.eks. skriver 4 betyr det at du har smerte 4 av 10 dager. Om du har smerte hver dag, 
skriver du 10. 
 
Antall dager med smerte: _________ 
 
3. a) Har du oppblåst og/eller spent mage? Sett en ring rundt svaret ditt. JA NEI 
 
b) Dersom ja, hvor mye plaget er du? (marker på linja) 
0%          100% 
 
 




4.  Hvor fornøyd er du med dine avføringsvaner? (marker på linja) 
0%          100% 
 
 
Veldig fornøyd       Veldig misfornøyd 
  
      
5.  Angi med en strek på linja nedenfor hvor mye dine IBS- plager påvirker livet ditt 
generelt. 
0%          100% 
 
 






Lider du av følgende: 
a) Kvalme og/eller oppkast? 
0%          100%  
aldri          hele tiden 
       
b) Vanskelig for å spise opp alt ved måltidet? 
0%          100%  
aldri          hele tiden 
 
c) Hodepine? 
0%          100%  
aldri          hele tiden 
 
d) Ryggsmerter? 
0%          100%  
aldri          hele tiden 
 
e) Uopplagt eller trøtt? 
0%          100%  
aldri          hele tiden 
 
f) Raping og/eller gassavgang? 
0%          100%  
aldri          hele tiden 
 
g) Halsbrann? 
0%          100%  
aldri          hele tiden 
 
h) Hyppig eller plutselig trang til vannlating? 
0%          100%  
aldri          hele tiden 
 
 
i) Smerter i låret? 
0%          100%  
aldri          hele tiden 
 
 
j) Smerte i muskler og ledd? 
0%          100%  






Attachment 3: SF-36 
 
                   SF-36 Norsk versjon 
 
SF-36® Health Survey© 1988, 2002 by JE Ware, Jr., MOT, Health Assessment Lab, 
QualityMetric Incorporated – All rights reserved 
SF-36® is a registered trademark of the Medical Outcomes Trust (MOT) 
 
Vi spør deg her om hvordan du opplever din egen helse. Vi ønsker å vite hvordan du føler deg 
og hvordan du mestrer dine vanlige aktiviteter.  
Vær snill å svare på alle spørsmål. Noen av spørsmålene ligner på hverandre, men alle er 
forskjellige. Ta deg tid til å lese spørsmålene nøye og svar med et kryss for det alternativ som du 
velger! 









2.  Sammenlignet med for ett år siden, hvordan vil du si at helsen din stort sett er nå? 
 
Mye bedre 
nå enn for 




nå enn for 


























    









  3.  De neste spørsmålene handler om gjøremål som du kanskje utfører i løpet av en vanlig 
dag. Er din helse nå slik at den begrenser deg i utførelsen av disse aktivitetene? Hvis ja, 
hvor mye? 






meg ikke i 
det hele tatt 
Anstrengende aktiviteter, som å løpe, løfte tunge 
gjenstander, delta i anstrengende idrett 
○ ○ ○ 
Moderate aktiviteter, som å flytte et bord, støvsuge, gå en 
tur eller drive med hagearbeid 
          ○           ○           ○ 
Løfte eller bære en handlekurv 
○ ○ ○ 
Gå opp trappen flere etasjer 
○ ○ ○ 
Gå opp trappen en etasje 
○ ○ ○ 
Bøye deg eller sitte på huk 
○ ○ ○ 
Gå mer enn to kilometer 
○ ○ ○ 
Gå noen hundre meter 
○ ○ ○ 
Gå hundre meter 
○ ○ ○ 
Vaske deg eller kle på deg 
○ ○ ○ 
 
 4  I løpet av de siste fire ukene, har du hatt noen av følgende problemer i ditt arbeid eller 














Har du redusert tiden du har brukt på 
arbeidet ditt eller andre aktiviteter 
○ ○ ○ ○ ○ 
Har du utrettet mindre enn du hadde 
ønsket 
○ ○ ○ ○ ○ 
Har du vært hindret i visse typer arbeid 
eller andre aktiviteter 
○ ○ ○ ○ ○ 
Har du hatt vansker med å utføre arbeidet 
ditt eller andre aktiviteter (for eksempel 
fordi det krevde ekstra anstrengelser) 





  5.   I løpet av de siste fire ukene, har du hatt følelsesmessige problemer som har ført til 
vanskeligheter i ditt arbeid eller i andre av dine daglige gjøremål (for eksempel fordi du har 

















Har du redusert tiden du har brukt 
på arbeidet ditt eller andre aktiviteter 
○ ○ ○ ○ ○ 
Har du utrettet mindre enn du hadde 
ønsket 
○ ○ ○ ○ ○ 
Har du ikke arbeidet eller utført andre 
aktiviteter like nøye som vanlig 
○ ○ ○ ○ ○ 
 
6.   I løpet av de siste 4 ukene, i hvilken grad har din fysiske helse eller følelsesmessige 




















       ○ 


























 8. I løpet av de siste 4 ukene, hvor mye har smerter påvirket ditt vanlige arbeid (gjelder 



























  9.   De neste spørsmålene handler om hvordan du har følt deg og hvordan du har hatt det 
de siste 4 ukene. For hvert spørsmål, vennligst velg det svaralternativet som best 















følt deg full av tiltakslyst? ○ ○ ○ ○ ○ 
følt deg veldig nervøs? ○ ○ ○ ○ ○ 
vært så langt nede at ingenting 
har kunnet muntre deg opp? 
○ ○ ○ ○ ○ 
følt deg rolig og harmonisk? ○ ○ ○ ○ ○ 
hatt mye overskudd? ○ ○ ○ ○ ○ 
følt deg nedfor og trist? ○ ○ ○ ○ ○ 
følt deg sliten? ○ ○ ○ ○ ○ 
følt deg glad? ○ ○ ○ ○ ○ 
følt deg trøtt? ○ ○ ○ ○ ○ 
 
 
10.   I løpet av de siste 4 ukene, hvor mye av tiden har din fysiske helse eller 







        ○ 
En del av 
tiden 
        ○ 
Litt av 
tiden 
         ○ 
Ikke i det 
hele tatt 
       ○ 
 











Det virker som jeg blir litt lettere syk enn 
andre 
○ ○ ○ ○ ○ 
Jeg er like frisk som de fleste jeg kjenner ○ ○ ○ ○ ○ 
Jeg forventer at min helse vil bli dårligere ○ ○ ○ ○ ○ 




Attachment 4: Compliance with gluten free diet (group A) 
 
Overholdelse av strikt glutenfri kost gjennom 6 uker  
Hvor fornøyd er du med strikt glutenfri kost som symptomlindring?  
Svært fornøyd                                                                         Svært misfornøyd 
0%                                                                                                           100% 
 




 Kun dersom jeg får videre veiledning 
 
Hvis nei, hvorfor: 
 For tidkrevende 
 Savner for mange matvarer 
 Ble ikke bedre 
 For dyrt 
 
Hvor nøye har du fulgt strikt glutenfri kost gjennom de 6 ukene? 
Ikke fulgt den i det hele tatt       Kun spist strikt glutenfri kost  
0%                                                                                            100% 
 
Hvor ofte hadde du avvik fra dietten i løpet av de 6 ukene: 
 Ingen ganger 
 1-5 ganger i løpet av de 6 ukene 
 1-3 ganger i uken 
 4-6 ganger i uken 
 
Hvor store mengder inntok du ved avvik fra dietten? 
 En munnfull 
 2-5 munnfull 
 Et helt måltid 
 Alle måltidene i løpet av dagen 
 
Hvor lenge gikk du på dietten før du spiste matvarer med hvetestivelse/spor av gluten? 
 Ingen dager 
 1-3 dager 
 4-7 dager 
 2-3 uker 




Hvordan synes du det var å følge dietten: 
Kjempelett          Veldig utfordrende 
  0%                                                                                                      100% 
  
Hvorfor spiste du matvarer som inneholdt hvetestivelse/spor av gluten: 
 Spiste kun strikt glutenfri kost  
 Ikke tilgang på mat uten hvetestivelse/spor av gluten på restaurant/gatekjøkken 
 For tidkrevende  
 Hadde lyst på mat med hvetestivelse/spor av gluten 
 Mat uten hvetestivelse/spor av gluten var for dyr 
 Visste ikke at matvaren inneholdt hvetestivelse/spor av gluten 
 
Hvor fornøyd er du med informasjonen du fikk om dietten: 





















Attachment 5: Compliance with low FODMAP diet, 6 weeks (group B)  
 
Overholdelse av lav-FODMAP dietten gjennom 6 uker 
 
Hvor fornøyd er du med lav-FODMAP dietten som symptomlindring?  
Svært fornøyd                                                                         Svært misfornøyd 
0%                                                                                                          100% 
 




 Kun dersom jeg får videre veiledning 
 
Hvis nei, hvorfor: 
 For tidkrevende 
 Savner for mange matvarer 
 Ble ikke bedre 
 For dyrt 
 
Hvor nøye har du fulgt lav-FODMAP dietten gjennom de 6 ukene? 
Ikke fulgt den i det hele tatt       Kun spist lav-FODMAP mat                                                                                                                                                                       
 0%                                                                                            100% 
 
Hvor ofte hadde du avvik fra dietten løpet av de 6 ukene: 
 Ingen ganger 
 1-5 ganger i løpet av de 6 ukene 
 1-3 ganger i uken 
 4-6 ganger i uken 
 
Hvor store mengder FODMAPs inntok du ved avvik fra dietten? 
 En munnfull 
 2-5 munnfull 
 Et helt måltid 
 Alle måltidene i løpet av dagen 
 
Hvor lenge gikk du på dietten før du spiste matvarer med FODMAPs: 
 Ingen dager 
 1-3 dager 
 4-7 dager 
 2-3 uker 
 3-5 uker 
104 
 
Hvilke matvarer inneholdt avvik fra dietten: 
 Fruktoseholdige matvarer som eple, pære, honning, juice, tørket frukt (rosiner, svisker, 
aprikos), asparges  
 Laktoseholdige matvarer som melk/fløte/yoghurt og matvarer med laktose (vafler, 
boller, kaker, is etc.), melkesjokolade. 
 Fruktanholdige matvarer som inneholder hvete, rug og bygg som for eksempel brød, 
boller, vafler, kjeks, middagsmat med hvetemel. 
 Fruktanholdige matvarer som inneholder løk eller hvitløk, f.eks. middagsmat, krydder, 
ferdigretter.  
 Galaktanholdige matvarer som bønner, linser, kikerter eller pistasjnøtter.  
 Polyoler som man finner i sukkerfrie pastiller eller tyggis. 
 Polyoler som man finner i avokado, aprikos, blomkål, plomme, sopp, vannmelon. 
 
Hvordan synes du det var å følge dietten: 
 
Kjempelett          Veldig utfordrende         
  0%                                                                                                      100% 
  
Hvorfor spiste du matvarer som inneholdt FODMAPs: 
 Spiste kun lav-FODMAP mat 
 Ikke tilgang på lav-FODMAP mat på restaurant/gatekjøkken 
 For tidkrevende å lage lav-FODMAP mat 
 Hadde lyst på mat med FODMAP 
 Lav-FODMAP mat var for dyr 
 Visste ikke at matvaren inneholdt FODMAPs 
 
Hvor fornøyd er du med informasjonen du fikk om dietten: 









Attachment 6: Compliance with low FODMAP diet, 10 weeks (group B)  
 
Overholdelse av lav-FODMAP dietten én måned etter diettslutt 
 






Hvor godt har du oppretthold lav-FODMAP dietten etter 1 mnd.? 
Gått tilbake til mitt normale kosthold                                Kun spist lav-FODMAP 
0%                                                                                                           100% 
 
Hva er grunnen til at du ikke spiser 100% lav-FODMAP lenger? 
 Ikke aktuelt, følger fortsatt dietten for fullt 
 Merket ikke noe effekt av dietten 
 Merket ikke god nok effekt til å ofre mitt vanlige kosthold 
 Det er kun noen matvarer jeg reagerer på 
 Savnet for mange matvarer 
 
Dersom du har fulgt dietten, har du reintrodusert noen FODMAPs? 
 Ja 
 Nei 
 Kun noen matvarer 
 Prøvd, men ble dårlig av alt 
 
Hvordan synes du det var å reintrodusere matvarer til dietten? 
Kjempelett                                                                       Meget vanskelig 
0%                                                                                                       100% 
 
Hva var utfordrende med reintrodusering av matvarer: 
 Visste ikke hvordan jeg skulle gjøre det 
 At jeg mest sannsynlig kom til å få symptomer av den matvaren 
 Vanskelig å skille «normale symptomer» med strikt diett (jeg ble ikke helt frisk med dietten) og 
symptomer jeg evt får når jeg innfører ulike FODMAPs igjen 
 Vanskelig å vite om jeg fikk symptomer fra akkurat den matvaren 
 Hadde ikke problemer med re-introdusering 





Hva var det du prøvde å reintrodusere først? 
 Fruktoseholdige matvarer som eple, pære, honning, juice, tørket frukt (rosiner, svisker, 
aprikos), asparges  
 Laktoseholdige matvarer som melk/fløte/yoghurt og matvarer med laktose (vafler, 
boller, kaker, is etc.), melkesjokolade. 
 Fruktanholdige matvarer som inneholder hvete, rug og bygg som for eksempel brød, 
boller, vafler, kjeks, middagsmat med hvetemel. 
 Fruktanholdige matvarer som inneholder løk eller hvitløk, f.eks middagsmat, krydder, 
ferdigretter.  
 Galaktanholdige matvarer som bønner, linser, kikerter eller pistasjnøtter.  
 Polyoler som man finner i sukkerfrie pastiller, tyggis, avokado, aprikos, blomkål, 
plomme, sopp og vannmelon. 
 
Kommer du til å fortsette på lav- FODMAP dietten fremover? 





Hvilken type FODMAP tror du at du ikke tåler? Flere kan krysses av. 
 Tåler alle 
 Tåler ingen 
 Fruktoseholdige matvarer som eple, pære, honning, juice, tørket frukt (rosiner, svisker, 
aprikos), asparges  
 Laktoseholdige matvarer som melk/fløte/yoghurt og matvarer med laktose (vafler, 
boller, kaker, is etc.), melkesjokolade. 
 Fruktanholdige matvarer som inneholder hvete, rug og bygg som for eksempel brød, 
boller, vafler, kjeks, middagsmat med hvetemel. 
 Fruktanholdige matvarer som inneholder løk eller hvitløk, f.eks middagsmat, krydder, 
ferdigretter.  
 Galaktanholdige matvarer som bønner, linser, kikerter eller pistasjnøtter.  
 Polyoler som man finner i sukkerfrie pastiller, tyggis, avokado, aprikos, blomkål, 













NAVN  ___________________________________________________ 
 
ADRESSE  ___________________________________________________ 
   ___________________________________________________ 
 
FØDSELSNR  ___________________________________________________ 
 
HØYDE  ___________________________________________________ 
 
VEKT   ___________________________________________________ 
 
KLINISK ERNÆRINGSFYSIOLOG  ______________________________________ 
 
Skjemaet returneres i utfylt stand til: 
Helse Bergen HF 









Slik går du frem: 
 
For at vi skal kunne beregne næringsstoffinntaket ditt så nøyaktig som mulig, er det nødvendig at du noterer alt du 
spiser og drikker i løpet av en 4 dagers sammenhengende periode. Perioden onsdag til lørdag (evt. søndag til 
onsdag) er best, for da får du med én helgedag. 
Det er vesentlig at du spiser slik som du pleier i registreringsperioden. 
 Angi klokkeslett for hver gang du spiser eller drikker noe.  
 Beskriv mat og drikke så nøyaktig som mulig 
- Brød: Type, navn, grovhet, tykkelse på skiver, antall skiver. Ev. rundstykke, knekkebrød.. 
-Fett på brødet: Type, navn, mengde, lett eller vanlig 
- Pålegg: Type, mengde, produktnavn, lett eller vanlig  
- Middag: Type kjøtt, fisk, kjøttfarse-/fiskeprodukt. Produktnavn. Fettprosent. 
- Frukt og grønnsaker: Rå, kokt eller hermetisk.  
 Beskriv hvordan maten er tilberedt. 
-Kokt, bakt, stekt, grillet eller varmet i mikrobølgeovn 
- Er maten er renset for skinn og/eller fett? 
 Hjemmelagede matretter beskrives i detalj, gjerne ved å skrive ned oppskriften bak på arket. 
 Notér alt tilbehør, som saus, pickles, rømme, dressing eller krem, med navn/produsent. Oppgi også om du 
bruker sukker på gryn, grøt eller i te.  
 Få med alle mellommåltider, samt tilfeldig spising og drikke utenom de faste måltidene.  
 Kosttilskudd, som tran, vitamintabletter o.l. skal også noteres, med navn, produsent og mengde. 
 Mengder kan beskrives på følgende måte: 
- aller helst skal du veie maten og føre mengden opp i gram 
- hvis du ikke kan veie, kan du angi mengder i husholdningsmål, som   
- spiseskje, glass, desiliter eller antall, alt ettersom hva som er hensiktsmessig  
- oppgi størrelse på glassene du bruker i dl 
Eksempel: 
Kl Tirs dag 14 / 1 / 11 Produktnavn/Produsent Vekt  
0730 1 butikkskåret skive kneip Bakers 30g 
 m/ skrapet lag margarin Soft Soya  
 3 høvelskiver hvitost, 16% fett Norvegia, Tine  
 1 stor grapefrukt  200g 
 1 stort glass lettmelk (Stort glass = 2 dl) Tine  
1100 1 beger fruktyoghurt Yoplait Dobbel 0%, mango 125g 
 1 melkesjokolade  Freia 100g 
 1 kopp svart kaffe  150g 
1500  kokt torsk  140g 
 3 små potete, kokt  150g 
 3 toppede ss revet gulrot   
 1 ss remulade Idun  
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Har du nettopp fått diagnosen cøliaki? 
Se kapittel 14 for praktiske tips og råd den første tiden. 
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1. Hva er gluten? 
Gluten er en fellesbenevnelse på tre forskjellige, men likevel ganske like, proteiner som 
finnes i hvete, rug og bygg. Vanlig havre kan også inneholde gluten på grunn av forurensing fra 
andre kornslag. Kornslagene spelt, dinkel, kamut og rughvete inneholder også gluten. 
 
2. Hvem trenger glutenfri kost? 
Cøliaki 
Ved cøliaki skades tarmen ved inntak av gluten, og evnen til å fordøye maten avtar. Dette medfører at 
en redusert mengde av matens næringsstoffer tas opp som igjen kan føre til magesmerter og 
underernæring 
Hos barn er et vanlig symptom på cøliaki at vekstkurven flater ut. 
Hos voksne er de klassiske symptomene på ubehandlet cøliaki jernmangel, diaré og avmagring, mens 
noen opplever trøtthet og dårlig matlyst. Det er heller ikke uvanlig å ikke ha symptomer i det hele tatt. 
 
Frisk tarm                                          Skadet tarm 
 
Når de som har fått stilt diagnosen cøliaki konsekvent holder en glutenfri kost, vil tarmen leges. 
Fordøyelsesproblemene vil avta og kroppen vil kunne utnytte maten på vanlig måte. 
Tarmslimhinnen vil alltid reagere på gluten og selv små mengder kan gi tilbakefall, med eller uten 
symptomer. Derfor må et glutenfritt kosthold følges strengt og vare livet ut. 
Det er viktig at ingen starter på glutenfri diett før sikker diagnose er stilt ved tynntarmsbiopsi. 
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Dermatitis herpetiformis (DH) 
Dette er en relativt sjelden hudsykdom med kløende utslett og væskefylte blemmer. Tarmslimhinnen er 
også angrepet på lignende måte som ved cøliaki, men vanligvis i noe mindre grad. Dette fører i mange 
tilfeller til underernæring, men sjelden til større problemer med fordøyelsen. Glutenfri kost er en viktig 
del av behandlingen av DH. 
Tarmslimhinnen blir normal på glutenfri kost og hudsymptomene vil ofte bedres, men det kan ta opptil 
et par år. 
Enkelte kan også ha nytte av jodredusert kost, og vil kunne få veiledning i forhold til dette. 
 
Hveteallergi / hveteintoleranse 
Ved  hveteproteinallergi  og  hveteintoleranse  vil  det  i  tillegg  til  reaksjon  på  hvete  ofte 
forekomme kryssreaksjoner på rug og bygg. Derfor brukes ofte glutenfri kost. 
Samtidig intoleranse overfor havre er mindre vanlig, men vanlig havre kan være forurenset med 















3. Innholdsdeklarasjon og merking av glutenfrie produkter 
 
Alle ferdigpakkede matvarer skal være merket med en innholdsdeklarasjon, som skal være skrevet på 
norsk, svensk, dansk eller engelsk. Innholdsdeklarasjonen er det beste hjelpemiddel man har til å 
vurdere om et sammensatt produkt er glutenholdig. 
 
Merkeforskriften setter særlige krav til merking av allergener. Dette innebærer at en rekke 
matallergener inkludert gluten/glutenholdige ingredienser alltid skal deklareres i ingredienslisten, selv 
om de er tilsatt i ørsmå mengder.  Det er en rekke ingredienser som inneholder gluten (se side 10). 
Matvarer som er merket med svært lavt gluteninnhold eller glutenfritt kan brukes uten at man må sjekke 
ingredienslisten. 
Dessverre er ikke  alle  matvarer  merket  med  innholdsdeklarasjon.  Dette  gjelder  bl.a. ferskvarer og 
andre produkter som selges i løs vekt. I slike tilfeller må man forhøre seg hos butikkbetjeningen eller 
produsenten. Ikke bruk matvarer med ukjent sammensetning! 
Det forekommer en gang i blant at produsenten endrer oppskrifter slik at tidligere glutenfrie produkter 
får ny, glutenholdig ingrediens, sjekk derfor deklarasjonen på produkter du kjenner fra tid til annen. 
 
Et nytt, strengere, regelverk for merking av glutenfrie produkter trådde i kraft i 2012. Det nye 
regelverket innebær at den øvre grensen for innhold av gluten senkes fra 200 mg gluten/kg til 100 mg 
gluten/kg. 
Svært lavt gluteninnhold: 
Produkter merket med ”svært lavt gluteninnhold” kan ikke ha et gluteninnhold som overstiger 
100 mg/kg i produktet som selges til forbrukeren.  Gluteninnholdet i disse matvarene er så lave at de kan trygt 
brukes av de aller fleste med cøliaki. 
Glutenfri: 
Produkter merket med ”glutenfri” skal inneholde mindre enn 20 mg gluten/kg ferdig produkt. Produkter som 
tidligere ble merket ”naturlig glutenfri” skal i henhold til den nye forskriften merkes ”glutenfri”. 
 
Ubearbeidet frukt, bær, grønnsaker, kjøtt og fisk vil ikke bli merket som glutenfrie selv om de er 
naturlig glutenfrie men kan trygt benyttes, se også Kostsirkelen side 6. 
 
Image: m_bartosh / FreeDigitalPhotos.net 
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”Kan inneholde spor av...” 
Mange matvarer  er  merket  med  ”spor  av”  hvete,  gluten  eller  andre  glutenholdige 
ingredienser.   Denne  merkingen  innebærer   ikke   at   hvete   eller   andre   glutenholdige 
ingredienser inngår som en del av produktet, men at produktet er laget i omgivelser der det 
også lages glutenholdige varer. Produksjonsomgivelsene innebærer altså en risiko for at det 
merkede produktet kan være kontaminert.  Erfaring tilsier at disse produktene kan brukes av 
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Kan inneholde gluten. 











Rene råvarer fra matvaregruppene melk, kjøtt, fisk, egg, ris, poteter, grønnsaker, frukt og bær er 
naturlig frie for gluten. Disse matvarene er en viktig del av et næringsrikt kosthold, og bør inngå i 
glutenfritt kosthold. 
Spis normale mengder kjøtt, fisk, egg og meieriprodukter, som gir protein, vitaminer og mineraler. 
Grønnsaker, poteter, frukt og bær gir i tillegg karbohydrater og fiber, og bør brukes i større mengder 
hver dag. Som i sunn kost ellers bør man begrense inntaket av produkter rike på fett og sukker, som 









5. Havre ved cøliaki 
 
Glutenfri havre / Ren havre 
Glutenfri havre tåles av de fleste med cøliaki. Vanlig havre kan være forurenset med gluten fra 
industriell produksjon og bearbeiding. Det må derfor kun brukes havre og havreprodukter som er merket 
”ren” eller ”glutenfri”. 
Det anbefales at havre introduseres etter at glutenfri diett er veletablert og pasienten er symptomfri. 
Eventuelle reaksjoner på havre kan da lettere oppdages og følges opp. Fordi noen kan få mage-
tarmsymptomer på grunn av det høye fiberinnholdet i havre, anbefales gradvis innføring av havre i 
kostholdet. Bruk av havre kan på en positiv måte bidra til økt fiberinntak i glutenfri kost og kan gi større 
variasjon i kosten. 
For  barn  anbefaler  fagrådet  i  Norsk  cøliakiforening  at  man  venter  med  å  introdusere 





6. Laktoseredusert kost 
Fordøyelsen av melkesukker (laktose) er ofte nedsatt når tarmen er skadet. Vanlig melk, brunost og 
iskrem medfører ofte mageknip og mye luft i tarmene. 
Laktosefrie melkeprodukter og alle hvitoster inneholder ingen laktose og tåles godt. Syrnede 
melkeprodukter, som kulturmelk og yoghurt i begrensede mengder, samt laktoseredusert lettmelk, tåles 
også av de fleste. Etter ca 6 uker tåler de fleste noe laktose, og melk og brunost kan gradvis 
introduseres i kosten igjen. 









7. Oversikt over matvarer som er glutenfrie, samt matvarer som 
inneholder glutenholdige ingredienser 
 
Matvarer Glutenfritt/svært lavt 
gluteninnhold 
Glutenholdig, kan ikke brukes 




Rømme, kesam, creme 
fraiche 
Yoghurt m/müsli 




Alle sorter rent kjøtt, innmat, 
farsevarer uten gluten. 
Alle sorter ren fisk, lever, rogn, 
farsevarer uten gluten. 
Alle sorter skalldyr. 
Eggeretter uten gluten. 
Pølser, panert kjøtt og kjøttfarser 
tilsatt glutenholdige ingredienser.  
 
Leverpostei kan inneholde hvetemel.  
 
Panert fisk og fiskefarser tilsatt 
glutenholdige ingredienser. 
Fiskekaker o.l. kan være tilsatt 
glutenholdige ingredienser som 
kavring/hvetemel 
Griljert og fritert mat kan inneholde 
mel og kavring. 
Gryn, mel 
og brød 
Flak, gryn og mel av amarant, 
bokhvete, hirse, mais, ris, soya, 
tapioka, quinoa og teff. 
Ren havre (merket glutenfri) 
Polentagryn, potetmel, potetfiber, 
sagogryn, kastanjemel ,arrowrot, 
sesamfrø, solsikkefrø, linfrø, 
valmuefrø, kokosmasse, 
sukkerroefiber og psylliumfrøskall. 
Glutenfrie melblandinger, 
Glutenfrie varianter av brød, 
knekkebrød, flatbrød, kjeks, kaker, 
pølsebrød, rundstykker, kavring og 
lomper. 




Semulegryn, hvetekli, hvetekim 
Cous-cous, bulgur 
Vanlig brød, knekkebrød, kjeks, 
flatbrød og andre bakverk 
 






Puffet ris, cornflakes uten 
maltekstrakt, 
Glutenfri pasta, ris. 
Barnegrøt: ris- og maisgrøt og andre 
glutenfrie grøter. Sinlac grøt. 
 
Sausejevning av mais. 
Vanlig pasta, hveteris, byggris 
 




frukt og bær 
Alle rene varer. Stuinger o.l. tilsatt glutenholdige 
ingredienser. 
Sprøstekt løk kan inneholde hvetemel. 
Fett, olje Olje, margarin, smør, majones, 





Søtt pålegg, honning, drops, 
sjokolade uten glutenholdig 
kjeks/crisp, ekte marsipan, lakris, 
lakrisprodukter uten gluten og 
karamell uten gluten. 
Sjokolade/sjokoladepålegg med 
kjeks/crisp, mandelmasse tilsatt 
gluten, enkelte lakris- og 
karamellprodukter, maltekstrakt og 
konfekt med glutenholdig fyll. 
Drikke Kaffe, te, melk, juice, saft, iste, kakao og 
smoothie (uten glutenholdig gryn/korn) 
 
Øl laget på malt fra glutenfrie 
kornsorter som hirse, bokhvete, 
sorghum eller teff. 






Øl Diverse Sauser, gryteretter, supper o.l. uten 
gluten. 
 
Soyasaus uten gluten, buljong uten 
gluten, krydder og ølgjær uten gluten. 
De fleste sauser, gryteretter og 
supper. 
Enkelte chipstyper og nøtteblandinger kan 
være tilsatt kavring/brødsmuler. 
Maltekstrakt, soyasaus med hvete, buljong 
med gluten, krydderblandinger tilsatt 







Produsenter er forpliktet til å oppgi om et sammensatt produkt inneholder glutenholdige ingredienser men 
det krever at man selv vet hvilke ingredienser det gjelder. 
 Ingredienser* som inneholder gluten: Ingredienser* som er glutenfrie 
A  Amarant, Arrowrot, 
B Bygg, Brødsmuler Bakepulver, Bokhvetemel 
C Cous-cous Carob, 
D Dinkelhvete, Durumhvete  
E  E-nr. (alle er glutenfrie), Emulgeringsmel, 
F Fullkornsmel Fruktkjernemel, Fortykningsmiddel, 
G Grynmel, Grahamsmel Glukosesirup av hvete, Glutamat, Glutaminsyre, 
Glutinous (ris), Glukosesirup (alle typer), 
Glyserol, Guarkjernemel, Guargum, Glutenfri 
havre 
H Havre (vanlig), Havrekli, Havrekorn, Havremel, 
Hvete, Hvetekim, Hveteprotein, 
Hvetestivelse** 
Havre (glutenfri), Hirse, Humle, 
Hvetestivelse**, Husk (psylliumfrøskall), 




Kamut (egyptisk hvete), Kavring, Kim, Kli, 
Korn, Kruskablanding 
Kastanjemel, Kikertmel (rent), 
Klumpforebyggende middel, Kostfiber 
(produsenten opplyser dersom kostfiber er fra 
glutenholdige råvarer), 
  Linfrø, 
M Malt, Maltekstrakt, Maltsirup Maltodextrin (fra hvete), Maltarom, Maltose, 
Maltsukker, Mandelmel (rent), Modifisert 
stivelse (dekstrin fra hvete), MSG- 
smaksforsterkere E621 og E637, 
N Nudler  
P Puffet havre, Puffet hvete Polentagryn, Potetfiber, Potetmel, Prekokt, 
rismel, Psylliumfrø, Psylliumfrøskall (husk) 
Q  Quinoamel, 




Semulegryn, Spelt, Strøkavring, Strømel Soyagryn, Soyamel, Sorghummel, Sesamfrø, 
T Tritikale Tapioka, Tarakjernemel, Teff, 
V  Valmuefrø 
Ø Ølgjær.  
* Listen er ikke komplett. Se  www.ncf.no for bredere oversikt. 
**Hvetestivelse kan være glutenfri og glutenholdig, avhengig av hvor godt renset hveten er. Dette opplyses det oftest 






Stivelse og maltsukker 
Både maltsukker, maltodekstrin og maltose er glutenfrie karbohydrater som ikke inneholder gluten.  Stivelse  kan  
være  utvunnet  av  hvete,  potet,  ris  eller  annet.  Dersom  det  er hvetestivelse skal dette være angitt på pakken. 
Hvetestivelse er renset for gluten, slik at den kommer under definisjonen ”glutenfri”, og produkter med hvetestivelse 
inngår derfor i den glutenfrie kosten. Noen få cøliakere med veldig sensitiv tarm kan likevel reagere på hvetestivelse 
og må utelate dette fra kosten. 
 
Vegetabilsk protein 
Hydrolyserte og modifiserte vegetabilske proteiner, som for eksempel er i buljongpulver og buljongterning, har 
gjennomgått så store forandringer at de ikke gjenkjennes som gluten og gir dermed ikke tarmskade, selv om det 
skulle være proteiner fra hvete, rug eller bygg. 
 
Tilsetningsstoffer (E-nummer) 
Alle tilsetningsstoffer (E-numre) som er godkjente for bruk i Norge er glutenfrie og hvetefrie. Dette gjelder også 









Norsk cøliakiforening (NCF) gir ut et 
Ingrediensleksikon som kan bestilles fra 










9. Glutenfrie spesialprodukter 
Det finnes en rekke glutenfrie varianter av brød, melblandinger, pølsebrød, kjeks, kaker, knekkebrød osv. Slike 
glutenfrie spesialprodukter bør erstatte de matvarer som må fjernes fra kosten. Produsenter av glutenfrie produkter er 
(listen er ikke fullstendig). 
 
·   Toro 
·   Finax 
·   Semper 
·   Hammermühle 
·   Schär 
·  Holmen Crisp 







10.   Forhandlere av glutenfrie produkter 
 
De  fleste  matvarebutikker  og  helsekostforretninger  har  glutenfrie  produkter  i  varierende utvalg.  Det finnes 
også flere nettbutikker som har et omfattende sortiment av glutenfrie varer og  som  leveres  per  post,  f.  eks.  
www.allergikost.no  eller   www.allergimat.no.  For  flere nettsteder, se  www.ncf.no og klikk på Linker 
 
Mange bakerier produserer glutenfritt brød som kan fås ferskt på bestilling og ellers frossent. Flere spisesteder, 








11.   Gode råd for glutenfri baking og matlaging 
 
Her følger noen tips fra erfarne cøliakere som det kan være verdt å ta med seg: 
Det viktigste bakerådet: Bruk fiberhusk i all gjærbakst! 
Fiberhusk løses i væske i et par minutter og tilsettes melet. Du får en mye bedre deig å arbeide med, og du får et 
saftigere bakverk som holder seg lenger uten å smule. Bruk 1 ss per ½-1 kg mel. Fiberhusk er psylliumfrøskall som 
virker ved å øke innholdet av geldannende fibre i brødet. 
·  Til brødbaking kan du gjerne velge grov brødmix og tilsette linfrø, sesamfrø, hirse, solsikkefrø    og/eller 
bokhvete for å øke fibermengden i brødet. NB! Mengden bør ikke være for stor, for da  holder ikke brødet ikke 
sammen. Opptil 1 dl pr brød går bra, prøv deg frem. For dem som ikke liker  ”klumper” i brødet kan man male 
nøttene før man tilsetter det til brød. 
·   Frys brødet ferskt hvis du baker mer enn det du trenger for en dag. Del det gjerne opp slik at du kan ta frem 
mindre mengder om gangen. 
·   Litt olje i brødet forbedrer holdbarhet og konsistens. 
·   Bokhvete, hirse, mais, soyabønner og ris finnes som mel, flokker og gryn/bønner, og kan brukes til baking og i 
matlaging. Det vil øke matens fiberinnhold, næringsinnhold og ikke minst gi variasjon. Ferdig kokte linser kan 
også tilsettes baksten. 
·   Pannekaker, vafler, kjeks og kaker kan lages av glutenfri brødmix, gjerne tilsatt fiberhusk. 
Varier gjerne ved å tilsette soyamel, bokhvetemel og/eller andre typer glutenfrie gryn eller mel. 
·   Supper, sauser og stuinger kan jevnes med lys melblanding, f.eks Toro’s fin kakemix, eller maisenna. 
·   Glutenfri panering og strøbrød kan lages av glutenfritt brød som tørkes og males, eller det kan kjøpes ferdig i 
helsekostbutikken. 
·   De fleste vanlige oppskrifter på kokosboller, kokosmakroner, kransekake og marengs er glutenfrie. 
·   Dekk brødformen med smurte strimler av bakepapir så slipper brødet. 
·   Mange av dine «gamle» oppskrifter kan brukes.   Erstatt hvetemel med glutenfritt mel, doble mengden 
hevemiddel, og tilsett et egg for å få det til å henge bedre sammen. I stedet for egg kan du øke mengden 
glutenfritt mel i forhold til mengden hvetemel. 
·   Bruk kjøkkenmaskin til gjærbakst, lag deigen løs og la maskinen arbeide deigen godt. 
Deigen kan være klisset, og i stedet for å bake brødene kan de helles rett i brødformer. Ved utbaking av boller og 
rundstykker kan det hjelpe å fukte hendene med olje eller lunkent vann og hjelpe til med en skje for å få form. 
Kjevle og bakeunderlag i plast egner seg ekstra godt til glutenfri baking. 
·   Tørt bakverk kan fuktes litt og varmes i f. eks brødrister. Mange synes glutenfritt brød smaker bedre når det 
er ristet. 






12.   Oppskrifter 
 
Oppskrifter på glutenfritt bakverk og matretter er det ikke blitt plass til i dette heftet. Det finnes en rekke 
kokebøker med glutenfrie oppskrifter som du kan kjøpe i bokhandelen. Det finnes også flere nettsteder og blogger 
med oppskrifter og råd om glutenfri matlaging. 
Norsk cøliakiforening arrangerer forskjellige matlagings- og bakekurs. 
Et utvalg av glutenfrie kokebøker: 
-    Glutenfrie tradisjoner fra hele verden. Henriette Pecühle (2011) Kolofon. 
-    Glutenfri  mat  godt  og sunt.  Gjærbakst  og  kaker.  Else  Lill  Münter  Rolfsen,  Ruth 
Solheim Aag (2007) Kolibri forlag. 
-    Glutenfri mat - godt og sunt. Småretter og middager. Else Lill Bjønnes og Bjørn 
Wiborg (2010) Kolibri forlag. 








13.   Litt mer informasjon 
 
- om cøliakiforeningen 
Norsk Cøliakiforening (NCF) er en interesseorganisasjon/pasientforening for mennesker med cøliaki eller dermatitis 
herpetiformis (DH). NCF ble opprettet i 1974. De har utarbeidet flere informasjonsbrosjyrer om cøliaki og 
glutenfritt kosthold og utgir medlemsbladet Cøliaki-nytt fire ganger årlig. De arbeider kontinuerlig for å ivareta 
medlemmenes interesser gjennom informasjon, opplysning og bidrag til forskning. De arbeider for å bedre 
tilgangen til glutenfrie produkter og bevisstgjøring av produsenter på betydningen av korrekt deklarering av alle 
matvarer. 
 
NCF har en informativ hjemmeside på internett som oppdateres jevnlig og har lenker til andre nyttige 
hjemmesider: www.ncf.no 
 
Du kan også kontakte foreningen per brev eller telefon: 
 Norsk Cøliakiforening, Pb 351 – Sentrum, 0101 Oslo. Telefon: 22 40 3900 
 
- om lokallaget 
NCF har et aktivt fylkeslag i Hordaland og Sogn og Fjordane, som arrangerer bl.a. møter og bakekurs. De har 
opprettet kontaktpersoner som bistår med hjelp til nydiagnostiserte cøliakere. 
 
- om cøliaki-poliklinikken 
Du  kan også ringe cøliakipoliklinikken på Haukeland  universitetssykehus:  55  97  29 40, tirsdager klokken 
16-18. Telefonen bemannes av frivillige fra cøliakiforeningen. 
 
- om grunnstønad: 
Diagnosen cøliaki gir automatisk rett til grunnstønad for å dekke merutgifter til matvarer. For tiden (juni 2011) 










14.   Første uken på glutenfritt 
Kjøp ferdigbakt glutenfritt brød til hele første uken, skjær i skiver og frys ned. 
Glutenfri baking krever trening. Du kan ikke regne med å få godt bakeresultat de første gangene 
du prøver, så sørg for å ha nok brød, knekkebrød og kjeks den første tiden. Mesteparten av maten kan du 
kjøpe i dagligvarebutikken. 
 
Handleliste med glutenfrie matvarer 
·    Potet og ris 
·    ·    Glutenfri pasta og glutenfritt brød/knekkebrød 
Rene kjøttprodukter (inkl. karbonadedeig og kjøttdeig) ·    
Kjøtt (rent) fra kylling, kalkun og andre fugler ·    
Kjøtt (rent) fra fisk og skalldyr ·    
Egg ·    
·    Hvitost, brunost og de fleste smøreoster 
Syltetøy ·    
·    Melk og melkeprodukter (yoghurt, rømme, fløte etc, ev laktosefrie alternativ) 
Frukt og bær ·    
Grønnsaker og rotfrukter ·    
Margarin, lettmargarin, smør, flytende margarin og olje 
·    Salt, pepper og alle rene urtekrydder 
·    For jevning: Maisenna eller potetmel 
 
- bibliotek, bokhandel eller internett 
En glutenfri kokebok er god å ha. Foruten oppskrifter finner du informasjon om andre korn- og melsorter som kan 
erstatte hvetemel, fibertilskudd og bakeråd. Mye av denne informasjonen  finner  du  også  på  internett.  Start  på  
hjemmesiden  til  cøliakiforeningen: www.ncf.no og benytt lenkene derfra. 
 
-cøliakiforeningen 
Kontaktpersonene i cøliakiforeningen vet at det kan være tøft å få diagnosen cøliaki, spesielt hvis baksten slår feil og 
maten smaker annerledes. Kontakt de dersom du har spørsmål om glutenfri matlaging eller om du bare vil prate litt. 
 
- trygdekontoret 
Kontakt trygdekontoret for å få sendt inn søknad om grunnstønad så fort som mulig, slik at du  raskt  får  utbetaling  
av  merkostnader  i  forbindelse  med  dietten.  Diagnosetidspunktet regnes som diettstart og du får betalt fra denne 




For å unngå at smuler fra vanlig brød kommer i kontakt med glutenfritt brød, kan det være lurt med egen 
brødboks til glutenfritt brød, egen skjærefjøl, egen brødkniv og kanskje en egen brødkurv. Dersom det brukes 
mye, kan det være praktisk med en egen brødrister til glutenfritt brød. Eventuelt kan man bruke toastposer utenpå 














Attachment 9: Additional information for group A 
 
 GLUTENFRITT UTEN HVETESTIVELSE OG SPOR AV (NOEN EKSEMPLER): 
 - Semper: Semper produkter som inneholder hvetestivelse er merket med rød ring i venstre hjørne. Grov         
Mix, chips chili og sitron, grovt knekkebrød, fusilli pasta, flakes & fibre frokostblanding, fin mix, brownies, 
bondeknekkebrød, landknekkebrød, kick natural frokostblanding, havreknekkebrød, havregryn, linguine 
pasta, linfrøknekkebrød, pasta til lasagne 
- Schar: Surdeigsbrød, baguetter, minibaguetter, knekkebrød, ciabatta rustica, wraps, brødet vital, lyst 
skivet brød, flerkornsbrød, landbrød, mørk melblanding, brødmix 
- Finax: Crunch frokostblanding, melmix melkefri 
- Holmen Crisp: Jyttemjøl original, teff, fibrateff, mix 
- Toro: Glutenfri lasagne, glutenfri brun saus, glutenfri hvit saus, lys melblanding, vafler, knekkebrød, 
havrebrød 
- Fria: Har hvetestivelse i det aller meste 
- Bakers: Kjernebrød, loff 



















Attachment 10: Low FODMAP brochure 
 
Kostråd ved irritabel tarm 
FODMAP-redusert kost 
I denne brosjyren finner du informasjon om FODMAP og tips til hvordan en FODMAP-redusert kost 
kan settes sammen. 
Hva er irritabel tarm? 
Irritabel tarm, eller irritable bowel syndrome (IBS), er en tilstand som kan medføre ulike plager i mage 
og tarm. Typiske symptomer er kvalme, mageknip, magesmerter, oppblåsthet, utspilt mage og luft/gass 
og rumling i tarmen. Man kan også oppleve avføringsforstyrrelser som diaré, forstoppelse eller 
vekslende løs og hard avføring. Symptomene kan komme og gå i perioder. Stress og bekymring kan 
forverre symptomene, og for noen kan plagene utløses eller forverres av mat eller drikke. Irritabel tarm 
kan være plagsom, men ikke farlig. Det er ikke kjent hva som er årsakene til irritabel tarm. Tilstanden er 
utbredt, og oppleves hos 15-20% av befolkningen. 
 
Generelle råd ved irritabel tarm 
Mange opplever bedring når de følger disse rådene: 
    Regelmessige måltider med sunn og variert kost 
    Flere små måltider er bedre enn få store 
   o 4-6 måltider daglig, med ca. 3-4 timer mellom hvert måltid 
    Ro rundt måltidet 
    Regelmessig liv med god balanse mellom aktivitet og hvile 
    Tilskudd av geldannende fiber, som ViSiblin, FiberHusk, Psyllium og Benefiber. 
      NB! Viktig med rikelig væskeinntak i tillegg. 
    Mat som kan gi problemer: 
   o Fet mat 
   o Stekt mat 
   o Røkt og sterkt saltet mat 
   o Sterkt krydret mat 
   o Mye kostfiber 
   o Mat med mye tungtfordøyelige karbohydrater (FODMAPs) 
   o Kaffe og annen koffeinholdig drikke (te, cola og energidrikker) 
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Australske forskere (Peter Gibson og Sue Shepherd) har utviklet en kost, «FODMAP-redusert kost», som har 
vist seg å redusere plagene hos mange som sliter med irritabel tarm. 
 
Hva er FODMAP? 
FODMAP er en forkortelse for fermenterbare oligo-, di- og monosakkarider og (and) polyoler. Dette er 
karbohydrater som tynntarmen kan ha vanskeligheter med å bryte ned og absorbere. Når de ufordøyde 
karbohydratene kommer til tykktarmen, vil de trekke til seg væske og forårsake gjæring. Dette kan gi problemer med 
gassdannelse, magesmerter, oppblåsthet, diaré og/eller forstoppelse. 
 
Slik går du fram 
En rekke studier har vist at flesteparten av alle som lider av irritabel tarm har god effekt av FODMAP-redusert kost. 
Dersom du vil teste om denne dietten kan ha effekt hos deg, anbefales det å unngå/begrense matvarer med høyt 
FODMAP-innhold i 4-8 uker. 
Se tabelloversikt fra neste side, hvor matvarene er kategorisert i rød, oransje og grønn kolonne. Matvarer i grønn 
kolonne har lavt innhold av FODMAP og kan brukes. Motsatt har matvarer i rød kolonne høyt innhold av 
FODMAP, og bør unngås/begrenses. Matvarer i oransje kolonne kan brukes i moderate mengder. For å få ideer om 
hvordan kosten kan settes sammen i denne perioden, -se siste del av brosjyren, side 11-19. Der finner du 
menyforslag og oppskrifter. 
 
Hvis du ikke merker noen bedring/effekt innen 4-8 uker, har det ingen hensikt å fortsette med dietten. Blir du bra bør 
du på en systematisk måte forsøke og reintrodusere de matvarene du har fjernet fra kosten, slik at du til slutt får et 
«skreddersydd» kosthold som holder magen i orden, og ikke er mer begrenset enn det behøver å være. Se side 9-10, 
som handler om reintroduksjon av FODMAPene. 
 












Bilde: Redigert kostholdssirkel Helsedirektoratet. 
 
FODMAP-redusert kost er ikke det samme som lavkarbo eller glutenfri kost! 
FODMAP-kilder 





Tabelloversikten viser matvarer med høyt, middels og lavt FODMAP-innhold. 
Matvaregruppe Høy FODMAP 
Unngås/brukes i 
svært små mengder 
I mindre mengder Kan brukes i moderate 
mengder 
















Større porsjoner frisk 
frukt og smoothie. 
Hermetisk frukt i egen 
juice 
Tørket frukt/bær (se 

















































Løk, hvit og rød 




Vårløk (hvit del) 
Tørkede belgfrukter: 
-    erter 
-    bønner 

















Kålrot Mais Noriark Okra 
Oliven (sorte og grønne)  
Paprika (Grønn) 
Paprika * (Rød) Pastinakk 
Potet 








Sellerirot Squash Søtpotet 
Tomat Vannkastanjer 
Vårløk (grønn del) 
Urter/krydder Hvitløk 
Krydderblandinger og 













Matvaregruppe Høy FODMAP  










Brunost og prim 
Ferske og myke hvite oster 
(og kremoster) 
 




Laktosefri yoghurt  
Laktosefri fløte  
Laktosefri rømme  
Laktosefri kesam 
Faste hvite oster (norvegia o.l.) 
Lagrede hvite oster (brie, 
camenbert, roquefort etc.)  
Cottage cheese 4 ss 
Mozzarella  
Chevre ,Feta  
Kokosmelk 
Soyamelk av soyaprotein 
Rismelk 
Iskrem basert på laktosefri 
melk/fløte/.  
Rismelk, eller sorbet og saftis. 
Sukker/søtstoff Fruktose (fruktsukker) 











Sirup, lønnesirup, ris malt 








(som hovedingrediens i brød, 
knekkebrød, bakverk, pasta, 
kornblandinger) 
Glutenfri havre < 25 g per porsjon 




Brød, pasta og kornvarer som er 








FODMAPs er en gruppe karbohydrater. 
Rent kjøtt, fjærkre, fisk, egg og fett/olje inneholder ikke FODMAP. 
Mer om ulike typer FODMAP 
Hva er forskjellen mellom FODMAP og andre karbohydrater? 
Karbohydrater er energirike molekyler som fungerer som energikilde og energilager hos alle planter og dyr. 
De er bygget opp av én eller flere sukkerenheter som er bundet sammen i korte eller lange kjeder. Under 
fordøyelsen må karbohydratene i kosten brytes ned til enkle sukkermolekyler før de kan absorberes i 
tynntarmen og nyttiggjøres av kroppen. Det som kjennetegner FODMAP-karbohydratene, er at de er små 
(består av én eller noen få sukkerenheter), absorberes dårlig og gjæres lett. 
Karbohydrater som vanligvis ikke gir besvær: 
 Glukose (druesukker) er ett enkelt sukkermolekyl som lett absorberes i tynntarmen. 
Tåles godt ved IBS. Finnes i frukt og bær. 
Sukrose (vanlig sukker) består av et fruktose- og et glukosemolekyl som er bundet sammen. Fordøyes og 
absorberes lett, men inntaket bør begrenses av hensyn til den generelle helsen. 
Stivelse er lange kjeder av glukose. Disse brytes raskt ned og absorberes fullstendig i tynntarmen og er 
derfor uproblematisk ved IBS. Finnes i kornvarer, pasta, rotgrønnsaker og poteter. 
Kostfiber er langkjedede karbohydrater som ikke brytes ned i tynntarmen. Finnes i grove kornvarer, 
grønnsaker og frukt. Kostfiber er viktig for tarmfunksjonen og bidrar til å gi avføringen riktig konsistens. Vi 
skiller mellom vannløselige og ikke-vannløselige fibertyper. Vannløselig fiber er mest gunstig ved IBS. 
 
FODMAP: 
Fruktose (fruktsukker) er et monosakkarid, det vil si at det består av bare ett sukkermolekyl. Finnes i 
frukt, bær, fruktjuice og honning, ofte sammen med glukose (Tabell 1).  Fruktose absorberes godt sammen 
med like store mengder glukose, og 30-40% av befolkningen (både friske og personer med IBS) absorberer 
ikke overskudd av fruktose. Inntak av mat som inneholder mer fruktose enn glukose, kan skape problemer 
hos dem som lider av irritabel tarm. 
 
Laktose (melkesukker) finnes i melk og melkeprodukter (Tabell 2). Laktose er et disakkarid og består av 
to sukkermolekyler (glukose og galaktose) som er bundet sammen. Under fordøyelsen spaltes de to 
sukkerenhetene fra hverandre ved hjelp av enzymet laktase, som produseres i tarmslimhinnen. Mangel på 
enzymet fører til laktosemalabsorpsjon. Genetisk betinget laktasemangel er svært utbredt på verdensbasis, og 
forekommer ofte hos innvandrere, men sjelden blant etnisk norske. Tarminfeksjoner og skader på tarmen kan 
også føre til laktasemangel, som regel av forbigående type. 
 
Sorbitol og andre søtstoff som ender på –ol, som mannitol, maltitol og xylitol, er polyoler (også kalt 
sukkeralkoholer). Disse absorberes ikke fullstendig i tynntarmen og større inntak kan forårsake diaré og 
luftplager hos alle. Ved irritabel tarm kan også mindre inntak gi symptomer. Sukkeralkoholer forekommer 
naturlig i visse typer frukt og grønnsaker og brukes i sukkerfri tyggegummi, drops og pastiller (Tabell 3). 
 
Fruktaner er korte kjeder av fruktose og tilhører gruppen oligosakkarider. Finnes i løk, hvete og rug. 
Galaktaner er også oligosakkarider og finnes i belgfrukter. Disse stoffene brytes ikke ned av enzymene i 






















Tabell 2: Mat som inneholder LAKTOSE 
Begrenses ved laktosemalabsorpsjon 
Melk og melkeprodukter 






Ferske og myke hvite oster 
Iskrem 
Tabell 1: Mat som inneholder overskudd av 
FRUKTOSE 














Høy fruktose maissirup 
Gir et høyt totalinntak av fruktose 








Tabell 3: Mat som inneholder 
SORBITOL og/eller andre POLYOLER 



















Isomalt (E953)  
Laktitol (E966)  
Maltitol (E965)  
Mannitol (E421)  
Sorbitol (E420)  











Tabell 4: Mat som inneholder 
FRUKTANER og/eller  GALAKTANER 
Frukt 
Nektarin 






















Frukto-oligosakkarider (FOS)  





Hvorfor tåler noen FODMAP dårligere enn andre? 
Sorbitol, fruktaner og galaktaner absorberes dårlig av alle mennesker, og fruktosemalabsorpsjon er like 
vanlig hos friske personer som hos individer med IBS. Folk flest tåler likevel FODMAP godt. 
Grunnen til at personer med irritabel tarm får plager av FODMAP, kan være følgende: 
Tarmoverfølsomhet for gassproduksjon 
Ved irritabel tarm er tarmen mer følsom for gassen som blir produsert, og den trykkøkningen i 
tarmen som gassen forårsaker, oppleves mer smertefull og ubehagelig. 
Bakteriell overvekst i tynntarmen 
Noen av de bakteriene som normalt er lokalisert i tykktarmen, kan bevege seg over i tynntarmen. 
Dette kalles bakteriell overvekst i tynntarm og forekommer hos opptil 50% av de som har irritabel 
tarm. Når FODMAP gjæres av bakterier i tynntarmen, vil gassen som produseres, øke trykket i et 




Reintroduksjon av FODMAP-grupper 
Da man ikke nødvendigvis reagerer på alle FODMAP-gruppene, anbefales det å teste toleransen 
for hver enkelt gruppe. Før du gjør dette er det anbefalt å følge FODMAP- redusert kost i 4-8 
uker, til du er symptomfri, for så å innføre én og én FODMAP-gruppe. 
Det er viktig å reintrodusere gruppene enkeltvis på en systematisk måte for å finne din egen 
toleransegrense og hvilke typer FODMAP du reagerer på. 
Forslag til reintroduksjon 
Det er opp til den enkelte hva man ønsker å gjeninnføre først. Det kan være en idé å starte med det 
man har savnet aller mest. Det anbefales å starte med en liten mengde av en matvare som kun 
inneholder en type FODMAP om gangen. 
Se forslag til gode testmatvarer i tabelloversikt under, og ellers på side 7-8. 
Følgende matvarer egner seg godt til testing fordi de inneholder mye av én FODMAP-type og lite 
eller ingenting av de øvrige. Start forsiktig og øk etter hvert til normale porsjonsstørrelser: 
FODMAP-gruppe Testmatvare 
Fruktose (tabell 1): ¼ Mango eller 1 ts honning 
Laktose (tabell 2): 125 ml melk (søtmelk) eller 1 skive brunost (15g) 
Polyoler (tabell 3): 2 tørkede aprikoser, 1 stk sukkerfri tyggegummi eller et par 
sukkerfrie pastiller (med sorbitol) 
Fruktaner (tabell 4):  1 ss tilberedt løk, purre, eller 1 fedd hvitløk. 
Galaktaner (tabell 4): 2 ss bønner eller linser 
Fruktose og polyoler En kombinasjon av fruktose og sorbitol kan tolereres dårligere 
enn gruppene enkeltvis. For å teste toleransen for en 
kombinasjon, kan pære benyttes 
 
Ved laktoseintoleranse 
Dersom du gjennom utprøvingen finner ut at du tolererer laktose dårlig, kan du ha nytte av 
preparater med laktaseenzym. Disse selges reseptfritt på apotek, og finnes i flere varianter. 
Kerutabs tabletter og Lactrase kapsler virker slik at man tar 1-3 tabletter/kapsler i forbindelse 
med måltid som inneholder laktose. Med disse vil du kunne nyte et måltid på restaurant, i 





Følgende modell kan brukes når du tester en ny matvare: 
 
Dag 1 













Forsøk dobbelt så stor 












Forsøk 3 ganger så stor 







Forsøk en ny matvare 
 
Gjennomfører du tre hele dager med en ny matvare uten å få symptomer, kan matvaren på sikt kunne 
inngå i kosten igjen. Test kun nye matvarer når du ikke har symptomer.  Når du skal teste neste 
matvare anbefales det å ta ut den matvaren du har testet av kosten igjen. Dette er viktig fordi 
summen av de to matvarene med mye FODMAP kan overstige din toleransegrense for total mengde 
FODMAPs. Dette kan illustreres som et beger som flyter over. Det kan være at man tåler små 
mengder fruktaner og fruktose, eller fruktaner enkeltvis, men når alle kombineres kan den totale 
mengden få begeret til å flyte over, og man får symptomer. 
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Praktiske råd ved FODMAP-redusert kost 
Når du reduserer inntaket av FODMAP, er det fortsatt mulig å ha et sunt og variert kosthold. Dette er 
en veileder til hvordan du selv kan sette sammen måltider som har et lavt innhold av FODMAP. 
 
Frokost/Lunsj/Kvelds 
 2 skiver glutenfritt brød/knekkebrød/rundstykker med pålegg. 
    Glutenfri havregrøt med vann/laktosefri melk (og eventuelt bringebær/ jordbær/        
blåbær/banan) 
    Glutenfri havregryn eller glutenfri cornflakes med laktosefri melk/ yoghurt/ Biola 
 Omelett (med skinke, kokt potet, og FODMAP-reduserte grønnsaker som paprika, tomat, vårløk 
(grønn del), squash, oliven) 
    Salat 
o FODMAP-reduserte grønnsaker og frukt, eks salat, tomat, agurk, gulrot, vårløk (grønn del), oliven, 
appelsin, druer og honningmelon 
o Glutenfri pasta 
o Kylling/kjøtt/egg/fisk/sjømat 
o 1 ss gresskarkjerner 
Middag 
    Rene produkter av hvitt og rødt kjøtt, egg, fisk og sjømat 
o Les innholdsliste på blandingsprodukter- begrens ingredienser med mye FODMAP 
    Poteter, ris, glutenfri pasta, risnudler, quinoa 
    Pai/pizzabunn av glutenfritt mel. 
    Eggeretter 
    Pannekaker lagd med glutenfritt mel og laktosefri melk 
    Hjemmelaget suppe av grønnsaker, kjøtt mm. 
    Stekte grønnsaker/salat (se under oppskrifter) 
 
Tilsett smak til maten: 
    Oljer til steking/marinade 
    Sitronsaft 
    Laktosefri rømme/kesam – med og uten urter 
 Friske urter, som for eksempel: basilikum, koriander, 
persille, rosmarin, timian 
    Chili, Ingefær, salt og pepper 
    Lønnesirup 





Olje med hvitløksmak (legg store biter hvitløk i olivenolje, la den trekke en ukes tid. Ta vekk hvitløksbitene 
før du bruker oljen i matlaging) 




    Kjøttpålegg: kokt skinke, skinkestek, spekeskinke, kalkun- og kyllingskinke naturell 
    Egg 
    Reker og annen sjømat 
    Rene fiskepålegg som røkelaks, tunfisk, påleggslaks og sardiner 
    Kaviar 
    Majones 
    Ost: Hvitost, brie, cottage cheese , cheddar, edamer, 
mozzarella, camembert og fetaost. 
    Syltetøy av bringebær, jordbær og blåbær. 
    Lønnesirup 
    Peanøttsmør 
    Banan 
    Agurk, tomat, paprika, salat 
 Snacks 
Nøtter/frø 
    Hasselnøtter, 10 stk 
    Mandler, 10 stk 
    Macadamia, 20 stk 
    Peanøtter, 28 g 
    Pekan, 10 stk 
    Valnøtter, 10 halve 
    Pinjekjerner, 1 ss 
    Chiafrø, 2 ss 
    Gresskarkjerner, 2 ss 
    Solsikkefrø, 1 ts 
    Sesamfrø, 1ss 
    Sorbetis laget av lav-FODMAP frukt. 
 1 glass smoothie av lav-FODMAP frukt som banan og 
bær, og laktosefri yoghurt og eventuelt glutenfrie havregryn 
    Tortillachips, potetchips med salt/pepper. 
    Glutenfrie kjeks og kaker 
    Fruktsalat med laktosefri yoghurt og lønnesirup 
    Riskaker med peanøttsmør og banan 
    Mørk sjokolade 
 Pannekaker og vafler med glutenfritt mel og laktosefri 
melk 
    Glutenfri havrekjeks med nøtter og mørk sjokolade 
    Haribo Eldorado vingummi. 
























Mengde frukt: Det anbefaler maks 2-3 porsjoner à 100g med lav FODMAP frukt daglig, da 
fruktose i større mengder kan gi symptomer  
 
 
Frukt og bær,  
lav FODMAP  
Opp til i en 
porsjon  
Gønnsaker,  
lav FODMAP  































140 g  
130 g  
100 g  
330 g  
150 g  
100 g  
80 g  
40 g  
135 g  
160 g  
166 g  
150 g  
85 g  
100 g  
140 g  
130 g  
30 g  
1 ss  
94 g  
 
 
60 g  
90 g  
140 g  
Agurk  









Gresskar, Butternut  
Gresskar, Hokkaido  
Kålrot  
Mais  
Mangold (sølvbete)  
Noriark  
Okra  
Oliven, sorte og 
grønne  
Paprika (Grønn)  
Paprika (Rød)  
Pastinakk  
Potet  








Bok Choy/ Pak Choy  









Vårløk (grønn del)  
65 g  
20 g  
30 g  
120 g  
40 g  
20 g  
50 g  
50 g  
100 g  
60 g  
30 g  
60 g  
100 g  
40 g  
115 g  
2 stk  
100 g  
60 g  
 
100 g  
50 g  
60 g  
120 g  
100 g  
115 g  
40 g  
20 g  




160 g  
40 g  
35 g  
35 g  
150 g  
35 g  
100 g  
70 g  
120 g  
55 g  





Tips! Er noen av fruktene eller grønnsakene ukjente for deg? Søk de 
opp i frukt.no sitt leksikon for å se bilde. 
Vær oppmerksom på 
 Ikke alle glutenfrie produkter er lav-FODMAP. Veldig ofte tilføres eple eller annet som 
er høy-FODMAP for bedre smak osv. Sjekk ingredienslisten. 
    Konsentrert fruktjuice, f.eks. fra eple og pære, brukes iblant som søtstoff. 
    Dipper og dressinger inneholder ofte løk og hvitløk. 
    Smakstilsatt vann kan inneholde fruktose - les innholdsfortegnelsen. 
    Yoghurt kan være tilsatt fruktose. 
 Inulin er en fruktantype og brukes iblant som fiber eller prebiotikum i yoghurt, brød eller 
müsli. 
    Dersom du reagerer på mye kostfiber, begrens matvarer med mye fiber, og velg 
heller fine produkter enn grove.  En gradvis økning av fiber kan bedre toleransen. 
 
På varedeklarasjonen skal alle ingrediensene oppgis i rekkefølge etter vekt. Den 
ingrediensen det er mest av nevnes først, og den det er minst av til sist. Bruk denne 
kunnskapen når du skal vurdere om en matvare kan inngå i kostholdet ditt.  Små mengder 
FODMAP går som regel bra.  
 
For mer inspirasjon, informasjon, matvarelister og oppskrifter: 
Helse Bergen:        Nasjonal Kompetansetjeneste for Funksjonelle Mage-tarm sykdommer. 
www.helse-bergen.no/nkfm 
Monach University: http://www.med.monash.edu/cecs/gastro/fodmap/ 
  Til mobil: LowFODMAPdiet App fra Monach University. 
Bøker på norsk:       
 
Stine Junge Albrechtsen, Mette Borre, Lisbeth Jensen, Marianna Lundsteen Jacobsen & Cæcilie 
Gamsgaard Seidel: For deg med irritabel  tarm.LowFODMAP-dietten gir ro i magen. Iris forlag 2014 
 
Cecilie Hauge Ågotnes: LavFODMAP. God mat for sensitive mager. Aschehoug 2015 
 






Et lite utvalg oppskrifter 
Scones (8-10 stk.) 
6 dl lys, glutenfri melblanding (for grovere scones kan man erstatte ca 50% av lys 
melblanding med grov glutenfri melblanding). 
2 dl glutenfri havremel/ havregryn 
2 ts bakepulver 
1 ts sukker 
0,5 ts salt 
100 g margarin (kan reduseres) 
Litt solsikkefrø eller gresskarkjerner 
4 dl laktosefri yoghurt 
1 egg 
 
Slik gjør du: 
Bland alt det tørre og smuldre inn margarin. Tilsett solsikkefrø/gresskarkjerner, egg og 
yoghurt. Rør raskt sammen. 
 
Del deigen i 4 like store deler, lag et stort kryss på midten (så brytes de lett når de er ferdig) eller lag 8-
10 scones. 
Stekes ved 250 ⁰C i ca. 20 minutter. 
(Denne oppskriften kan brukes til å lage hamburgerbrød, pølsebrød mm) 
 
Banan og havregrynspannekaker ( 1 porsjon) 
Mos ½ eller 1 liten banan i en skål, og rør inn 1 egg og 1 neve glutenfri havregryn/havremel (ca 25 
g). Fordel røren på to mellomstore pannekaker/ lapper i en panne og stek på middels varme i ca 1 
min hver side. Spises alene eller med eks. pålegg som cottage cheese og blåbærsyltetøy. 
Vafler og pannekaker: Ta utgangspunkt i en vanlig oppskrift og bytt ut hvetemel med ca 2/3 
glutenfritt mel og 1/3 havremel. Melken erstattes med laktosefri melk. 
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Stekt ris (2 porsjoner) 
4 dl kokt langkornet middagsris 
200 g skinke 
1 gulrot 
1 vårløk (den grønne delen) 
50 g maiskorn 
2 ss rapsolje 
1 egg 
Litt salt og pepper 
 
Slik gjør du: 
1. Del skinke og gulrot i terninger, og vårløk i skiver. 
2. Varm wokpannen/stekepannen. Stek skinken i halvparten av oljen. Ha i kokt ris og la 
det steke til det er gyllent. Bland inn grønnsakene og la det surre i 2 minutter. 
3. Lag et hull i midten av risblandingen og ha i resten av oljen og egg. Rør godt. 
4. Smak til med salt og pepper. 
 
TIPS: Risen som brukes i stekt ris bør være avkjølt, så den ikke blir "grøtete". En panne med 
slippbelegg krever mindre stekefett. Varier gjerne med kjøtt og grønnsaker som for eksempel 
renskåret svinekjøtt, reker/ scampi, kylling, paprika, grønne bønner, ingefær. Du kan også 
bruke frossen grønnsaksblanding, men vær obs på FODMAP-holdige grønnsaker. 
 
Kyllinglår med stekte grønnsaker (4 porsjoner) 
4-8 grillede kyllinglår avhengig av størrelse 
4-6 poteter 
1 paprika 
1 grønn squash 
1-2 gulrot, 8 oliven 
1 ss hakkede friske urter (f.eks. basilikum, koriander, persille, rosmarin, timian) 
 
Slik gjør du: 
1. Legg kyllinglårene i en form og stek dem midt i ovnen ved 180 °C til kyllinglårene 
er gjennomvarme. Beregn 15-20 minutter. 
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2. Skjær potetene i litt tykke skiver. Del resten av grønnsakene i passe store biter. 
3. Start med potetskivene og fres dem raskt i panne. Tilsett resten av grønnsakene 
etterhvert og fres videre til alt er mørt. Tilsett oliven og finhakkede urter rett før 
servering. 
 
Kyllingpai med spinat (4 porsjoner) 
Paibunn: 
150 g smør/margarin 
200 g glutenfri melblanding ca. 2 ss vann 
 
Fyll: 
4 kyllingfileter i biter 
200 g frisk spinat 
5 egg 
3 dl laktosefri melk 
1 ts salt 
½ ts pepper 
10 sorte oliven 
100 g revet hvitost, mozzarella eller smakfull ost 
Slik gjør du: 
1. Smuldre smør/margarin og mel, og tilsett vann til en smidig deig. La deigen hvile kaldt i ca. 1/2 time. 
2. Trykk deigen ut i en paiform og prikk med en gaffel. Stek i ovn ved 200 °C i ca. 15 minutter. 
3. Stek kyllingbitene. Tilsett renset og vasket spinat og fres det til spinaten faller sammen. Fordel alt på den 
forstekte pai bunnen. 
4. Hell over sammenvispet egg, melk, salt og pepper. Dryss delte oliven og revet ost på toppen. Stek paien 
videre i ca. 25 minutter til den er gyllenbrun. 
TIPS: Bruk annet kjøtt enn kylling. Paistykker kan pakkes i folie og lunes over grillen. 
 
Kylling/biffsalat med frukt og valnøtter (4 porsjoner) 
1 hodesalat og evt andre grønnsaker med lite FODMAP. 
3 kyllingfileter i strimler/ kjøtt i strimler i tilsvarende mengder 
1 ½ ss rapsolje til steking 
½ cantaloupe/honningmelon 
1 boks hermetisk ananas i ringer (liten boks) 
100 g blå druer 
75 g valnøttkjerner, grovhakket eventuelt litt revet appelsinskall 
Dressing: 
175 ml laktosefri yoghurt naturell 
1 ss toppet lønnesirup 
Smak evt. til med sukker 
Slik gjør du: 
1. Skyll salaten. Ta ut de midterste bladene på salathodet, og skjær vekk roten slik at 
bladene løsner. Legg salaten på serveringsfat. 




3. Skjær melonkjøttet i terninger. Del ananasringene i mindre biter. Del druene i to, 
og ta eventuelt bort stenene. 
4. Bland alle ingrediensene og legg dem i midten på salathodet. Pynt med revet 
appelsinskall. 
5. Varm lønnesirupen til den er flytende og rør den inn i yoghurten. Smak eventuelt 
til med sukker. 
Server dressingen i en skål ved siden av salaten. 
 
Torskegryte med paprika og sorte oliven (4 porsjoner) 
 
400-500 gram torskefilet, i biter 
4-6 poteter, i skiver 
1/4-1/2 rød chili, finhakket 
2-3 ss tomatpurè 
1 rød paprika, i strimler 
1 boks hermetiske tomater 
1/2-1 dl vann  
½ sitron,  
salt og pepper 
en neve steinfrie oliven  
eventuelt friske krydderurter 
Tilbehør: Glutenfritt brød 
Slik gjør du: 
Finn frem en stekepanne med høye kanter eller en gryte. Fres chili i olivenolje og tilsett 
tomatpuré, rør godt sammen og la det stå og surre et par minutter. Tilsett hermetiske 
tomater og vann, og smak til med salt og eventuelt litt pepper. Ha i potetskiver og paprika. 
Dytt potetene godt nedi tomatblandingen, sett på lokk og la det trekke i ca. 20 minutter på 
middels varme, til potetene er knapt møre. Pass på at det ikke svir seg, så rør forsiktig eller 
«rist» på retten innimellom. 
Når potetene er nesten ferdige dytter du fiskebitene oppi gryta/stekepannen. Pass på at 
fiskestykkene er omtrent like store. Da blir de også ferdige omtrent samtidig. Ha over 
nypresset sitronsaft og sorte oliven. Sett på lokket og la retten trekke på lav til middels 
varme i 5-7 minutter, til fisken er ferdig og så vidt «flaker» seg. Gi retten et dryss med 









Laktosefri iskrem (6 porsjoner) 
4 eggeplommer 
100 g sukker 
1 vaniljestang 
3 dl laktosefrie kremfløte 
Tilbehør: Friske bær og mørk sjokolade 
 
Slik gjør du: 
1. Pisk eggeplommer og sukker til eggedosis. 
2. Splitt vaniljestangen på langs og skrap frøene over i kremfløten. Pisk kremfløten stiv og bland med 
eggedosis. 
3. Fyll iskremblandingen i tomme yoghurtbegre eller liknende og sett i fryseren til den har stivnet. Server 
gjerne med friske bær og revet mørk sjokolade på toppen. 
 
 
Havrekjeks med nøtter og sjokolade (ca. 40 stk.) 
200 g smør/margarin 
2 dl brunt sukker 
2 dl hvitt sukker 
1 ts vaniljesukker 
2 egg 
3 dl glutenfri melblanding 
½ ts salt 
1 ts bakepulver 
6 1/2 dl glutenfri havregryn 
ca. 100 g mørk sjokolade, grovhakket 
ca. 80 g mandler, grovhakket 
 
Slik gjør du: 
Rør smør, sukker og vaniljesukker til det blir en porøs smørkrem. Tilsett eggene, ett om gangen, og rør godt. 
Bland i mel, salt og bakepulver og rør godt. Tilsett til slutt havregryn og hakkete mandler og sjokolade. 
Sett kjeksene med skje på stekeplate dekket med bakepapir, og ha litt god avstand mellom kakene. 
Stekes ved 150⁰C i ca. 15 minutter. 







Attachment 11: Additional information for group B  
 
Ved glutenfri diett unngår man glutenproteinet som finnes i hvete, rug og bygg. Disse kornsortene er 
også høye i FODMAPs (fruktaner) i tillegg til å være glutenholdige. Ved lav FODMAP skal man 
unngå fruktaner og andre FODMAPs, men dette har ingenting med gluten å gjøre.   
Glutenholdige produkter kan inneholde ingredienser som er høy FODMAP. Det er derfor viktig å lese 
innholdsfortegnelsen før man spiser en matvare.  










 Oligofruktose  
 
Glutenfrie varer som er lav FODMAP:  
Brødprodukt 
- Semper: Grovt knekkebrød, havreknekk, landknekkebrød, linfrøknekkebrød, minibaguetter 
- Fria: Grova, Fiber, Loff 
- Hatting: Glutenfri rundstykker, glutenfri havrerundstykker (begrenset)  
- BFree wraps  
 
Melblandinger  
- Semper: Fin Mix, Grov mix  
- Toro: Lys melblanding, kakemix, langpannekake 
- Det glutenfri verksted: Flere produkter  
 
Melk: Havremelk (begrensing på 30 ml),, mandelmelk rismelk, kokosmelk, laktosefri melk (anbefales 
pga. kalsium og protein).  
 





Attachment 12: Protocol 
The effect of FODMAP reduction in addition to gluten free diet in coeliac 
disease  
 
Background     
Coeliac disease is a common autoimmune disease, where ingestion of gluten will cause an 
immune reaction in predisposed individuals.  The immune reaction can cause intestinal 
damage such as villous atrophy, crypt hyperplasia and chronic inflammation. The only 
treatment of coeliac disease is a lifelong gluten-free diet, and strict adherence to such a diet 
will lead to full mucosal healing and symptom relief in the majority of patients. However, a 
part of coeliac disease patients also have IBS-like symptoms in addition to their gluten 
intolerance, thus not responding fully to a gluten free diet. The inflammation of the mucosa 
seen in coeliac disease is thought to predispose for functional bowel disorders such as IBS (1). 
These patients will possibly benefit from a FODMAP reduced diet, as the diet has been shown 
to give significant symptom relief and increased quality of life in many IBS patients (2, 3). 
 
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder, affecting 10-20% of 
the general population, and is characterized by altered bowel habits and abdominal 
discomfort. IBS can be diagnosed using the Rome III criteria (4). IBS is a diagnosis of 
exclusion, which means that the ruling out of other possible diseases is essential before 
diagnosis is set. The cause behind IBS is not fully understood yet; but several hypotheses 
have been proposed. Visceral hypersensitivity, gut dysmotilty and disturbance in the brain-
gut-axis are assumed to be of importance in its pathophysiology. The best treatment available 
for IBS patients per se is diet. The FODMAP diet was developed by the dietician Susan 
Sheperd and her research group in 1999, when they started to exclude several foods IBS 
patients reported as symptom triggering. FODMAP is short for fermentable oligosaccharides, 
disaccharides, monosaccharaides and polyols, and is a grouping of carbohydrates that are 
inadequately absorbed in the small intestine and instead fermented by intestinal bacteria. 
 
There are several hypotheses on why FODMAPs trigger symptoms in IBS patients, some 
being thought to have more significance than others. FODMAPs are thought to have an 
osmotic effect on the gut, and also the fermentation by gut bacteria resulting in production of 
gas and small chain fatty acids are thought to cause pain and discomfort in IBS patients (5). 
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However, the FODMAPs cannot be considered as the cause of IBS, but the diet represents a 
treatment alternative that can offer symptom relief for these patients.  
 
Purpose and objectives 
The purpose of the study is to investigate whether coeliac disease patients with IBS-like 
symptoms can have a symptomatic and a quality of life benefit from FODMAP reduction in 
addition to their gluten free diet. Another objective is to investigate whether a FODMAP 
reduced diet will have any effect on the gut microbiota or influence the degree of fermentation 
by gut bacteria.  
 
Ha1: A FODMAP reduction in addition to a gluten free diet will give symptom relief and 
increased quality of life in coeliac disease patients with IBS-like symptoms.  
Ha2: A FODMAP reduction will affect the microbiota and the degree of fermentation 
 
Separately from the study of FODMAP reduction, we will also follow a group of newly 
diagnosed coeliac disease patients for 6 weeks. The objective here is to investigate whether 
there will be a change in the degree of fermentation and in the microbiota after 6 weeks of 
gluten free diet. 
 
Design and method 
The study is an open, prospective, randomised, and controlled study consisting of an 
intervention group and a control group, where ideally, each group will consist of 
approximately 20 subjects. The participants will be recruited between June and December 
2015, mainly from the Norwegian Coeliac Society (NCF) and Læring- og mestringssenteret 
(LMS). Some may also be recruited from the polyclinic for coeliac disease at Haukeland 
University Hospital.  
 
The intervention group will follow a low FODMAP diet in addition to their gluten free diet 
for 6 weeks, whilst the control group will follow their regular gluten free diet. The 
intervention group will receive dietary counselling on how to follow a low FODMAP diet, 
and the control group will receive additional dietary counselling on the gluten free diet. After 
end of study, the control group will be offered counselling on the FODMAP diet.  
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Inclusion criteria:  
- Confirmed coeliac disease diagnosis for at least 6 months  
- IBS-like symptoms confirmed by the Rome III criteria 
- Score >75 on the IBS Symptom Severity Score (IBS-SSS) 
- Subjects between 18 - 60 years of age 
 
Exclusion criteria:  
- Subjects with therapy-resistant coeliac disease  
- Recent biopsy with abnormal findings   
The group of newly diagnosed coeliac disease patients will consist of approximately 20 
subjects, and will be recruited in the same time period from Læring- og mestringssenteret 
(LMS). The subjects included in this group will be those with a new diagnosis who is about to 
commence on a gluten free diet.   
 
Variables  
Variables included in the study will be the following:  
Symptoms 
Quality of life  
Microbiota  
Hydrogen breath test  
Blood tests  
 
Collection of data  
Data will be collected through questionnaires, biological material and breath tests.  
 
In order to measure symptoms we will use the standardized and validated IBS-Symptom 
Severity Score (IBS-SSS). This scheme includes five different questions with a score from 0-
100, and offers a classification of symptom severity. We will also use the Rome III criteria to 
confirm IBS-like symptoms. To measure quality of life, we will use the questionnaire Short 
Form Survey (SF-36). This scheme includes questions regarding physical and mental health. 
A compliance scheme will be used in the intervention group in order to assess adherence to 
the diet. There will be taken serological test for coeliac disease at baseline off all participants. 
These will be included in the study as a possible explanatory variable. All participants will do 
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a 4-day prospective food dairy at baseline and after the intervention.   
 
At baseline, both groups will fill in these questionnaires regarding their symptoms and quality 
of life. They will be asked to fill in the same questionnaires after 3 weeks and at the end of 
study (at 6 weeks). The subjects in the intervention group will also fill in the compliance 
scheme at 3 weeks and 6 weeks of diet, and also at 10 weeks (4 weeks after end of study). The 
questionnaires will be filled out when the participants are present at Haukeland University 
Hospital for collection of data at baseline and after 6 weeks. Ideally, the questionnaires at 3 
weeks will be filled out during follow-up at Haukeland University Hospital. For those who are 
not able to attend this follow-up, the questionnaires will be mailed.  
 
We will perform a breath test in both the intervention group, the control group and in the 
group of newly diagnosed coeliac disease patients. The breath test will be performed using a 
“Model SC MicroLyzer”.  
The principle behind the breath test is to measure the amount of hydrogen breathed out, which 
correlates to the production of hydrogen by the bacteria in the intestines. We will perform a 
60-minute breath test, measuring breath at 0, 15, 30, 45 and 60 minutes. The breath test will 
be done on the basis of their diet, comparing degree of fermentation on their normal diet at 
baseline, after 3 weeks and after 6 weeks of diet.    
 
The stool samples will be collected at baseline, after 3 weeks and after 6 weeks of diet in the 
intervention group, control group and in the group of newly diagnosed coeliac disease 
patients. The stool samples will be sent to a laboratory in Oslo; Genetic Analysis (GA), who 
will perform the microbiota analyses. The stools samples will be tested utilizing DNA 
sequences within the 16S rRNA gene of the bacteria in order to identify any bacterial 
imbalance in the microbiota. We want to investigate whether the microbiota changes based on 
what the participants eat. 
 
Analyses 
The data will be summarized in figures and/or tables. We will use STATA or SPSS to 






Kamilla Nuland, Ida Serine Melhus Strindmo, the main supervisor and co-supervisors will not 
receive any form of remuneration. 
 
Time schedule  
February – April 2015  Writing of protocol and applying to REC 
June – December 2015  Recruiting of patients and performance of study  
February – March 2016  Data analyses 
April – May 2016   Writing of Master’s Thesis  
 
Ethics 
There is no risk of harm in this study. The intervention and the data collection may be 
perceived as demanding for some, but it will not cause any harm to the participants. The study 
is voluntarily and the participants can withdraw from the study at any point without providing 
any justification 
 
Reference list  
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disease and irritable bowel-type symptoms. The American journal of gastroenterology. 
2002;97(6):1463-7. 
2. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs 
reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67-75.e5. 
3. Gibson PR, Shepherd SJ. Evidence-based dietary management of functional 
gastrointestinal symptoms: The FODMAP approach. Journal of gastroenterology and 
hepatology. 2010;25(2):252-8. 
4. The Rome Foundation. Rome III Diagnostic Criteria for Functional Gastrointestinal 
Disorders 2015 [cited 2015 01.05.2015]. Available from: 
http://www.romecriteria.org/criteria/. 
5. Shepherd SJ, Lomer MC, Gibson PR. Short-chain carbohydrates and functional 
gastrointestinal disorders. The American journal of gastroenterology. 2013;108(5):707-17. 
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Attachment 13: Information letter 
 
Forespørsel om deltakelse i forskningsprosjektet: 
Effekt av FODMAP-reduksjon i tillegg til glutenfri kost ved 
cøliaki 
Bakgrunn og hensikt 
 
Det er kjent at mange pasienter med sikker cøliaki opplever begrenset eller ingen symptomlindring av 
glutenfri kost, tross normalisering av blodprøver og evt. tynntarmsbiopsi. Det er usikkert hvordan 
disse symptomene skal behandles best. Dette er derfor et spørsmål til deg om å delta i en 
forskningsstudie hvor vi vil sammenligne de to behandlingsalternativene som finnes. Den ene gruppen 
vil få en grundig veiledning i strikt glutenfri kost, mens den andre vil få en såkalt FODMAP-redusert 
kost. Vi vil se på tilleggseffekten av en slik diett hos personer med cøliaki og mageplager i forhold til 
en streng glutenfri diett. 
 
FODMAP er en forkortelse for fermenterbare oligo-, di-, og monosakkarider og polyoler. Dette er 
karbohydrater som gir næring til bakterier i tarmen og som hos enkelte kan forårsake mageplager som 
diaré, forstoppelse, magesmerter og oppblåsthet. Matvarer som inneholder FODMAP er blant annet 
hvete, rug, visse melkeprodukter, løk, bønner, søtstoffer, epler, mango, brokkoli og plommer. Lav-
FODMAP-diett går ut på å unngå å spise matvarer med høyt innhold av FODMAP.  
 
Du er valgt ut til å få tilbud om å delta i studien fordi du er i alderen 18-60 år, har cøliaki og har vært 
på cøliakikurs. Du har spist glutenfri kost i minst seks måneder, men har likevel ubehag og 
mageplager. Dette oppfatter vi som symptomer på «irritabel tarm». Det finnes forskning som viser at 
lav-FODMAP diett kan gi symptomlindring ved irritabel tarm. Det er imidlertid ikke forsket på om 
dietten kan være nyttig for cøliakere med irritabel tarm, og derfor spør vi om du vil være med på 
denne studien som kan vise oss om FODMAP-restriksjon i tillegg til glutenfri kost gir mer effektiv 
symptomlindring enn innskjerpet glutenfri kost alene.  
 
Studien er en åpen, kontrollert studie utført av to masterstudenter i klinisk ernæringsfysiologi, veiledet 
av overlege/professor ved Universitetet i Bergen og Haukeland Universitetssykehus og klinisk 
ernæringsfysiolog ved Haukeland Universitetssykehus, som er ansvarlige for prosjektet. 
 
Hva innebærer studien? 
Studien innebærer at du over en periode på seks uker enten spiser en strikt glutenfri kost (gruppe A) 
eller at du spiser en spesiell kost som inneholder lite FODMAP i tillegg til strikt glutenfri kost (gruppe 
B). Det vil være tilfeldig om du havner i gruppe A eller gruppe B. En lav FODMAP-kost betyr at du 
må kutte ut ulike typer matvarer. Havner du i gruppe B, vil du senere få en detaljert oversikt over 
matvarer du ikke kan spise, og en liste med alternativer til de matvarene du må kutte ut. Dersom du 
velger å delta i studien, vil du bli invitert til et møte der du får utdypende forklaring om hva som skal 
skje i studien. Dersom du havner i gruppe A vil du også få mer informasjon om glutenfri kost, men 
dersom du havner i gruppe B vil du få mer informasjon om lav-FODMAP-dietten. Du skal møte opp 
på Haukeland Universitetssykehus tre ganger for å ta blodprøver og pusteprøver og for samtaler med 
studentene i klinisk ernæringsfysiologi. Du skal også avgi avføringsprøver, fylle ut noen 
157 
 
spørreskjemaer og fylle ut en kostdagbok over 4 dager. Dette gjøres før oppstart av studien, etter 3 
uker og etter 6 uker, og i tillegg skal noen skjemaer fylles ut 4 uker etter avsluttet studie. Dette kan 
gjøres hjemme og deretter sendes i posten. 
 
Mulige fordeler  
Fordelen ved å delta er en mulig bedring av symptomene, dette er imidlertid usikkert. Det betyr mulig 
mindre diaré, mindre forstoppelse, mindre magesmerter og/eller mindre oppblåsthet. En bedring av 
symptomer fra tarmen vil ofte også medføre en bedring i livskvalitet. 
 
Mulige ulemper 
Det er usannsynlig at studien kan medføre bivirkninger eller ubehag. Det er mulig at du ikke får noen 
bedring av dietten. Utover dette er det ingen risiko forbundet med studien. Du må møte opp på 
Haukeland Universitetssykehus tre ganger, noe som kan oppleves som belastende og/eller 
tidskrevende for enkelte. Du må også ta to avføringsprøver, blodprøver og to pusteprøver. Dietten du 
skal følge fører også til at du sannsynligvis må kutte ut en del matvarer som du vanligvis spiser, noe 
som kan oppleves som vanskelig for noen. Det kan også være en utfordring å gå på diett i sosiale 
sammenhenger. 
 
Hva skjer med prøvene og informasjonen om deg?  
Avføringsprøvene, blodprøvene og pusteprøvene som er tatt av deg, og informasjonen som registreres 
om deg, skal kun brukes slik som beskrevet i hensikten med studien. Alle opplysninger og prøver vil 
bli behandlet uten navn og fødselsnummer eller andre direkte gjenkjennende opplysninger. En kode 
knytter deg til dine opplysninger og prøver gjennom en navneliste. Det betyr at opplysningene er 
avidentifiserte. Det er kun autorisert personell knyttet til prosjektet som har adgang til navnelisten og 
som kan finne tilbake til deg. Avføringsprøvene og blodprøvene vil destrueres etter at nødvendige 
analyser er tatt. Ved publisering av resultatene vil identiteten din ikke komme fram. 
 
Frivillig deltakelse 
Det er frivillig å delta i studien. Du kan når som helst, uten å oppgi noen grunn, trekke ditt samtykke 
til å delta i studien. Dette vil ikke få noen konsekvenser for din videre behandling. Dersom du ønsker å 
delta, undertegner du samtykkeerklæringen på siste side av dette skrivet. Om du nå sier ja til å delta, 
kan du senere trekke tilbake ditt samtykke uten at det påvirker din øvrige behandling. Dersom du 
senere ønsker å trekke deg eller har spørsmål til studien, kan du kontakte studentene i klinisk 
ernæringsfysiologi Ida Serine M. Strindmo (Telefon: 900 31 585, e-post: ist104@student.uib.no) 
og/eller Kamilla Nuland (Telefon: 988 45 679, e-post: knu030@student.uib.no). Eventuelt kan 




Ytterligere informasjon om studien finnes i kapittel A – utdypende forklaring av hva studien 
innebærer. 
Ytterligere informasjon om biobank, personvern og forsikring finnes i kapittel B – Personvern, 
biobank, økonomi og forsikring.  
 




Kapittel A- utdypende forklaring av hva studien 
innebærer 
 
Kriterier for deltakelse 
Du er valgt ut til å forespørres til å delta i studien fordi du er i alderen 18-60 år, har cøliaki, har vært på 
cøliakikurs, gått på glutenfri kost, men har allikevel ubehag og symptomer etter seks måneder. I tillegg 
har du scoret 75 eller mer på spørreskjemaet IBS-SSS og scoret på Roma III-kriteriene for IBS, og har 
dermed symptomer på «irritabel tarm». 
Bakgrunnsinformasjon om studien 
Ikke alle med en sikker cøliakidiagnose blir symptomfrie på glutenfri kost, på tross av at antistoffer i 
blodprøver og eventuelt tynntarmsbiopsier er normaliserte. Det er kjent at personer med cøliaki har en 
overhyppighet av irritabelt tarm syndrom (IBS). Cøliakere med IBS kan tenkes å ha en positiv effekt 
av FODMAP-redusert kosthold, men dette er ikke undersøkt tidligere, og det er derfor nyttig å 
kartlegge. Kan FODMAP-restriksjon gi symptomlindring hos cøliakipasienter som ikke har 
tilfredsstillende effekt av bare glutenfri kost? 
 
Matvarer som inneholder mye FODMAPs (fermenterbare oligo-, di-, og monosakkarider og polyoler) 
kan gi plager fra mage- tarm området, særlig hos de med irritabel tarm. Mat som inneholder FODMAP 
blir fermentert i tykktarmen. Det betyr at bakterier i tykktarmen omdanner ufordøyd mat til gass og til 
energi (korte fettsyrer). Dette er en normal og viktig prosess, og det er blant annet essensielt for 
tarmcellenes helse. Fermentering er noe som i ulik grad skjer hos alle mennesker, men de med irritabel 
tarm får antageligvis mer plager av dette enn friske.  
 
Ved irritabel tarm skjer det en unormal respons i mage- tarm kanalen som kan skyldes overfølsomhet i 
tarmen. Det kan også skyldes en unormal respons fra nervesystemet i tarmen, en forstyrrelse i 
bakteriefloraen, motilitetsforstyrrelse (unormal bevegelse av tarminnholdet) eller smerter på grunn av 
gassdannelse fordi det blir en utvidelse av tarmen. Dette kan gi de typiske symptomene på irritabel 
tarm, som oppblåsthet, magesmerter, gassdannelse, diaré og/eller forstoppelse. Tanken ved lav-
FODMAP diett er å redusere inntak av mat som kan fermenteres av bakterier slik at det blir mindre 
fermentering i tarmen, og dermed mindre plager. 
 
Blodprøver, avføringsprøver og pusteprøver 
Før oppstart av studien skal du ta en blodprøve for å sjekke betennelsesmarkører. Blodprøven tas på 
sykehuset i forbindelse med gruppemøtet før oppstart av selve dietten. Du skal også avgi en 
avføringsprøve som skal analyseres for å studere bakteriesammensetningen. Avføringsprøven kan tas 
hjemme og sendes i posten i en spesial-emballasje. Pusteprøver vil bli gjort på sykehuset før oppstart 
av studien for å se på grad av fermentering av bakteriene i tykktarmen. Du vil bli tildelt time for dette 
og undersøkelsen tar ca. 60 minutter. Blod-, avførings- og pusteprøver vil bli gjentatt etter seks uker. 
 
Spørreskjemaer og kostregistrering 
Du skal svare på fire spørreskjemaer før oppstart av studien, etter tre uker og etter seks uker. Disse 
skjemaene er Rome III (kriterier for irritabel tarm), IBS-SSS (symptomer på irritabel tarm), SF-36 
(livskvalitet) og compliance (overholdelse av FODMAP-dietten). I tillegg skal du utføre en 4-dagers 




Tidsskjema – hva skjer og når skjer det? 
Du har blitt kontaktet og blitt forespurt om å delta i studien. Dersom du er villig til å være med i 
studien, signerer du samtykkeskjemaet bakerst i dette skrivet.  
 
Du skal deretter møte opp på tre møter, som alle vil finne sted på Haukeland sykehus på dagtid så 
langt det lar seg gjøre. 
 
Du vil bli invitert til et gruppemøte med opptil 1-3 andre deltakere. Avhengig om du er havnet i 
gruppe A eller gruppe B vil studentene i klinisk ernæringsfysiologi der gi grundig informasjon om 
strikt glutenfri kost (gruppe A) eller lav-FODMAP-dietten (gruppe B) og hva som skal skje fremover. 
Du skal også ta en blodprøve og en pusteprøve, før eller etter dette møtet. Dette gjøres også på 
Haukeland Universitetssykehus og pusteprøven tar ca. 60 minutter, hvor du puster inn i et rør hvert 
15.minutt. Litt ventetid før og etter må beregnes. Disse kan gi nyttig informasjon som kan hjelpe deg 
til å minske IBS-symptomene.  
 
Du vil også få utdelt skriftlig informasjon. Spørreskjemaer om hvor plaget du er av irritabel tarm og 
hvordan det påvirker din livskvalitet skal fylles ut og leveres en av studentene før eller etter møtet. Du 
skal også gjøre en 4 dagers prospektiv kostregistrering der du noterer ned alt du spiser. Etter at du har 






Du skal også avgi en avføringsprøve som du kan levere før eller etter møtet, eller som kan tas hjemme 
og sendes til adressen ovenfor. Dersom du er havnet i gruppe B, får du også med deg et compliance-
skjema som skal fylles ut etter tre uker og tas med neste gang. 
 
Andre møte blir tre uker etter oppstart av studien, altså etter at du har gått på den strikte glutenfrie 
dietten i tre uker dersom du havnet i gruppe A, eller etter at du har gått på lav FODMAP-diett i tillegg 
til glutenfri diett i tre uker (gruppe B). Der vil eventuelle spørsmål og problemer diskuteres. I forkant 
av dette møtet skal du på ny ha fylt ut spørreskjemaene og ta disse med på møtet. Dersom du havnet i 
gruppe B som går på FODMAP-redusert kost i tillegg til glutenfri kost, skal du også ha med deg et 
ferdig utfylt compliance-skjema som går på overholdelse av dietten etter tre uker.  
 
Tredje og siste møte blir så når studien er avsluttet, etter at du skal ha gått på dietten i seks uker. Dette 
er også et møte med 1-3 andre deltakere. Eventuelle problemer og spørsmål kan tas opp. Du har også 
mulighet til å kontakte studentene på telefon eller e-post (se kontaktinformasjon på andre side) hvis 
det oppstår problemer underveis. Du kan eventuelt også ringe den ansvarlige legen. Dersom du er i 
gruppe A, vil du på dette møtet få informasjon om FODMAP-dietten. Dersom du er i gruppe B, vil du 
på dette møtet få informasjon om gradvis reintroduksjon av FODMAPs. Igjen tar du med ferdig utfylte 
spørreskjemaer i tillegg til 4 dagers kostregistrering. Også i forkant eller etterkant av dette møtet skal 
du ta pusteprøve og blodprøve, og du skal også ta med deg en avføringsprøve.  
 






Alternative prosedyrer dersom du velger å ikke delta i studien: 
Dersom du ikke ønsker å delta i studien vil det ikke få noen konsekvenser for din videre behandling. 
Dersom du underveis i studien ønsker å trekke deg kan du ta kontakt når som helst. Da vil du bli 
invitert til en samtale, og eventuelle problemer vil bli diskutert. Du har selvfølgelig fortsatt rett til å 
slutte i studien når som helst uten å oppgi grunn. Dersom du ønsker å slutte med dietten, så vil du få 
tilbud om å få andre generelle råd for hva du kan gjøre for å lindre symptomene.  
 
Studiedeltakerens ansvar: 
Som deltaker i denne studien ber vi om at du setter deg inn i informasjonen og følger diettene så godt 
som mulig. Tid og dato for møtene, pusteprøvene, blodprøvene og avføringsprøvene (skal gjøres 
samme dag) skal avtales slik at det passer for begge parter. Med tanke på at det vil være 1-4 deltakere 
på hvert møte i tillegg til to mastergradsstudenter i klinisk ernæringsfysiologi, ber vi om at du er 
fleksibel på tid og dato for møtene og prøvetakningene. Du må også møte opp til avtalt tid, eller 
eventuelt ringe i god tid hvis timen ikke passer. Du har også ansvar for å fylle ut skjemaene som 
avtalt, ta dem med på møtene og sende de i posten før avtalt frist. På det første møtet med studentene 
vil du få mer nøyaktig informasjon enn det som står i dette skrivet. 
 
Endringer i planen: 
Dersom det skjer en endring i planen, eller en tidligere avslutning av dietten, vil du bli informert så 
raskt som mulig. Du vil også bli orientert dersom ny informasjon blir tilgjengelig som kan føre til at 
du ikke lenger vil delta i studien. Dersom det oppstår en uforutsett hendelse som gjør at studien må 
avsluttes vil du bli kontaktet snarest mulig. 
 
Utgifter 
Du vil få kompensasjon for reiseutgiftene til og fra Haukeland Universitetssykehus. Du får ikke 
kompensasjon for eventuell tapt arbeidstid, godtgjørelse for deltakelse eller tilskudd til diett.  
 
 
Kapittel B - Personvern, biobank, økonomi og forsikring 
 
Personvern 
Opplysninger som registreres om deg er informasjon om symptomer og livskvalitet fra forskjellige 
skjemaer. Resultater fra blodprøver, pusteprøver og avføringsprøver vil også bli registrert, men selve 
prøvene vil bli destruert etter at analysene er gjort. Kontaktinformasjon (navn og telefonnummer) om 
deg vil bli lagret. Det er kun vi som holder på med studien som har tilgang til opplysninger om deg, og 
de vil bli lagret innelåst i et skap på studieleders kontor. 
 
Biobank 
Avføringsprøver og blodprøver kastes etter analyse, det vil si at det ikke opprettes en biobank. 
 
Utlevering av materiale og opplysninger til andre 
Hvis du sier ja til å delta i studien, gir du også ditt samtykke til at prøver og avidentifiserte 
opplysninger kun brukes til denne studien ved Haukeland Universitetssykehus i Bergen. 
Avidentifiserte opplysninger skal ikke sendes til andre foretak eller foretak i andre land. 
 
Rett til innsyn og sletting av opplysninger om deg og sletting av prøver  
Hvis du sier ja til å delta i studien, har du rett til å få innsyn i hvilke opplysninger som er registrert om 
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deg. Du har videre rett til å få korrigert eventuelle feil i de opplysningene vi har registrert. Dersom du 
trekker deg fra studien, kan du kreve å få slettet innsamlede prøver og opplysninger, med mindre 
opplysningene allerede er inngått i analyser eller brukt i vitenskapelige publikasjoner.  
 
Økonomi og Haukeland Universitetssykehus’ rolle 
Studien er finansiert gjennom forskningsmidler fra Medisinsk avdeling og ved Klinisk Institutt 1 ved 
Universitetet i Bergen. De vil bidra med personell til analyser av blodprøver. Firmaet Genetic Analysis 
i Oslo vil analysere avføringsprøvene. Det er ingen mulige interessekonflikter.  
 
Forsikring 
Forsikringsordningen som gjelder er Norsk Pasientskadeerstatning, idet du som deltaker er under 
behandling ved Haukeland Universitetssykehus.   
 
Informasjon om utfallet av studien 
Du har som deltaker i studien rett til å få informasjon om utfallet av studien når dette er klart. Det vil 
mest sannsynlig bli våren 2016. 
 
 
Samtykke til deltakelse i studien 
 

























Attachment 14: Information from REK 
 
Region:             Saksbehandler:            Telefon:        Vår dato:                          Vår referanse: 
REK sør-øst Hege Holde Andersson 22845514 01.07.2015 2015/915 
      REK sør-øst B 
    Deres dato: 
Deres 
referanse: 
    12.05.2015   
                                                                                             Vår referanse må oppgis ved alle henvendelser 
 
Jan Hatlebakk 
Helse Bergen HF 
2015/915 Effekt av FODMAP-reduksjon som tillegg til glutenfri kost ved coeliaki 
Forskningsansvarlig: Helse Bergen HF 
Prosjektleder: Jan Hatlebakk 
Vi viser til søknad om forhåndsgodkjenning av ovennevnte forskningsprosjekt. Søknaden ble 
behandlet av Regional komité for medisinsk og helsefaglig forskningsetikk (REK sør-øst) i møtet 
08.06.2015. Vurderingen er gjort med hjemmel i helseforskningsloven (hfl.) § 10, jf. 
forskningsetikkloven § 4. 
Prosjektleders prosjektbeskrivelse 
«Ca.30% av pasienter med coeliaki blir på ikke fri for symptomer som smerter, oppblåsthet og endret 
avføringsmønster. Dette ligner sykdommen irritabel tarm og vi vil se om de har nytte av kost som er 
redusert i innhold av kullhydrater som fermenteres i tykktarm. Pasienter som har diagnosen coeliaki 
og som oppfyller kriteriene for irritabel tarm, vil bli randomisert til enten: (1) kost redusert i slike 
karbohydrater, eller (2) kvalitetssikret glutenfri kost. Begge grupper blir veiledet av masterstudenter i 
klinisk ernæring. Pas fyller i kostliste i 4 dager før og under diett, tar blodprøver for coeliakistatus, 
leverer avføringsprøver og deltar i pusteprøver for å måle nivå av fermentering i tarmen. Diett følges i 
6 uker og symptomer og livskvalitet sammenlignes i spørreskjemaer. En gruppe av nydiagnostiserte 
coeliakipasienter vil bli bedt om 
å delta med kostliste, pusteprøve og avføringsprøve før og etter 6 uker på standard glutenfri kost, for å 
se om fermentering endres.» 
Komiteens vurdering 
Komiteen har ingen forskningsetiske innvendinger til at prosjektet gjennomføres. 
Under punkt 5.7 Håndtering av data etter prosjektslutt i søknadskjema skriver prosjektleder at data 
skal slettes etter prosjektslutt. Komiteen gjør oppmerksom på at avidentifiserte opplysninger skal som 
hovedregel lagres i 5 år etter prosjektslutt av dokumentasjonshensyn, og skal deretter slettes eller 
anonymiseres. 
Biobank 
I søknadskjema står det at det biologiske materialet skal oppbevares i en tidligere godkjent generell 
forskningsbiobank; Forskningsbiobank for mage-tarmsykdommer. I informasjonsskrivet til deltagerne 
står det imidlertid at; Avføringsprøver og blodprøver kastes etter analyse, det vil si at det ikke 
opprettes en biobank. Sekretariatet i REK-sør øst har vært i kontakt med prosjektleder for å oppklare 
hvordan materialet skal oppbevares. I e-post til sekretariatet 19.06.2015 skriver prosjektleder 
at Prøvene skal samles gjennom prosjektperioden for så å bli analysert samlet i februar 2016. Siden 
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det humant biologiske materialet skal oppbevares i mer enn 2 måneder er det behov en spesifikk 
forskningsbiobank i prosjektet. Komiteen oppretter derfor en spesifikk forskningsbiobank «Effekt 
av FODMAP-reduksjon som tillegg til glutenfri kost ved coeliaki.» Ansvarshavende er Jan Hatlebakk. 
Biobanken planlegges å vare til 24.06.2016. 
Komiteen ber om at informasjonsskriv og samtykkeerklæring revideres slik at det fremkommer at det 
humant biologiske materielt skal oppbevares i en forskningsbiobank. Det reviderte skrivet må sendes 
komiteen til orientering. 
Ut fra dette setter komiteen følgende vilkår for prosjektet: 
1.Informasjonsskrivet revideres i tråd med det ovennevnte og sendes komiteen til orientering. 
Vedtak 
Komiteen godkjenner prosjektet i henhold til helseforskningsloven § 9 og § 33 under forutsetning av 
at ovennevnte vilkår oppfylles. 
I tillegg til ovennevnte vilkår, er godkjenningen gitt under forutsetning av at prosjektet gjennomføres 
slik det er beskrevet i søknaden. 
Tillatelsen gjelder til 24.06.2016. Av dokumentasjonshensyn skal opplysningene likevel bevares inntil 
24.06.2021. Opplysningene skal lagres avidentifisert, dvs. atskilt i en nøkkel- og en opplysningsfil. 
Opplysningene skal deretter slettes eller anonymiseres, senest innen et halvt år fra denne dato. 
Komiteen godkjenner også oppførelsen av en spesifikk forskningsbiobank som beskrevet i søknaden. 
Biobankregisteret blir underrettet ved kopi av dette brev. 
Hvis forskningsbiobanken opphører, nedlegges eller overtas av andre, skal det søkes REK om 
tillatelse, jf. helseforskningsloven § 30. 
Forskningsprosjektets data skal oppbevares forsvarlig, se personopplysningsforskriften kapittel 2, og 
Helsedirektoratets veileder ”Personvern og informasjonssikkerhet i forskningsprosjekter innenfor 
helse- og omsorgssektoren” 
Sluttmelding og søknad om prosjektendring 
Dersom det skal gjøres endringer i prosjektet i forhold til de opplysninger som er gitt i søknaden, må 
prosjektleder sende endringsmelding til REK. Prosjektet skal sende sluttmelding på eget skjema, se 
helseforskningsloven § 12, senest et halvt år etter prosjektslutt. 
Klageadgang 
Du kan klage på komiteens vedtak, jf. forvaltningslovens § 28 flg. Klagen sendes til REK sør-øst B. 
Klagefristen er tre uker fra du mottar dette brevet. Dersom vedtaket opprettholdes av REK sør-øst B, 
sendes klagen videre til Den nasjonale forskningsetiske komité for medisin og helsefag for endelig 
vurdering. 
Komiteens avgjørelse var enstemmig. 
Med vennlig hilsen 
Geir Olav Hjortland  
nestleder REK sør-øst B                                                                                       Hege Holde Andersson 
                                                                                                                                         komitésekretær 
Kopi til: 
-Avdelingsdirektør Lars Birger Nesje, Helse Bergen HF 
-Helse Bergen HF - Haukeland universitetssjukehus ved øverste administrative ledelse 
 
Besøksadresse: Telefon: 22845511 All post og e-post som inngår i 
Gullhaugveien 1-3, 0484 Oslo E-post: post@helseforskning.etikkom.no saksbehandlingen, bes adressert til REK 
  Web: http://helseforskning.etikkom.no/ sør-øst og ikke til enkelte personer 
 
Kindly address all mail and e-mailsto the Regional Ethics Committee, REK sør-øst, not to individual staff 
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Attachment 15: Announcement  
 
Har du cøliaki, spiser glutenfri kost, men har likevel mye 
mageplager?  
Vi søker voksne i alderen 18-60 år med sikker cøliaki og som har spist glutenfri kost i minst 
seks måneder og likevel har ubehag og mageplager. Det er usikkert hvordan disse 
symptomene skal behandles best.  
Vi vil sammenligne de to behandlingsalternativene som finnes. Den ene gruppen vil få 
grundig veiledning i strengt glutenfri kost, mens den andre vil bli bedt om å redusere sitt 
inntak av visse typer karbohydrater (FODMAP). 
 
Deltakelse innebærer: 
 Undervisning ved studenter i klinisk ernæringsfysiologi 
 Blodprøver, pusteprøver og avføringsprøver  
 Utfylling av spørreskjemaer 
 Fylle ut kostdagbok over 4 dager i to perioder 
 Tre fremmøter ved Haukeland Universitetssykehus 
Godkjenning 
Studien er godkjent hos Regional forskningsetisk komité. Prosjektleder og medisinsk 
ansvarlig er Jan Gunnar Hatlebakk, professor ved klinisk institutt 1, Universitetet i Bergen, og 
overlege, Haukeland Universitetssykehus. 
 
Kontakt 
Ønsker du mer informasjon og er interessert i å delta, kan du kontakte en av oss: 
 
Ida S. M. Strindmo, student i klinisk ernæringsfysiologi   
E-post: ist104@student.uib.no 
Telefon: 900 31 585 
 
Kamilla Nuland, student i klinisk ernæringsfysiologi   
E-post: knu030@student.uib.no 































Attachment 17: Abstract sent to United European Gastroenterology Week in Vienna 
 
FODMAP RESTRICTION OF A GLUTEN FREE DIET IN PATIENTS WITH 
COELIAC DISEASE: A RANDOMIZED, CONTROLLED CLINICAL STUDY 
K. Nuland1, I. Strindmo1, G. E. Kahrs2,3 and J.G. Hatlebakk4 
1Department of Clinical Medicine, University of Bergen, 2Department of Occupational Medicine, and Sections of 3Clinical 
Nutrition and 4Gastroenterology, Department of Medicine, Haukeland University Hospital, Bergen, Norway3. 
 
INTRODUCTION: 20-30 % of coeliac patients on a gluten free diet still have irritable bowel 
syndrome (IBS) symptoms. A low FODMAP (fermentable oligo-, di-, monosaccharides and 
polyols) diet is effective to reduce symptoms in IBS patients.  
AIM&METHOD: We wanted to investigate the benefit from restricting the FODMAP 
content of the diet. 40 patients with coeliac disease and IBS symptoms confirmed by the 
Rome III criteria and IBS-SSS (Symptom Severity Scale) were randomized and instructed by 
dieticians: Group A excluded all wheat starch and “traces of gluten” from their diet, Group B 
excluded FODMAPs as well as gluten. Symptoms on IBS-SSS were recorded at baseline, 3 
and 6 weeks, as well as quality of life (SF-36). Four days prospective dietary intake records at 
baseline and 6 weeks, compliance and satisfaction after 6 weeks, and 1 month later. Dietist 
Net Free was used for FODMAP calculations. Statistics: T-tests, nonparametric tests.  
 
RESULTS: 20 patients were included in each group; A (18F/2M, age 39±15) and B 
(15F/5M, age 43±12). 42.5% had constipation, 27.5% diarrhoea and 30% both.  
The mean total IBS-SSS score was significantly reduced: Group A from 260 to 204 
(p=0.0022), group B from 263 to 145 (p<0.0001), p=0.0247, group B vs. A. In group A 10% 
reached remission, in Group B 25% (p=0.408). All subscales improved significantly in group 
B, but only abdominal pain severity in group A. SF-36 physical health score improved in 
group B (p= 0.0081), but not in group A. Patients in group B were significantly more satisfied 
with pain relief (p=0.0132), but it was also more challenging to follow their diet (p=0.0008).  
 
CONCLUSION: Patients with coeliac disease and IBS-symptoms had significant 
improvement in abdominal symptoms and physical health from a low FODMAP diet for 6 
weeks. A gluten free diet with reduced FODMAP content was more effective than a more 
strict gluten free diet, and should be offered to coeliac patients with refractory IBS-symptoms 
on a gluten free diet. 
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